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Summary
Human blood platelet responsiveness can be modulated by 
a variety of stimulatory and inhibitory agonists. These 
agents are recognised by specific receptors which presumably 
are situated on the outer surface of the platelet plasma 
membrane. Receptors have been characterised for a number of 
endogenous compounds including adrenaline, ADP, vasopressin, 
platelet-activating factor, PGI^, PGD^ and adenosine. Platelets 
are electrically non-excitable, hence, there must exist 
transduction processes which link events at.the cell surface 
(i.e. agonist-receptor interaction) to the key intracellular 
reactions which control cellular responsiveness.
In platelets, as in many other cell types, it has been 
established that inositol phospholipid hydrolysis serves as 
one of the transduction processes that link stimulatory 
receptor occupancy to cellular activation. Phospholipase C- 
catalysed hydrolysis of phosphatidylinositoi 4,3-bisphosphate 
yields 1,2-diacylglycerol, an activator of protein kinase C, 
and inositol (1,4,3) trisphosphate which can mobilise calcium 
ions from intracellular stores. Inositol phospholipid 
hydrolysis may also be involved in the agonist-induced influx 
of calcium ions which also occurs in platelets. Inhibition of 
platelet reactivity is associated with agonist-induced stimulation 
of adenylate cyclase activity and increased intracellular 
levels of cyclic AMP. Cyclic AMP, via activation of cyclic 
AMP-dependent protein kinase, can modify a variety of platelet 
intracellular reactions.
-  X l l  -
In vivo platelets may be exposed to combinations of 
stimulatory and/or inhibitory agonists. Hence, the phenomena 
of synergism and desensitization, which have been demonstrated 
in vitro, may occur vivo and may be of major importance in 
haemostasis and in the pathogenesis of occlusive vascular 
disease. This study examined the effects of agonists, alone 
and in combination, on platelet responsiveness and the putative 
underlying transduction processes of inositol phospholipid 
hydrolysis, elevation of cytosolic free calcium concentration
) and cyclic AMP concentration. Platelet responsiveness 
was monitored by measuring (a) shape change; (b) aggregation 
in whole blood (by a single platelet counting method); (c) 
aggregation in platelet-rich plasma (by two methods ; 
turbidometrieally and by counting single platelets); (d) 
aggregation in gel-filtered platelets and (e) release of dense 
granule constituents.
Stimulation of inositol phospholipid metabolism was 
assessed as [^^p] -Ptd OH formation in platelets prelabelled 
with p ^ P  ] Changes in ^ were measured using the
fluorescent calcium-indicator dye Quin 2 and cyclic AMP levels 
were measured by radioimmunoassay.
1. In platelet-rich plasma, the single platelet counting method 
provided a much more sensitive index of aggregation than did 
the measurement of changes in light transmission in an 
aggregometer.
-  X l l l  -
2. PAF and vasopressin induced concentration-dependent platelet 
activation, j^^P j-Ptd OH formation and elevation of |ca^^j ^ . 
ADP-induced platelet activation was associated with elevation 
of but not ^^^P ] -Ptd OH formation. Adrenaline also
caused platelet activation but had no direct effect on ^
or p ^ P  ] -Ptd OH levels.
3 . Adrenaline potentiated ADP-, vasopressin- and PAF-induced 
platelet activation and elevation of |ca^^j . Agonist 
(vasopressin)-induced ^^^P j-Ptd OH formation was also 
potentiated.
4. Potentiation of platelet activation by adrenaline may be 
mediated by enhanced inositol phospholipid hydrolysis and 
elevation of |ca^^j .
5. PGl^» PGE^, 6-keto-PGE^, PGD^ and adenosine induced 
concentration-dependent elevations in platelet cyclic AMP 
content.
6. PAF-induced functional platelet responses and transduction 
processes show differential sensitivity to inhibition by PGD^ 
and PGI^. A doubling in the platelet cyclic AMP content 
resulted in abolition of PAF-induced aggregation and ATP 
secretion, whereas maximal inhibition of shape change, j^ ^^ P j - 
Ptd OH formation and elevation of jca^^j required a greater 
than ten-fold elevation in cyclic AMP. This differential 
sensitivity of the various responses to inhibition by cyclic 
AMP suggests that the mechanisms underlying inhibition of 
PAF-induced aggregation and ATP secretion differ from those 
underlying shape change. Thus a major component of cyclic 
AMP-dependent inhibition of PAF-induced aggregation and ATP
- XIV -
secretion is mediated by suppression of certain components 
of the activation process that occur distal to the formation 
of di acyl glycerol or elevation of |ca^^j .
7« Inhibitors of adenylate cyclase (adrenaline, ADP) but not 
vasopressin or PAF, prevented elevation of cyclic AMP content 
and inhibition of platelet responsiveness and transduction 
processes by adenylate cyclase stimulants (PGI^» PGD^) but 
not by other means (e.g. inhibition of phosphodiesterase 
activity).
8. Activation of protein kinase C by PMA directly inhibited 
PGD^- but not PGI^-j PGE^-,6-keto-PGE^- or adenosine-induced 
cyclic AMP formation. PMA had no effect on the inhibition 
of cyclic AMP formation by adrenaline.
9« A preliminary study confirmed the presence of cyclic AMP- 
dependent protein kinase activity in crude platelet soluble 
and particulate fractions. Measurement of this enzyme activity 
may provide a sensitive index of the effects of agonists on 
cyclic AMP metabolism in platelets.
This study has examined a number of questions in relation 
to the control of platelet reactivity in the presence of 
multiple stimulatory or inhibitory agonists. A detailed 
understanding of the mechanisms which mediate responsiveness 
under these conditions may facilitate the development of 
therapeutic agents to specifically modulate platelet reactivity
in VIVO
— J_ —
INTRODUCTION
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I. Platelet formation
Since their discovery over 100 years ago (Bizzozero, 1882), 
blood platelets have been shown to play an essential role in 
haemostasis and thrombosis by virtue of their ability to adhere 
to damaged endothelium or foreign surfaces and initiate various 
processes leading to formation of a haemostatic plug. Platelets 
have their origin in megakaryocytes which follow a unique 
pattern of proliferation and maturation. Committed megakaryo- 
cytic stem cells develop from the common blood cell precursors, 
pluripotential stem cells, in the bone marrow. From these are 
derived the diploid megakaryoblast precursors which do not 
undergo further cell division (Feinendegen ejfc al., I962). 
Endomitosis occurs to give the morphologically recognisable 
cells of the megakaryocyte series. Megakaryocytes develop in 
three stages; (l) megakaryoblast, (2) basophil megakaryocyte 
and then (3 ) granular megakaryocyte. The intense biosynthetic 
activity during maturation is accompanied by the development 
of a complex demarcation membrane system throughout the cytosol 
(Pennington, I981). When fully developed, the megakaryocytes 
seek out the marrow sinusoids. Between 20^ and 50?^  of mature 
megakaryocytes pass through the sinusoids into the circulation 
whilst the remainder discharge their cytosol into the sinusoids 
and are fragmented in the flowing blood. The mature mega­
karyocytes are carried to the microcirculation of the lung where 
they are then fragmented and discharge their cytoplasm. Small 
megakaryocytic fractions then take on the regular discoid form 
of platelets, probably as a result of the orderly rearrangement 
of the marginal microtubular bundle (Pennington, I98I). The
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normal circulating platelet count is around 2-4 x 10 per
7
ml and the turnover rate is approximately 3»3 x 10 per ml 
per day (Harker & Pinch, 1969). The platelet life-span is 
usually 7-10 days, spent platelets being removed by sequestration 
in the liver and spleen (Gordon & Milner, I976).
II• Platelet structure
Platelets normally circulate as anucleate biconvex discs 
around 2-3 ]im in diameter. The main structural features of 
quiescent platelets are illustrated schematically in Figure 1.
The plasma membrane is rich in glycoproteins which make up 
the *glycocalyx’. This appears as a fuzzy surface coat in 
electron micrographs. Immediately below the plasma membrane 
in the equatorial plane lies a bundle of microtubules which 
form a ring round the platelet. These have a cytoskeletal 
function to maintain the characteristic discoid shape of 
quiescent platelets (Gordon, I98I). In direct continuity with, 
the plasma membrane is the surface-connected cannalicular system 
(sees). This series of invaginations in the platelet surface 
greatly increases the platelet surface area. Platelet granule 
contents may be secreted into the SeeS by exocytosis before 
diffusing to the external medium. Plasma-borne substances 
may also enter the SCCS and be transferred to the cytoplasm 
and granules (White, I970). The dense tubular system (DTS), 
immediately associated with the SCCS, contains calcium storage 
vesicles (White, 1973) and may be the main site of arachidonic 
acid metabolism in the platelet (Gerrard ejfc al., I98I).
Rosmo 
membrane
Glycogen Mitochondrionicrotubules
Lysosome
Alpha /  Dense Dense
granule gronule tubulor
system
Surface connected 
canoliculor system
Figure 1. Illustration of the main structural features of quiescent 
platelets.
See text for explanation. Taken from Nichols jet (1981).
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Platelets contain a number of different granular 
organelles. The dense granules (dense bodies) contain high 
concentrations of amines, particularly 5HT, and adenine 
nucleotides (ADP, ATP) and bivalent cations (Ca^*, Mg^*).
5HT is taken up into platelets and then into dense granules 
by a selective active transport process which mops up free 
plasma 5HT (Humphrey & Toh, 1934). The dense granule contents 
are secreted upon platelet activation. Alpha granules and 
lysosomes are the other main storage organelles whose contents 
are secreted upon platelet activation. The alpha granules are 
heterogeneous in nature and contain a range of proteins 
including (l) platelet-factor 4 (PF4) and #-thromboglobulin 
(both are anti-heparin proteins), (2) low affinity PF4 (a 
precursor of F -thromboglobulin), (3 ) platelet-derived growth
factor and 13-transforming growth factor (which stimulate smooth 
muscle proliferation and collagen formation by fibroblasts),
(4) fibrinectin, fibrinogen and thrombospondin (aggregation 
cofactors), (3 ) Von Willebrand Factor (possibly involved in 
mediation of platelet adhesion to arterial subendothelium) 
and (6) albumin (Kaplan, I98I). The lysosomes contain a range 
of enzymes including acid phosphatase and P—N-acetylglucosamini- 
dase. Platelets also contain glycogen granules (the smallest 
and most abundant platelet granules) and mitochondria.
III. Platelet reactions
The main reactions which platelets undergo in response to 
stimulation are shape change, adhesion, aggregation, secretion 
of granule contents and eicosanoid synthesis and secretion.
- 3 -
111.1 Shape change
As previously described (Section II), the characteristic 
discoid shape of platelets is maintained by the orderly 
circular arrangement of the microtubules. The microtubule 
organisation is disrupted when the platelets are activated 
and the other elements of the platelet's structural and 
contractile apparatus, actin and myosin, interact leading to 
a dramatic and rapid change in platelet shape. This shape 
change is isovolemic and consists of a rounding-up of the 
central platelet body and the extension of long thin pseudopodia 
which effectively increase the platelet surface area and 
facilitate the platelet-platelet contact essential for 
aggregation (Born, 1970; Gordon, I98I). Platelet shape change 
can be monitored, iji vitro, by measuring the transmission 
and/or scattering of light through plasma or washed platelet 
suspensions. Shape change results in an increase in optical 
density and hence a decrease in light transmission (Michal & 
Born, 1971).
111.2 Adhesion
Platelets will readily adhere to exposed vascular collagen 
and this can lead to aggregation and secretion of granule 
contents. This is the primary step in the formation of a 
haemostatic plug. The molecular mechanisms of platelet 
adhesion to the subendothelium are not fully understood.
However, adhesion probably involves the interaction of platelet 
surface glycoprotein Ib (and possibly the glycoprotein Ilb-IIIa 
complex) and factor VIII (von Willebrand factor) with the 
exposed vascular collagen (Hardisty, 1983)» Platelets do not
— 6 -
readily adhere to other biological macromolecules but will 
adhere to a variety of artificial surfaces. Adhesion can be 
quantitated dm vitro by a number of different techniques. In 
its simplest form, this can be achieved by passing a blood 
sample through a column of glass beads and measuring the 
difference in platelet count before and after passage through 
the column (Salzman, I963). However, more physiologically 
relevant models have been developed which involve perfusing 
collagen-coated coverslips or endothelium-denuded blood vessels 
at physiological shear rates (Baumgartner & Mugli, 1976; 
Sakariassen et al., 1983)*
III.3 Aggregation
As well as sticking to foreign surfaces, activated platelets 
will also stick to each other resulting in the formation of a 
multicellular mass or aggregate. This process is known as 
aggregation. Platelet aggregation is normally preceded by 
shape change. Adrenaline, however, is unusual in causing a 
qualitatively distinct change in platelet shape without 
pseudopodia formation. This has been described as 'mild' 
shape change and occurs in the absence of changes in light 
transmission (Gerrard et al., I98I). Reversible or 'primary' 
aggregation can be induced by low agonist concentrations. 
Irreversible or 'secondary' aggregation can be induced by 
higher agonist concentrations and is associated with secretion 
of granule contents and prostanoid formation (Smith & Willis,
1971)" Aggregation requires platelet-platelet collision and 
extracellular cofactors including Ca^ "*" and fibrinogen to forr 
bridges between colliding platelets (Mustard et al., 1978).
— 7 —
The platelet glycoprotein Ilb-IIIa complex, which is exposed 
at the surface membrane upon stimulation, functions as the 
receptor for fibrinogen. The glycoprotein Ilb-IIIa-fibrinogen 
complex is stabilised by thrombospondin which is released from 
the alpha granules (Silverstein al. , I986). Aggregation
can be monitored in plasma or washed platelet suspensions by 
measuring increases in light transmission through stirred 
samples (Born, I962). Aggregation can be monitored in whole 
blood (as well as platelet-rich plasma or washed platelet 
suspensions) by platelet counting where numbers of single 
platelets are counted by an electrical impedance method before 
and after addition of an aggregating agent (Lumley & Humphrey, 
1981).
III.4 Secretion
(a) Degranulation
Stimulated platelets may selectively release the contents 
of their dense granules, alpha granules and lysosomes. The 
dense granule contents (3HT, ADP, ATP and Ca^*) can be selectively 
liberated by agents such as ADP or adrenaline with little 
concomitant secretion of alpha granule contents or lysosomal 
enzymes (Mills e_t al. , I968). Dense granule contents (with 
the notable exception of ATP) are pro-aggregatory and their 
main function is presumably, to promote the growth of a 
haemostatic plug. Release of the alpha granule contents and 
lysosomal enzymes normally requires stronger stimuli e.g. high 
concentrations of agonists like thrombin and collagen (Day & 
Holmsen, 1971)• However, some of the contents of the hetero­
geneous alpha granule population are secreted more readily
- 8 -
than the dense granule contents. Secretion is associated 
with granule centralisation which may be mediated by actomyosin 
contraction. Degranulation may result from fusion of the 
granule membranes with the inner parts of the SCCS (White, 1973)* 
Secretion of dense granule contents can be monitored by measuring 
released ATP by luciferin-luciferase luminescence (Feinman al_. , 
1977) or by a radio-isotopic (^^C- or ^H-5HT) prelabelling method.
(b) Secretion of newly-synthesized platelet products.
Stimulated platelets release arachidonic acid which is
rapidly converted to pro-aggregatory eicosanoids prostaglandin
(PCjC^, PGH^ and thromboxane (Tx^A^. Eicosanoid formation
constitutes a positive feedback mechanism to stimulate further
platelet aggregation, promote growth of a haemostatic plug
and cause local vascular constriction (Moncada & Vane, 1979)*
The mechanisms and significance of prostanoid formation are
discussed below (Section V.3)* Platelet arachidonic acid is
also metabolised by 12-lipoxygenase, especially in the presence
of inhibitors of cyclooxygenase such as aspirin or indomethacin.
This pathway of arachidonic acid metabolism leads to production
of 12-hydroperoxy—eicosatetraenoic acid (12-HPETE) which is
rapidly converted to 12-hydroxy-eicosatetraenoic acid (12-HETE).
Both are biologically active (12-HPETE > 12-HETE) as (l)
chemotactic and chemoattractant agents; (2) stimulators of
neutrophil degranulation; (3 ) probable mediators of anaphylactic
contraction of lung smooth muscle and (4) inhibitors of platelet
activation (Vargaftig et al., I98I). Eicosanoid formation and
/3 l4release can be monitored by a radio-isotopic ( H- or C- 
arachidonic acid) prelabelling technique; by bioassay of the
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active eicosanoids or by radioimmunoassay of the inactive 
breakdown products (e.g. TxB^ which is foxmed from TxA^)*
Activated platelets (as well as other inflammatory cells) 
may also synthesize and release platelet-activating factor 
(PAF; acetyl glyceryl ether phosphoryl choline). Vargaftig 
et al. (1981) proposed that PAF could be formed by (l) deacetyl- 
ation of membrane phospholipids, including analogues of phos­
phatidyl choline with an ether linkage at glycerol-sn-1 position, 
by a phospholipase A^-like enzyme to form lyso-PAF followed by
(2) acétylation, involving a hypothetical acetylating enzyme, 
at glycerol-sn-2. PAF has a wide range of biological actions, 
in addition to platelet activation, and may be an important 
mediator of inflammation (reviewed by Vargaftig e^ al., I98I).
111.5 Platelet energy metabolism
The energy required for the various platelet reactions 
is derived from glycolysis in the cytosol (utilising stored 
glycogen or extracellular glucose) and from oxidative phosphoryl­
ation in the mitochondria. The relative abundance of platelet 
glycogen granules, compared to mitochondria, is consistent 
with the platelet's metabolic energy being derived mainly 
by glycolysis rather than by oxidative phosphorylation 
(Gordon, I98I).
111.6 Synergism and desensitization
Platelets contain receptors for, and can be activated by, 
a number of agents which are normally present in the blood or 
which can be synthesized or secreted by the platelets themselves. 
When added individually to platelets, in vitro, the concentration:
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of agonists such as adrenaline, ADP, PAF and vasopressin 
required for stimulation of platelet aggregation markedly 
exceed those concentrations normally present in the blood 
(Scrutton & Wallis, I98I). Exposure of platelets, ijn vi tro, 
to two or more agonists can result in the synergistic 
stimulation of aggregation and dense granule secretion (i.e. 
produce a response which is significantly greater than the 
sum of the individual responses). Such synergistic responses 
have been observed when platelet aggregation is monitored 
turbi dome trie ally (O'Brien, 1964; Ardlie _et al. , I966; Mills & 
Roberts, I967; Nakanishi al. , 1971» Michal & Motamed, 1976; 
Grant & Scrutton, 1980a; Vargaftig al., I982). Synergistic 
induction of thrombocytopaenia has also been observed in vivo 
(Markwardt e_t al. , 1977)* This phenomenon may be of major 
importance in haemostasis and in the pathogenesis of occlusive 
vascular disease since it may permit significant action by 
agents which do not obtain the physiological concentrations 
required to have any effect alone. Although TxA^ formation 
and release of granule constituents are not prerequisite for 
synergism to occur (Rao et al», I980), the molecular mechanisms 
underlying this effect are largely unknown. It seems likely 
that positive agonist interactions will be mediated at the 
level of intracellular second messenger systems (Scrutton & 
Wallis, 1981). The biochemical basis of synergism has been 
investigated using tissues such as the parotid gland and pancreas. 
In the pancreas, agonist-induced enzyme release is a consequence 
of increased intracellular concentrations of cyclic AMP or 
free calcium ions. Synergism is only observed using combinations
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of agonists that act through different intracellular messengers, 
whereas desensitization is observed with agonists that share 
the same intracellular messengers (Gardner & Jensen, I980). 
Whether this general rule can be applied to other cellular 
systems such as the platelet remains to be determined.
The term desensitization describes a loss in cellular 
activity subsequent to the initial action of an agonist. This 
phenomenon occurs in a wide variety of cellular systems and 
is variously described as fade, tachyphylaxis, tolerance, 
refractoriness or subsensitivity. In specific, or homologous, 
desensitization pre-treatment with an agonist will inhibit 
responsiveness to the subsequent addition of agonists which 
act through the same but not different receptors. Non-specific 
or heterologous desensitization is associated with a general 
decrease in cellular responsiveness, irrespective of the 
receptors involved. Homologous desensitization is generally 
attributed to events at the specific receptor whilst heterologous 
desensitization is mediated via an effect(s) on the transduction 
processes which are common to different receptor types (see 
Section V).
There are a number of different potential mechanisms of 
desensitization. Acute desensitization of skeletal muscle 
nicotinic receptors is associated with rapid and transient 
changes in agonist-receptor binding affinity. Chronic de­
sensitization develops more slowly, is less rapidly reversible 
and is accompanied by receptor loss (down-régulâtion) and 
reduction in receptor sensitivity (Heidman & Changeux, 1978). 
Desensitization of hormone sensitive adenylate cyclase has
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been well characterised. In avian erythrocyte membranes, 
desensitization of P-adrenoceptor-mediated activation of 
adenylate cyclase is agonist-dependent and is prevented or 
reversed by antagonists (Lefkowitz & Williams, 1978). . In 
human astrocytoma cells, desensitization is apparently mediated 
by cyclic AMP-dependent phosphorylation reactions (Su e_t al. , 
1976), and in rat astrocytoma cells cyclic AMP-dependent 
desensitization is dependent on protein synthesis, presumably 
reflecting the generation of an endogenous inhibitor (Nickols 
& Brooker, 1979)* The process of heterologous desensitization 
is dependent upon cellular integrity and does not occur in 
membrane preparations.
The smooth muscle of guinea pig ileum responds to a range 
of compounds including acetylcholine, histamine and substance P. 
These are all coupled to stimulation of calcium influx from 
the extracellular space. In this system, substance P will 
induce homologous desensitization whilst both acetylcholine 
and histamine induce heterologous desensitization (Triggle,
1980). Here, homologous desensitization may reflect changes 
at the receptor level and heterologous desensitization is 
probably caused by membrane hyperpolarisation resulting from 
the electrogenic pumping of sodium ions that enter the smooth 
muscle cells during stimulus-induced depolarisation (Triggle,
1980).
Desensitization is also known to occur in studies of 
platelets vitro. Homologous desensitization can be demonstrate 
using a range of agonists including ADP, thrombin and vasopressin; 
addition of a subthreshold concentration of an agonist will
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inhibit responsiveness to the subsequent addition of the same 
agonist or agonists that act at the same but not other receptors 
( Schuman ejb al. , 1978; Huang & Detwiler, I986; Pollock & 
MacIntyre, I986). Although the molecular mechanisms of de- 
sensitization in platelets are not fully understood, the changes 
occurring in homologous desensitization are probably located 
at the receptor level rather than the common transduction 
processes of phosphoinositide hydrolysis and elevation of 
Ca^* ^ (MacIntyre & Pollock, I986). Recent evidence indicates 
a possible role for protein kinase C (see Section V ) in the 
induction of desensitization in a number of different cellular 
systems including platelets (Sibley et al., 1984; Drummond & 
MacIntyre, I983).
IV. Physiological and pathological roles of platelets
The main function of platelets, vivo, is to adhere to 
damaged blood vessel walls and initiate the haemostatic process 
necessary for the repair of vascular injury. Platelets do 
this firstly by adhering to the subendothelial collagen and 
secreting pro-aggregatory compounds such as ADP, 5HT and 
arachidonic acid metabolites in order to recruit more platelets 
into the haemostatic plug and secondly, by promoting efficient 
coagulation near the site of injury. Platelets promote 
coagulation in a number of ways; (l) by exposing platelet 
factor 3 (a procoagulant phospholipid complex) on their surface 
membrane in response to stimulation by collagen; (2) By 
carrying coagulation factor XI on their membranes which becomes 
activated when the platelets are in contact with collagen and
(3 ) by secreting procoagulant proteins from their alpha granules
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(e.g. fibrinogen, platelet factor 4 and -thromboglobulin).
Coagulation results from the conversion of prothrombin to 
thrombin which is itself a powerful platelet stimulant and 
which catalyses the conversion of fibrinogen to strands of 
fibrin which consolidate the haemostatic plug. Platelets may 
also promote wound healing by secreting mitogenic proteins 
including PDGF and P*-transforming growth factor which can 
stimulate smooth muscle proliferation (Gordon, 1981). Evidence 
in support of a role for platelets in haemostasis comes from 
the observation that deficiencies or defects in circulating 
platelets are associated with spontaneous haemorrhages from 
small vessels (e.g. see Tschopp ejb al. , 1974; Gordon & Milner, 
1976).
Platelets may also be involved in the maintenance of 
endothelial integrity. This is supported by the finding of 
increased vascular permeability in thrombocytopaenic animals 
(Johnson, 197l)« Platelets are capable of pinocytosis and 
exocytosis and may play an important role in scavenging 
particles from the blood (Van Aken & Vreeken, 1969)» There 
is some evidence that platelets could be involved in the 
inflammatory process (l) directly, by secreting agents which 
increase vascular permeability (e.g. 3HT) and (2) indirectly 
by stimulating leucocyte chemotaxis (via products of 12- 
lipoxygenase activity) and mast cell degranulation (Gordon & 
Milner, 1976).
The main pathological role of platelets is in the development 
of occlusive vascular disease by promoting thrombosis and 
atherosclerosis. Thrombosis is the pathological perversion of
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haemostasis and is characterised by thrombus formation in the 
presence or absence of vascular damage. Arterial thrombogenesis 
may be initiated by vascular trauma or by platelets interacting 
with damaged endothelial cells or by 'hyper-reactive* platelets 
forming aggregates without any vascular contact. The nature 
of the platelet or endothelial cell changes which promote 
thrombogenesis in the absence of gross vascular damage are 
largely unknown. Thrombosis can prove fatal when it results 
in occlusion of the cardiac or cerebral vasculature. Athero­
sclerosis is characterised by localised narrowing of the 
vascular lumen caused by formation of plaques containing 
fibrous tissue and lipid which produces focal thickening of 
the arterial intima. Although the contribution of platelets 
to atherogenesis is not fully established, they may participate 
in a number of ways; (l) by releasing agents which damage 
arterial endothelial cells (Mustard jejt ad., 1977); (2) by 
releasing factors which stimulate smooth muscle proliferation 
in the arterial wall (Ross & Glomset, 1973) and (3) through 
their involvement in the formation of persistent mural thrombi 
which are subsequently organised into intimai thickenings 
(Gordon & Milner, 197 6; Gordon, I98I). Platelets may also 
be involved in the pathological aspect of inflammation by 
releasing (a) a variety of inflammatory stimuli, e.g. PAP, 
eicosanoids, 3 HT; (b) lysosomal enzymes capable of degrading 
connective tissue and possibly (c) proteins that can increase 
vascular permeability (Gordon & Milner, 1976).
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V. Agonist-receptor-controlled transduction processes
Platelet responsiveness can be modulated by a number of 
different compounds which act to promote (stimulatory agonists) 
or retard (inhibitory agonists) platelet activation. These 
agonists are diverse in nature and act upon specific recognition 
sites or 'receptors*. Some of the platelet agonists which are 
thought to be of patho-physiological importance in the control 
of platelet reactivity and the receptor sub-types with which 
they combine to mediate their effects (where known) are listed 
in Table 1. Platelet receptors for agonist are generally 
assumed to be located on the plasma membrane although intra­
cellular receptors may exist for lipophilic compounds such 
as TxA^, the prostaglandins or PAP. Hence, transduction 
mechanisms must exist to allow the translation of external 
signals (i.e. agonist-receptor interaction) into changes in 
cellular responsiveness. This is normally achieved by the 
generation of internal signals which are carried by 'second 
messengers'. The second messengers can then either remain 
in the membrane or diffuse throughout the cell and combine 
with specific intracellular acceptors to modulate the activity 
or rates of the key biochanical reactions which control the 
cellular response (Figure 2; Berridge, I98I).
Since platelets are electrically non-excitable (MacIntyre 
& Rink, 1982; Doyle & Ruegg, I985), stimulus-induced changes 
in platelet reactivity must be mediated by chemical or electro­
neutral ionic processes. Indeed, the second messengers which 
thus far have been identified as important in the control of 
platelet reactivity are cyclic AMP, 1,2—diacylglycerol (DG),
TABLE 1. Some common platelet agonists and receptors.
Agonist Receptor Reference Response
Thrombin *I\1.C. Detwiler & McGowan, 1985
Collagen *N.C. --
ADP 2^l Gordon, 1986
TxAg/PG
endoperoxide TP Kennedy _et , 1983 Stimulation
PAF Paf^ Lambrecht & Parnham, 1986
Vasopressin Pollock & MacIntyre, 1986
5HT 5HT2(S2) de Chaffoyde Courcelles 
et al., 1985
Adrenaline a 2 Kerry & Scrutton, 1985
PGiyPGE^ IP Kennedy _et al., 1983
PGOg DP Kennedy at al., 1983
Inhibition
Adenosine
*2
Daly, 1982
Adrenaline P Jakobs _et al., 1978
*N.C. = receptor subtypes not classified.
Agonist o
Receptor
G protein
Amplifier enzyme
Out
Plasma
membrane
In
Second messengers O'' - O
O O ~ o
Acceptors 
(internal effectors)
T
Cellular 
response
Figure 2. General mechanism of stimulus-response coupling, 
See text for explanation.
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inositol 1, 5-trisphosphate (ins (l, 4, 3 )P^ ) and jca^^j
Inhibition of platelet responsiveness is associated with
agonist-induced elevation of the intracellular concentration
of cyclic AMP (Haslam ejfc a^.> 1978) whilst stimulation is
associated with agonist-induced elevations in the intracellular
concentrations of DG, Ins(l,4,3)P^ and j^Ca^^ ^  (Kaibuchi ejb al. ,
1983; Streb ejt al. , I983; O'Rourke aJL. , I983; Rink ejb al. ,
1982). The two second messenger pathways apparently have much.
in common (Fig. 2). In both, the receptor molecule on the
outer surface of the cell transmits information across the
plasma membrane via a family of *G' proteins: guanine nucleotide-
binding regulatory proteins which become active upon binding
of guanosine triphosphate (GTP)• The G proteins activate an
'amplifier* enzyme located on the inner face of the membrane
and which then converts precursor molecules into second
messengers. In the inhibitory second messenger pathway the
enzyme adenylate cyclase converts Mg^^.ATP into cyclic AMP
whilst in the stimulatory pathway, the enzyme phospholipase C
converts the membrane inositol-containing phospholipids
(phosphatidyl inositol 4,3-bisphosphate: PIP^ and possibly
also phosphatidyl inositol: Ptd Ins and phosphatidyl inositol
4-phosphate: PIP) into DG and the corresponding inositol
phosphates including Ins(l, 4 , 3 •  The final step in both
pathways is also similar: the second messengers interact
with their acceptor proteins to induce a conformational change
in their three dimensional structure. The acceptors for cyclic
2+
AMP, DG, and in some cases Ga , are components of distinct 
protein kinase enzymes which, upon activation, can phosphorylate
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various platelet proteins to induce functional changes (Krebs, 
1984; Berridge, 1983)» However, Ca^ **" can also directly modulate 
the activity of some enzymes in the absence of increased 
phosphorylation. Platelet responsiveness is ultimately 
controlled by the interactions of the two different second 
messenger pathways which effectively form a bidirectional 
control system similar to that defined by Berridge (1973)»
In addition to the second messenger pathways so far 
discussed, there may also be a role for cyclic GMP in the 
control of platelet function. Agents such as sodium nitro- 
prusside, which elevate intracellular cyclic GMP levels inhibit 
platelet function by a method which is poorly understood (Haslam 
et al., 1980). Cyclic GMP levels have been shown to rise in 
response to the addition of certain platelet stimulatory 
agonists. This occurs after a relatively long lag phase (Haslam 
et al., 1980). In some other cell types, guanylate cyclase, 
the enzyme that makes cyclic GMP from GTP, is not connected to 
a receptor and cyclic GMP formation often occurs after the 
activation of phosphoinositide hydrolysis (Berridge, 1983)» 
Since, in platelets, cyclic GMP inhibits agonist-induced 
elevation of ^Ca^^j it is possible that cyclic GMP could 
act as a negative feed-back regulator to limit platelet 
responsiveness (MacIntyre et al., 1983a)» Changes in intra­
cellular pH have also been shown to correlate with a number of 
cellular processes, suggesting a possible second messenger 
role for H^. It has been suggested that thrombin-induced 
platelet activation correlates with an increase in cytosolic 
pH (Horne e_t ^ .  , I98I). However, this finding is disputed 
(Rotman & Heidman, I982) and the lack of effect of other
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agonists on intracellular pH indicates that this may not be 
an important regulatory mechanism in platelets (Huang &
Detwiler, I986). The receptor-controlled second messenger 
systems are discussed in more detail below.
V.1. Cyclic AMP and platelet function
One of the first indications that cyclic AMP might be
involved in the regulation of platelet function was the
observation by Marcus and Zucker (1965) that addition of cyclic 
AMP to platelets resulted in inhibition of platelet aggregation. 
This was supported by the observation that phosphodiesterase 
inhibitors blocked ADP-induced aggregation (Ardlie ejfc al., 1967)» 
Since then, it has become clear that many of the agents which 
inhibit platelet activation produce their effect through 
increases in cyclic AMP levels (Haslam e_fc al., 1978). Besides 
inhibiting the functional platelet responses (Hawiger et al., 
I98O; Feinstein al., I98I) initiated after exposure to 
stimulatory agonists, the inhibitory effects of cyclic AMP are 
also evident on the transduction processes that link receptor 
occupancy to cellular activation (Kaser-Glanzmann et al., 1977; 
Fox e_fc al. , 1979; Feinstein e_t al. , I983; Sano eib al• , 1983; 
Lapetina, 1984). Platelet receptors for some agonists can be 
coupled to inhibition of adenylate cyclase activity (Aktories 
& Jakobs, 1983). Whether agonist-induced platelet activation 
could result from a decrease in the basal level of cyclic AMP, 
perhaps in some specific pool, is controversial (Salzman, 1972; 
Haslam ejfc al• , 1978).
—  20 —
Since the initial discovery that cyclic AMP acts as an 
intracellular second messenger (Sutherland & Rail, I960) 
intensive research efforts have been devoted to unravelling 
the detailed control mechanisms which regulate the generation 
and subsequent actions of this molecule. Studies in various 
cell types have clearly indicated that the membrane-bound, 
hormone-sensitive cyclic AMP generating system is composed of 
at least three distinct subunits. These include the receptors 
which discriminate the specificity of the external signals; 
the G proteins and adenylate cyclase which is the catalytic 
subunit of the complex (Schramm al. , 1977; Rodbell, I98O; 
Schramm & Selinger, 1984; Aktories & Jakobs, 1983)» This is 
illustrated schematically in Figure 3»
V.l.(l) Receptors
Some of the agonists and receptors coupled to stimulation 
or inhibition of adenylate cyclase in platelets are listed in 
Table 2. Receptors for PGI^ have been identified by radio- 
ligand-binding studies: two classes of binding site have been
identified: a low affinity, high capacity site (Kd = 1.6 p,M;
4000 sites per cell) and a high affinity, low capacity site 
(Kd = 10 nM, 30 sites per cell) which apparently corresponds 
to the functional PGI^ receptor (Siegl, 1982). PGE^ and 
6ketoPGE^ also are agonists at the PGI^ receptor, which has 
been termed an IP receptor (Kennedy e_t al. , 1983)» PGD^ acts 
via distinct so-called DP receptors. Radioligand-binding 
studies reveal a single class of PGD^ binding sites: Kd =
30-400 nM, 200-800 sites per cell (Siegl e_fc al., 1979)»
Platelet receptors for adenosine which are coupled to stimulation 
of adenylate cyclase have been identified as conforming to
Regulation of cyclic AMP formation by platelets
PGD, AdrenalineI \
Out
Plasma
membrane
ATP
PDE
CAMP ►  AMP
i
Kinase AI
Inhibition
Figure 3. Schematic representation of receptor-mediated control of cyclic 
AMP metabolism.
See text for explanation,
TABLE 2. Agonists and receptors which influence adenylate cyclase 
activity in intact platelets.
Agonists
(Receptors)
G Proteins
PGIg (IP)
PGE^ (IP)
PGDg (DP) "s
Adenosine (A^ )
Catecholamines ( ^^)
Catecholamines (
N.
ADP (Pg-r)
1
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the subtype on the basis of structure-activity relationships
(Daly, 1985)» Radioligand binding analyses reveal a single
class of adenosine binding sites with Kd 12 hM (Ukena a^.,
1986). The presence of P-adrenoceptors on human platelets is
indicated by the ability of isoprenaline and adrenaline to
stimulate adenylate cyclase activity in the presence of an
a-adrenoceptor blocking agent (Abdulla, I969; Jakobs e^ al.,
1978). Radioligand binding analyses reveal that the platelet
P-adrenoceptors are of the P^-subtype and are present in very
small numbers : around l/lO to l/20 of the platelet a^-adreno-
ceptors (Kerry & Scrutton, I983; Barnett ejb aJ^ . , 1985)*
The predominant platelet receptor for adrenaline has been
characterised as belonging to the a^-subtype by pharmacological
analyses using a range of agonists and antagonists (Hsu ^t al.,
1979» Grant & Scrutton, 1980b; Barnett ^t al., 1983)* The a^-
adrenoceptor is coupled to inhibition of adenylate cyclase in
intact platelets (Aktories & Jakobs, I983). Radioligand-binding 
3
studies using H -yohimbine suggest that there is a single 
class of binding sites; Kd = 3nM and 270 sites per platelet 
(Kerry & Scrutton, 1983)* Platelet receptors for ADP are also 
coupled to inhibition of adenylate cyclase in intact platelets 
(Haslam & Rosson, 1973). Radioligand-binding studies using 
a stable analogue of ADP reveal a single class of binding sites 
for ADP on human platelets: Kd = I3 hM and 400-1200 sites per 
platelet (Macfarlane et al*, 1983)* Pharmacological analyses 
using a range of compounds indicate that the receptor for ADP 
on human platelets is unique and it has thus been designated a 
P2T”P^^i'*^o^®ceptor (Cusack ejb al. , 1983; Gordon, I986).
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Receptors for PAF, vasopressin and thrombin can also be 
coupled to inhibition of adenylate cyclase in platelet lysates, 
but not in intact cells (Haslam & Vanderwel, 1982; Vandenrwel 
et al., 1983; Aktories & Jakobs, 1984). Kloprogge & Akkerman 
(1983) have identified a single class of PAF binding sites 
(Kd = 17 nM; 280 sites per cell) whilst Tuffin ejfc aJL. (1985) 
have identified two distinct PAF binding sites. Platelet 
receptors for PAF have been termed Paf^ and are distinct from 
the Paf^ receptor subtype present on macrophages (Lambrecht & 
Parnham, I986). Platelet receptors for vasopressin belong to 
the receptor subtype. Radioligand-binding analyses reveal 
a single class of binding sites Kd ranging from 1.3 - 24 nM 
(depending upon the presence or absence of divalent cations) 
and 9O-I3O sites per cell (Pletscher ejfc ad. , I983; Vittet al. , 
1986). The serine protease thrombin, is the most potent and 
efficacious platelet agonist. Two classes of thrombin binding 
site have been demonstrated; a high affinity low capacity 
site (Kd = 10 nm, 3OO sites per cell) and a lower affinity 
high capacity site (Kd = 100 nM, 3^,000 sites per cell)
(Detwiler & McGowan, I983)' Whether thrombin-induced platelet 
activation is a consequence of proteolytic hydrolysis of a 
particular substrate or of a classical agonist-receptor 
interaction is not known (MacIntyre et al., I986).
There is some dispute over whether receptors for TxA^ are 
coupled to inhibition of adenylate cyclase in intact platelets. 
Miller al. (l977) reported that TxA^ inhibited PGE^- 
stimulated cyclic AMP accumulation whilst Best ejb al. (1979) 
found no effect of the stable TxA^ analogues U44069 and U466l9
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on PGE^-indnced cyclic AMP formation. Using radiolabelled 
U44o69 as ligand, two high affinity binding sites have been 
identified, one of which (Kd = 70 nM; 2000 sites per cell) 
has the pharmacological characteristics of the receptor mediating 
platelet activation (Armstrong e_t al. , 1983)* Platelet receptors 
for TxA^ have been termed TP receptors (Kennedy ejb al. , I983) 
but may differ from TxA^ receptors situated elsewhere e.g. 
vascular smooth muscle.
V.l.(2) G Proteins
The stimulatory G protein, N^, was first identified with 
GTP-photoaffinity analogues as a heat-stable 42,000 Mr protein 
in detergent extracts of avian erythrocyte membranes (Pfeuffer, 
1977; 1979)* The binding of an agonist to the stimulatory 
receptor, R^, induces a conformational change which is transmitted 
through the plasma membrane to N^, making it more susceptible 
to GTP binding. The binding of GTP to constitutes an 
*on-reaction*. That is, a conformational change occurs enabling 
to activate adenylate cyclase resulting in increased 
formation of cyclic AMP. GTP bound to is then hydrolysed 
to form GDP resulting in loss of activity of N^. This ’off- 
reaction* is catalysed by the GTPase activity of (Rodbell,
1980). The conformational changes in resulting from GTP 
binding are reflected in changes in the agonist binding affinity 
of R^. GTP-N^ binding generally results in reduction of agonist 
high affinity binding at R^ (Jakobs et al., I986). Cholera 
toxin has been shown to ADP-ribosylate in the presence of 
a protein cofactor termed ADP-ribosylation factor; ARE (Kahn
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& Gilman, 1984). This leads to inhibition of GTPase activity 
and prevention of the off-reaction, effectively resulting in 
prolonged stimulation of cyclic AMP production. This has been 
observed in a variety of cell types, even in the absence of 
hormones (Pinkelstein, 1973; Cassel & Selinger, 1977; Cassel 
& Pfeuffer, 1978). This property of cholera toxin has made it 
a valuable tool in probing the role of N^. However, this toxin 
does not increase adenylate cyclase activity when added to 
intact platelets. Human platelets are apparently defective 
in ganglioside receptor(s) and/or other factors required for 
processing and activating cholera toxin (Hughes & Insel, 1983; 
Sekura et ^ .  , I983).
The existence of an inhibitory G protein, N^, was first
indicated by the ability of GTP to inhibit adenylate cyclase
in rat adipocyte membranes (Creyer e_fc al., 1969)* As with the
stimulatory system, the binding of agonists to inhibitory
receptors, R., results in association of R. with N. and the 
■ ^ 1  1 1
binding of GTP to N^. This leads to a conformational change 
in which allows it to inhibit adenylate cyclase. Subsequent 
hydrolysis of GTP to GDP results in loss of inhibitory activity 
of (Rodbell, I980). GTP-binding to results in modification 
of the high affinity binding of agonists to R^ (Grandt ejb a^. ,
1982). Pertussis toxin (islet-activating protein) has been 
shown to ADP-ribosylate resulting in inhibition of formation 
of the activated N^-GTP species thereby attenuating agonist- 
R^-dependent control of adenylate cyclase activity (Birnbaumer 
et al., 1985). This property of pertussis toxin has proven 
very useful in probing the role of in stimulus-response 
coupling. Pertussis toxin has no effect on cyclic AMP metabolism
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in intact platelets since they lack the glycoprotein(s) or 
ganglioside(s) required for binding and uptake of the toxin 
into the cytosol (Ui, 1984; Sekura ejfc al., 1983)* N^-mediated 
inhibition of adenylate cyclase can also be attenuated by 
proteolytic enzymes such as trypsin and the sperm protease(s) 
known as ninhibin ( Jakobs e_t al. , 1984).
and are structurally similar heterotrimers consisting 
of a larger a-subunit (4l - 4 3 , 0 0 0  M^) and two smaller sub­
units, ; 3 3 , 0 0 0  and y ; 1 0 , 0 0 0  (Gilman, 1984). The 
1^ - and  ^-subunits of and are functionally indistinguish­
able. These two subunits are closely associated as a - complex 
and are assumed to act as inhibitors of the a-subunits (Smigel 
et al., 1984). It has been proposed that, upon agonist-receptor 
interaction, the G proteins dissociate into free a-subunits 
and -complexes (Gilman, 1984). It is the a-subunits which 
are substrates for ADP-ribosylation in the presence of 
cholera toxin (a^) or pertussin toxin (o_) (Ui, 1984). G 
protein functioning can also be modulated by stable (non- 
hydrolysable) analogues of GTP (GppNHp, GTP^S) or GDP (GDPP S) 
resulting in persistent activation or inhibition, respectively 
(Jakobs & Aktories, I983)*
V.l (3 ) Adenylate cyclase
Compared to the detailed knowledge of the structure and 
function of agonist receptors and G proteins, relatively little 
is known of the structure and functioning of the adenylate 
cyclase subunit itself. It has recently been purified from 
rabbit myocardium and identified as a glycoprotein (M^ 130,000)
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which traverses the plasma membrane (Pfeuffer ejb ad., I983). 
Activity of the adenylate cyclase moiety can be modulated 
independently of receptors or G proteins by a number of agents. 
The diterpene, forskolin, stimulates adenylate cyclase from 
all cell types so far examined. This effect is probably 
mediated via interaction with a site or sites on the catalytic 
subunit or closely related protein (Seamon & Daly, I98I). In 
addition, forskolin also markedly potentiates R^-N^-stimulated 
adenylate cyclase activity, particularly in intact cells 
(Daly, 1984). The apparently incongruous finding that low 
concentrations of forskolin can inhibit adenylate cyclase 
activity of platelet membrane preparations has recently been 
reported (Watanabe & Jakobs, I986). Adenosine and some of its 
analogues can inhibit adenylate cyclase activity via an action 
at the so-called *P-site' which is probably associated with 
the catalytic subunit (Londos & Wolf, 1977; Florio & Ross,
1983). The physiological role of this P-site action of adenosine 
analogues is uncertain but it may represent an endogenous 
feedback mechanism to limit agonist-induced stimulation of 
adenylate cyclase (Jakobs et al., I986).
V.l.(4) Cyclic AMP phosphodiesterase
The other important enzyme in the control of cyclic AMP 
metabolism is cyclic 3 ' > 3 *-T^ucleotide phosphodiesterase which 
catalyses the inactivation of cyclic AMP by conversion to 
3 '-AMP. This enzyme was originally studied by Sutherland and 
colleagues (Butcher & Sutherland, I962) and it is now clear 
that multiple forms of phosphodiesterase exist. The different
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isozymes have been classified according to their substrate 
specificity: cyclic nucleotide phosphodiesterase (hydrolyses
both cyclic AMP and cyclic GMP), cyclic AMP phosphodiesterase 
and cyclic GMP phosphodiesterase. Subclassifications within 
these groups are based upon the regulatory and kinetic properties 
of the isozymes. Thus, cyclic AMP phosphodiesterase may be 
Ca^’*'/calmodulin-stimulated, cyclic GMP- or cyclic AMP-stimulated 
and may have low or high 'Km' (Beavo ejfc al. , I982). Pichard 
& Cheung (1976) reported three interconvertible forms of cyclic 
nucleotide phosphodiesterase in platelet soluble fractions.
The rate of cyclic AMP metabolism was stimulated by cyclic AMP. 
Coquil et al. (I98O) reported the presence of a cyclic GMP-
stimulated soluble cyclic nucleotide phosphodiesterase in 
platelets.
Elevations in platelet cyclic AMP content in response to 
inhibitory agonists like PGI^ or PGD^ are transient. The 
delayed decline in cyclic AMP levels correlates with increased 
cyclic AMP phosphodiesterase activity. This activation of 
phosphodiesterase activity is an indirect effect which may 
occur as a consequence of elevated cyclic AMP levels and could 
represent a homeostatic mechanism for the regulation of 
platelet cyclic AMP metabolism (Pichard & Cheung, 1976;
Alvarez et al., I98I). Cyclic nucleotide phosphodiesterase 
activity can be inhibited by 1-isobutyl 3-methyl xanthine 
(Marquis e_t ad., I969). This results in elevation of intra­
cellular cyclic AMP concentration and marked potentiation of 
agonist—induced elevations in cyclic AMP levels (Alvarez et al., 
1981).
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V.l. (5) Mechanism of action of cyclic AMP
Evidence from different cell types indicates that the 
many actions of cyclic AMP are mediated via activation of a 
protein kinase enzyme called cyclic AMP-dependent protein 
kinase or kinase A (Flockart & Corbin, 1982; Krebs, 1984; 
Berridge, 1983)* This enzyme has two principal classes of 
isozymes labelled type I and type II on the basis of their 
elution from DEAE-cellulose (Corbin et al., 1975)» The ratio 
of these different isozymes and their subcellular distribution 
varies in different tissues (Corbin ad., 1973)* The enzymes 
are tetramers consisting of two regulatory (r) and two 
catalytic (c) subunits. The catalytic subunits are identical 
in both isozymes and the molecular weight is around 40,000 M^. 
The regulatory subunits have molecular weights of around 
49,000 M^: type I and 3^‘"56,000 M^: type II (Flockhart &
Corbin, I982). The binding of cyclic AMP to the regulatory 
subunits induces a conformational change causing a decrease 
in the affinity of the regulatory dimer for the catalytic 
subunits. This results in the physical dissociation of the 
catalytic and regulatory subunits according to the following 
equation (Corbin, I983):-
R^C^ + 4cyclic AMP -7.-=^  R^* (cyclic AMP)^ + 2C
When the catalytic subunits are bound to R, they are inactive 
and the addition of cyclic AMP results in the liberation of 
free active C which can phosphorylate a number of different 
proteins (Krebs, 1984). Each R subunit monomer contains 
two different cyclic AMP binding sites and this allows intra-
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Chain cooperativity for cyclic AMP binding (Corbin al.,
1982; Beeb ejt al.» 1984). Thus, small increments in intra­
cellular cyclic AMP concentration can result in marked increases 
in cyclic AMP bound to R and significant enhancement of cyclic 
AMP-dependent protein kinase activity. For this reason, 
measuring cyclic AMP-dependent protein kinase activity ratio 
(i.e. the fraction of this enzyme which is in the active form) 
often gives a very sensitive index of small changes in cellular 
cyclic AMP content (Corbin, I983).
The importance of cyclic AMP-dependent phosphorylation 
in the control of platelet reactivity has been suggested by a 
number of findings. Inhibition of platelet activation by agents 
which elevate cyclic AMP content is associated with enhanced 
phosphorylation of several platelet proteins with apparent M^ 
of 22,000: 24,000; 50,000 and 240,000 (Haslam ^  , I98O;
Huang & Detwiler, I986). Addition of PGF^ to platelets results 
in increased phosphorylation of polypeptides which may be 
involved in the stimulation of active transport of Ca^*
(Haslam ejb al. , 1979» Kaser-Glanzmann al. , 1979)* In 
addition, purified myosin light-chain kinase is inhibited 
after phosphorylation catalysed by cyclic AMP-dependent 
protein kinase (Hathaway et al.» I98I). Both types I and II 
cyclic AMP-dependent protein kinase are present in platelets. 
Type I is mostly membrane-bound while type II is located in 
the cytosol (Salama & Haslam, 1984). Hence, circumstantial 
evidence indicates that inhibition of platelet activation by 
cyclic AMP is mediated via cyclic AMP-dependent protein 
kinase(s).
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Evidence from a number of different cell types indicates 
that cyclic AMP often acts primarily to modulate the activity 
of another second messenger pathway (Berridge, 1985)» In 
agreement with this general rule, cyclic AMP acts in platelets 
to modify the rate of production and inactivation of the 
stimulatory second messenger molecules Ca^^ and DAG (Kaser- 
Glanzmann ejfc ai., 1977; Feinstein e_t al. , I983; Lapetina, 1984). 
Moreover, besides influencing the concentration of stimulatory 
second messengers, cyclic AMP may also antagonize their 
effects to prevent or reverse agonist-induced platelet activation 
(Hathaway ejk al. , I98I).
V.2. Calcium, inositol phospholipid metabolism and platelet 
function
V.2.(l) Role of calcium in stimulus-response coupling
The importance of calcium in cellular physiology was first 
indicated over 100 years ago when Ringer reported that frog 
muscle contraction only occurred when calcium was present in 
the bathing medium (Ringer, I883). Since then it has become 
clear that intracellular free Ca^* regulates not only contraction 
but also many other cellular processes. A role for Ca^^ in 
the control of platelet reactivity was first suggested by 
the observation that Ca^* ions were required for thrombin- 
induced secretion at 15°C but not at 37°C (Grette, I962).
Studies using the ionophore A23I87 provided the best early 
evidence that Ca^^ is involved in mediating the responses of 
platelets to stimulation; i.e. shape change, aggregation, 
degranulation, glycogenolysis and arachidonic acid liberation
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(Feinman & Detwiler, 1974; White ^t al., 197^; Massini & Luscher, 
1974). The extents of dense granule release and prostanoid 
biosynthesis in response to A23187 are at least equivalent to 
those induced by thrombin (Feinman & Detwiler, 1974). 
Interestingly, A23I87 was shown to be ineffective as an 
activator of phospholinositide metabolism (Rittenhouse-Simmons,
1981).
Until recently, direct measurement of platelet cytosolic 
free calcium ion concentration (^Ca^^j^) has been difficult 
since platelets are too small to allow introduction of electrodes 
or microinjection of indicators. Hence several indirect 
approaches have been used with some success. Chlortetracycline 
has been used in platelets as a probe of membrane-bound Ca^* 
(Caswell, 1972). This technique has been used to demonstrate 
a decrease in membrane-associated Ca^^, measured as a decrease 
in fluorescence, which preceded secretion in response to 
thrombin or trypsin (Feinstein, I980). This was the first 
evidence of an agonist-induced shift in intracellular Ca^* 
which preceded the response. Agonist-induced modulation of
45 2+Ca association with platelets has also been monitored 
(Owen et al., I98O). ^^Ca^'*’ binds to the outer surface of the
platelet plasma membrane and can also be taken up into two 
intracellular pools; a rapidly exchanging pool located in the 
cytosol and a more slowly exchanging pool which probably 
represents the DTS (Brass, 1984). It has been reported that 
adrenaline, but not ADP, stimulates increased ^^Ca^^ association 
with platelets and this apparently represents an increase in
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both ^Ca —binding and ^^ Ca^ "*" influx into the platelets 
(Owen et al. , I980). The role of ^ in the control of
platelet function has also been investigated using platelets 
made permeable to Ca^* and other small molecules, by high 
voltage electrical discharge. Thus, |ca^^j could be manipulated 
hy alteration of the extracellular milieu thereby allowing 
equilibration of jca^^j with the imposed jca^^j ^  (Knight & 
Scrutton, I980).
Recently, a technique has been developed which allows 
direct measurement of |ca^^j in small intact cells including 
platelets (Tsien, I98O; Tsien ^  ^ .  , 1982a,b). i
reported by the fluorescence of a Ca^^-indicating dye trapped 
in the cytosol. The dye, called Quin2, is a calcium chelator 
which is relatively indifferent to Mg^^ and and undergoes 
fluorescence changes in response to calcium binding. Although 
Quin2 is a polycarboxylate anion which seems not to associate 
with or cross membranes significantly, it can be incorporated 
into intact cells if the carboxylate groups are suitably 
esterified. The resulting derivative, Quin2-acetoxymethyl 
ester (Quin2-AM) is uncharged, lipid-soluble and membrane- 
permeant, and is cleaved back into the parent compound by 
cytoplasmic esterases (Tsien, I980). Platelets suspended in 
platelet-rich plasma are incubated with the ester (30 min;
37°C) which penetrates the membrane and is hydrolysed to 
impermeant Quin2 which is then effectively trapped within the 
platelet cytosol (Tsien at al., 1982c).
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The available evidence indicates that the dye is distributed 
throughout the cytosol but not into mitochondria, lysosomes, 
dense tubular system or secretory granules (Tsien et al., I983). 
Fluorescence levels can be calibrated in terms of* ^Ca^^j by 
exposing the dye to known ^Ca^^j at the end of the experiment 
t>y lysing the cells and titrating the Ca^^ in the lysate with 
the chelator, EGTA. This technique reports a resting |ca^^j 
in platelets of around lOOnM. This is in agreement with the 
C^a^ '*'j ^  detected in different cell types by a variety of other 
techniques. Rapid, concentration-dependent increases in 
platelet ^Ca^^j have been reported in response to a range 
of stimulatory agonists including thrombin, PAP, vasopressin,
ADP, the endoperoxide analogue U44o69> 3HT and the calcium 
ionophores A23187 and ionomycin (Rink ejb al. , 1982; Hallam 
et al., 1984a; MacIntyre ejk al. , 1985b).
Quin2 has been used extensively in a range of cell systems 
to monitor changes in jca^^j . However this technique does 
have some weaknesses. In particular, the relatively low 
fluorescence intensity of Quin2 necessitates the use of intra­
cellular concentrations of up to ImM (Tsien ejfc ^ .  , 1982c).
Such high intracellular concentrations inevitably result in 
buffering of and the blunting of agonist-induced
elevations in Quin2 indicates increased
by an increase in fluorescence intensity when excited at 
339nm. Absolute fluorescence intensity is difficult to 
standardise since it is dependent upon a number of variables 
including dye concentration, tissue thickness and other factors
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such, as lamp intensity and detection efficiency. Whilst these 
factors can be standardised to a large extent, it is often 
difficult to obtain absolute values of (Tsien et al.,
1985).
Tsien et al. (1985) have recently reported the development 
of a new dye called *fura2’ which overcomes some of the problems 
associated with Quin2. Fura2 gives an approximate 30—fold 
greater fluorescence intensity when compared with Quin2 under 
identical conditions. Hence, with fura2 smaller intracellular 
concentrations are required resulting in less buffering of 
jca^'^j^. In addition, fura2 shifts its excitation peak upon 
binding Ca^* from around 340 to 360nm and both bound and free 
species have high fluorescence intensity. Hence, the ratio of 
Ca^^-bound to free dye can be monitored to give a measure of
K1i- Fura2 is less sensitive to other divalent cations
pi p , p , p .
(such as Mg , Mn , Zn and Fe ) than Quin2 and also has a 
larger dissociation constant (Kd) for Ca^^ than Quin2. This 
permits the measurement of higher Ca^* ^ . For these and 
other reasons, fura2 may eventually supercede Quin2 as the 
dye of choice for studying ^Ca^^j ^  in platelets and other cell 
systems (Tsien al. , 1983)»
Recently, a method has been developed for the incorporation 
of the calcium-sensitive photoprotein aequorin into platelets 
(Johnson et al. , I983)' The resting platelet jca^ '^ 'j ^  reported 
by aequorin is ten-fold higher than that indicated by Quin2.
This may indicate the existence of zones of elevated 
within platelets which are detected by aequorin but not by
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Quin2 which reports the average [ca^+j^ (Johnson _et , I985).
Elevations in luminescence of platelets loaded with aequorin 
have been observed in response to all agonists that evoke 
changes in Quin2 fluorescence and by some, e.g. adrenaline 
and PMA, that do not (Ware ^  ^ .  , I986).
Rink _et aJ. (1982) have used Quin2 and the Ca^^-ionophore 
ionomycin to estimate the extent of ^Ca^^j required to evoke 
different platelet responses. They concluded that shape change, 
dense granule secretion and aggregation result when 
is elevated to 0.3; 0.8 and 2p,M respectively. Thrombin, 
however, was able to induce platelet responses at ^Ca^^j 
below these * threshold’ levels indicating that is not
the sole intracellular messenger mediating thrombin-induced 
platelet activation. The extent of agonist-induced elevations 
in C^a^ '*’J^, as reported by Quin2, are reduced by around 80^ 
when ^Ca^^j ^  (imM) is removed by the addition of EGTA (Rink 
et al., 1982; MacIntyre et al., 1983c). It is concluded from
this that agonist-induced elevations in derive from
2+ 2+ both influx of extracellular Ca and mobilisation of Ca
from internal stores.
The nature of the platelet internal Ca^* store(s) has 
been extensively investigated. Around 959^  of the platelet 
calcium content is protein-bound (Steiner & Tateishi, 1974).
More than 609  ^of platelet calcium is in the dense granules 
(Murer, I969) in a secretory pool which is not in equilibrium 
with the cytosol and presumably plays no role as a source of 
second messenger Ca^^. Platelets also contain mitochondria
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which can sequester calcium. The finding that secretion can 
occur normally in the presence of inhibitors of mitochondrial 
respiration suggests that mitochondrial calcium fluxes may 
not have any significant role in stimulus—response coupling 
(Friedman & Detwiler, 1975; Huang & Detwiler, I986). It has 
been suggested that the platelet dense tubular system (DTS) 
plays a role analogous to that of the sarcoplasmic reticulum 
in muscle (White, 1973)* This is supported by the histochemical 
identification of a (Ca^*, Mg^ '*’)-ATPase in the platelet DTS 
(Cutler et al., 1978). A Ca^^-ATPase is a presumed requirement 
for any Ca^"*^-sequestering organelle. A platelet membrane 
preparation capable of concentrating Ca^* in an ATP-dependent 
manner has been described (Kaser-Glanzmann, 1977; 1979)* Ca^*-
uptake by this membrane fraction is enhanced by cyclic AMP, 
possibly via cyclic AMP-dependent phosphorylation of a 22 
kilodalton (kda) molecular weight protein (Kaser-Glanzmann 
et al., 1977; 1979)* This 22 kda protein resembles phospholambam, 
the cyclic AMP-dependent regulator of Ca^* transport in cardiac 
sarcoplasmic reticulum (Tada et al., 1978). Ca^^ uptake by 
the DTS is also promoted by elevated jua^^j ^  and is blocked by 
some calmodulin antagonists (Enouf & Levy-Toledano, 1984).
At around lOOnM, the resting |ca^^j in platelets is
approximately 10^-fold less than the free in plasma.
Hence, homeostatic mechanisms must exist to maintain this low
jca^'^J^. This is achieved by systems which act to limit Ca^^
2+influx and promote Ca sequestration and extrusion. Cyclic 
AMP may be involved in the maintenance of low [ c a ^ ^ j b y  
impairing Ca^* influx or mobilisation and/or by promoting 
Ca^* sequestration and extrusion (Kaser-Glanzmann et ,
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1977; 1979; Feinstein et al., I98I). The mechanism of active 
2+
Ca extrusion across the plasma membrane is unknown. However, 
a Ca pump similar to that present in erythrocyte membranes 
has recently been identified in purified human platelet plasma 
membrane vesicles (Enyedi £t ^ .  , I986).
The molecular mechanism underlying agonist—induced 
elevations in |ca^^j are not fully understood. Generally, Ca^* 
enters cells via voltage-operated channels (VOC) which open in 
response to membrane depolarisation or receptor—operated channels 
(roc) which open as a direct consequence of agonist-receptor 
interaction. Platelets are not electrically excitable and 
hence, agonist-induced Ca^^-influx into platelets must be 
mediated via ROC (MacIntyre & Rink, 1982; Doyle & Ruegg, 1985)* 
There is evidence that agonists open divalent cation channels 
in the plasma membrane of human platelets (Hallam & Rink, 1985)» 
Agonist-induced Ca^”*" influx and mobilisation may be associated 
with receptor-controlled phosphoinositide metabolism (Section
V.2 .(3 )).
V.2.(2) Mechanism of action of calcium
Calcium can act in two ways; (l) by direct combination 
with the target enzyme; or (2) via interaction with the 
ubiquitous Ca^^-acceptor protein calmodulin (Cheung, I980).
The presence of calmodulin in platelets has been demonstrated 
(Muszbek et ^ . , 1977) and calmodulin has been shown to be a 
subunit of platelet myosin light chain kinase (Dabrowska & 
Hartshorne, 1978; Hathaway & Adelstein, 1979). Thrombin-
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induced platelet activation is associated with enhanced 
phosphorylation of a number of proteins* Phosphorylation of 
two proteins, in particular has been detected by a number of 
different groups. These proteins have molecular weight 20kda 
and 4-0—47kda and are referred to as the 2OK and 4OK proteins 
(Lyons at aT., 1975; Haslam & Lynham, 1977). The 2OK protein 
has been identified as the light chain of myosin and its 
phosphorylation is a Ca^^—calmodulin—dependent reaction 
(Dabrowska & Hartshorne, 1978; Hathaway & Adelstein, 1979). 
Phosphorylation of the 2OK protein was shown to correlate 
with secretion and may be involved in stimulus-secretion 
coupling (Haslam & Lynham, 1977; Haslam et ^ .  , 1979; Huang & 
Detwiler, I986). Ca^* and calmodulin are also involved in the 
regulation of other platelet enzymes including adenylate 
cyclase and PLA^ (Feinstein ejk aT. , I98I).
V.2.(3) Inositol phospholipid metabolism in platelets
Inositol-containing lipids represent around 59^  of the 
total phospholipid content of most mammalian cells (Marcus 
et al., 1969). Phosphatidylinositol (Ptd Ins) is the major 
inositol phospholipid (around 909  ^of total) with the more 
phosphorylated derivatives, phosphatidylinositol 4-phosphate 
(pip) and phosphatidylinositol 4,5-bisphosphate (PIP^) (Fig. 4) 
present in very small amounts. Collectively, these lipids are 
referred to as pho sphoino si tides. The main fatty acids at 
positions 1 and 2 respectively are stearic acid and arachidonic 
acid (Marcus ejt , 19&9). Accelerated phosphoinositide 
metabolism (the 'Ptd Ins response*) occurs in a variety of
>C— 0 — CH'
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Figure 4. Structures of the phosphainositides.
Phosphatidyl inositol (Ptd Ins), phosphatidyl inositol 4-phosphate (PIP) 
and phosphatidyl inositol 4,5-bisphosphate (PIP^).
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cells in response to agonist-receptor interaction (reviewed 
by Hokin, 1985). The initial reaction resulting from agonist- 
receptor combination appears to be phospholipase C—catalysed 
hydrolysis of PIP^ to form inositol 1,4,3-triphosphate 
(ins(1 , 4 , 3 )  and 1,2-diacylglycerol (DG) (Michell et al.,
1981). Agonist-induced changes in PIP^ levels and formation 
of Ins(l,4,3)P^ have been reported in platelets (Agranoff et al., 
1983, Siess & Binder, 1983). However, Wilson et al. (1983a) 
have reported that the major phosphoinositide hydrolysed by 
agonist-induced phospholipase 0 activity is Ptd Ins. Resynthesis 
of the phosphoinositides involves (a) the sequential de­
phosphorylation of the inositol phosphates to form inositol 
and (b) the sequential action of DG kinase and CTP Ptd OH 
citidyl transferase to form CDP-DG which is combined with inositol 
to form Ptd Ins (Fig. 3)» The accepted scheme of phospho­
inositide metabolism has been complicated recently by the 
discovery of cyclic derivatives of the inositol phosphates 
which are generated as a result of phospholipase C-catalysed 
phosphoinositide hydrolysis (Wilson ejfc al., 1983a) and inositol 
phosphates containing 4,3 and 6 phosphate groups which are 
probably generated by sequential phosphorylation of Ins(l,4,3)P^ 
(Batty al. , I983; Michell, I986).
Phosphoinositide metabolism can be monitored by measurement 
of the mass of intermediates (e.g. Broekman ^  ^ .  , I980) or, 
more commonly, by measurement of radioactivity after prelabelling 
the cells. Platelets may be prelabelled with [^^p] -orthophosphate 
(-P.), which is incorporated into ATP. On stimulation of 
phosphoinositide hydrolysis, radioactivity will be incorporated
Agonist > Receptor
GIP tilno tng p ro te in
PIP;
DAG
PIP
Ptd OHIns IP
Ptd Ins
CDP-DAGInositol
INOSITOL PHOSPHATE CYCLE LIPID CYCLE
Figure 5o The inositol phospholipid cycle.
The initial receptor-controlled step is phospholipase C- 
catalysed hydrolysis of the phosphoinositides to yield 
diacylglycerol and the corresponding inositol phosphates.
Ins cl: 2-4,5 = inositol cyclic (l:2), 4,5~trisphosphate;
Ins cl: 2-4 = inositol cyclic (l:2), 4-bisphosphate;
Ins cl: 2 P = inositol (l:2) cyclic monophosphate.
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into phosphatidic acid (Ptd OH) and then into Ptd Ins and 
a second (PIP) and third (PIP^) labelled phosphorous will 
be incorporated. Initial increases in radioactivity in Ptd OH 
should approximate the rate of phosphoinositide turnover but 
after longer periods of time, a steady-state level will be
approached. Phosphoinositides can also be prelabelled with
3 l4 . n  1H- or C-arachidonate or -glycerol or H inositol.
Arachidonate prelabelling allows measurement of changes in all
intermediates except lysophospholipids, and the release of
free arachidonate can be monitored. Lysophospholipids can be
measured in cells prelabelled with glycerol. With labelled
inositol, the inositol phosphates can be measured. One of the
main limitations of these prelabelling methods is the presence
of heterogeneous pools of precursors within platelets. Hence,
quantitation may require measurement of the specific activity
of the metabolites. In addition, the cyclic nature of the
reactions and the existence of a number of points where label
can be lost or diluted by endogenous pools make it very difficult
to estimate a net flow of metabolite (Huang & Detwiler, I986).
The first evidence of a phosphoinositide response in platelets
32was the demonstration of agonist-induced incorporation of ^ P 
into Ptd Ins, PIP and PIP^ iti platelets prelabelled with 
p^pj -P^ (Lloyd £t 3^,9 1972).
Platelet receptors for a number of stimulatory agonists 
are coupled to phospholipase C-catalysed phosphoinositide 
hydrolysis. These include 3HT (^HT^/Sg receptors), TxA^ (TP),
PAF (Paf^), vasopressin (V^) and thrombin (Table l). It has 
recently become clear that the coupling of receptors to
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phospholipase C is mediated via G proteins similar to those 
involved in the regulation of adenylate cyclase. This was 
first indicated by the demonstration that GTP could alter 
agonist—binding affinity of a number of receptors which are 
coupled to phospholipase C but not to adenylate cyclase (e.g. 
Goodhardt et al., I982). This was confirmed by the observation 
that stable analogues of GTP stimulate phospholipase C in 
permeabilised platelets (Haslam & Davidson, 1984). Litosch 
et al. (1985) reported that 5HT-induced Ins(l,4,5)P^ formation 
in blowfly salivary gland membrane preparations only occurred 
in the presence of GTP and was enhanced by stable analogues 
of GTP. This synergism between receptor agonists and guanine 
nucleotides demonstrates an interaction between receptors, a 
G protein and phospholipase 0 (Taylor & Merrit, I986).
V.2.(4). Function of inositol phospholipid metabolism in platelets 
Much current research has been directed towards the second 
messenger roles of DG (in activating protein kinase C) and 
Ins(l,4,5)P^ (in mobilisation of Ca^*). However, it is possible 
that other products of phosphoinositide metabolism, e.g. Ptd OH 
or lysoPtd OH, may also be involved in the control of platelet 
activation. Kinetic analyses have indicated that formation of 
DG and Ins(l,4,5)P^ are amongst the earliest measurable events 
resulting from agonist-receptor interaction in a number of 
different cell-types (reviewed by Hokin, I983). This is 
consistent with a second messenger role for these molecules.
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(a) DG
The transient rise in DG levels that results from stimulus- 
induced phosphoinositide hydrolysis is correlated with activation 
of a. protein kinase enzyme (Takai et al. , 1979)» This enzyme, 
called protein kinase C, is present in many tissues and is 
activated in the presence of Ca^^ and phospholipids, especially 
phosphatidylserine (Takai et al., 1979)* DG greatly enhances 
the affinity of protein kinase 0 for Ca^^, thereby activating 
it at resting
Protein kinase C has a very wide substrate specificity 
when tested in vitro but its main substrate in intact platelets 
appears to be the 4 OK protein (Section V. 2.(2)) (SanO e_t al. ,
1983)* Protein kinase 0, cyclic AMP-dependent protein kinase 
and Ca^"*^-calmodulin-dependent protein kinase(s) share many 
phosphate acceptor proteins dji vitro, but with different rates 
of phosphorylation at different amino acid residues (Nishizuka,
1984). The nature of the 4OK protein(s) is the subject of 
much current study. It has been proposed that the 4OK protein 
could be lipocortin (Touqui ^t aT., I986) or Ins(l,4,5)P^ 
phosphatase (Connolly & Majerus, I986). Lipocortin is an 
endogenous inhibitor of phospholipase A^ which is inactivated 
by phosphorylation leading to increased phospholipase A^ 
activity and liberation of arachidonic acid (Touqui ^  ,
1986). Ins(1,4,3)P^ phosphatase is the enzyme which catalyses 
the inactivation of Ins(l,4,3)P^*
The effects of endogenous DG can be mimicked by tumour- 
promoting phorbol esters such as phorbol 12—myristate 13- 
acetate (PMA) (Castagna et ^ . , 1982). Addition of PMA to
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intact platelets results in aggregation and secretion which, 
is accompanied by activation of protein kinase C and phosphoryl­
ation of the 40K protein(s) (Nishizuka, 1984). PMA or synthetic 
DGs will synergise with the Ca^*—ionophores A23187 or ionomycin 
to induce platelet activation (Kaibuchi et ^ . , 1983b; Rink 
ot al., 1983; Nishizuka, 1984). It has been proposed that 
both Ca ^—calmodulin—dependent and protein kinase C—dependent 
phosphorylation reactions are necessary for full platelet 
activation (Kaibuchi et al., 1983b). Other possible roles for 
DG in stimulus-response coupling have been proposed. DG may 
act as a membrane fusogen to promote degranulation (Kaibuchi 
et al., 1983b). Moreover, the demonstration of DG-lipase in 
platelets suggests a possible role for DG as a source of free 
arachidonic acid (Bell ejfc ad., 1979)*
(b) Inositol phosphates
A role for Ins(l,4,3)P^ in stimulus-response coupling was 
indicated by its ability to induce Ca^^ release from an 
intracellular, non-mitochondrial store (Streb ejfc ad., I983)*
This has been confirmed in platelets (O * Rourke e^ ad., I983)*
In platelets made permeable to small molecules by saponin 
pretreatment, addition of Ins(l,4,3)P^ results in concentration- 
dependent stimulation of Ca^ '*’ mobilisation (probably from the 
DTS), 3HT release and phosphorylation of the 20K and 40K 
proteins (Lapetina et al., 1984; Brass & Joseph, I983)* These 
findings (and the reported rapid formation of Ins(l,4,3)p^ ) 
are consistent with the hypothesis that Ins(l,4,3)P^ mediates 
agonist-induced Ca^* mobilisation in platelets. Recently,
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Putney (1986) also proposed a role for Ins(l,4,3)P^ in 
mediating influx of Ca^* into cells.
The major mechanism for terminating Ins(l,4,3)P^ action 
is thought to be the removal of the 3—phosphate by specific 
phosphatase enzyme(s). However, it has recently become clear 
that Ins(1 ,4, 3 may also be rapidly phosphorylated to form 
Ins(l,3,4,3)P^ in various stimulated tissues (Batty et al.,
1983; Michell, 1986). The Ins(l,3,4,3)P^ is then dephosphoryl- 
ated at the 3-position to form Ins(l,3>4)P^. It has been 
suggested that the pathway for metabolism of Ins(l,4,3)P^ 
through Ins(l,3f4,3)P^ to Ins(l,3»4)P^ and hence its inactivation 
as a calcium-mobilising ligand may be at least as important 
as its dephosphorylation to Ins(l,4)P2 (Michell, I986).
Ins(l,3>4,3)P^> Ins(l,3»4)P^ and the cyclic derivatives of 
the inositol phosphates (wilson ejfc ad., 1983b) may have, as 
yet undiscovered, roles as intracellular messengers.
(c) Other putative messengers
It has been suggested that Ptd OH or lysoPtd OH may serve 
as links between receptor activation and influx of Ca^* by 
acting as ionophores in the plasma membrane (Putney, I98I;
Benton ejb ^ .  , I982). However, studies on the ionophoretic 
effects of Ptd OH in liposomes have produced negative results 
(Holmes & Yoss, 1983)*
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V*3« Arachidonic acid metabolism and platelet activation
Activation of platelets by a number of agonists is associated 
with liberation of free arachidonic acid (3,8 ,11,l4-eicosatetra- 
enoic acid). In platelets, arachidonic acid is rapidly converted 
to labile endoperoxides PGG^ and PGH^ by a cyclooxygenase enzyme. 
The endoperoxides, which can themselves activate platelets, are 
converted into the potent aggregating agent and vasoconstrictor 
TxA^ (Hamberg et al., 1975)* Cyclooxygenase is specifically 
acetylated and inhibited by aspirin (Roth ^  ^ . , 1973) and 
this is responsible for the anti-inflammatory effects of 
aspirin since prostaglandins are powerful pro-inflammatory 
agents as well as exerting several other biological effects 
(reviewed by Moncada & Vane, 1979)* In quiescent platelets 
virtually all of the arachidonic acid present is bound to 
membrane phospholipids (particularly phosphatidylcholine and 
Ptd Ins) esterified to glycerol at glycerol sn-2. Agonist- 
induced liberation of free arachidonic acid from complex 
phospholipids is the rate-determining step in eicosanoid 
formation (Rittenhouse-Simmons & Deykin, I98I). This can be 
achieved by activation of a phospholipase A^ enzyme which 
cleaves phospholipids at the sn-2 position. Free arachidonic 
acid may also be liberated as a consequence of stimulated 
phosphoinositide metabolism. Rittenhouse-Simmons & Deykin 
(1981) proposed that DG liberated from the phosphoinositides 
(by phospholipase C action) is hydrolysed by DG lipase to 
release free arachidonic acid whilst Majerus ^  (1983)
suggested that DG is first converted to monoacylglycerol (by 
DG lipase action at sn-l) before arachidonic acid is liberated
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by the action of monoglyceride lipase# Conversion of free 
arachidonic acid to PGG^, PGH^ and TxA^ provides a positivi 
feedback mechanism to promote platelet activation#
-  4 7  -
VI. Aims
The aims of this study were to investigate the effects 
of agonists and agonist combinations on several platelet 
responses and transduction processes including;—
(a) shape change
(b) aggregation in whole blood, platelet-rich plasma and 
gel-filtered platelet suspensions
(c) dense granule release
(d) [Ca2+],
(e) phosphoinositide hydrolysis
(f) cyclic AMP content.
By examining the effects of agents, alone and in combination, 
on platelet responsiveness and on the second messenger systems 
(using washed platelet suspensions), I attempted to investigate :-
(1) The roles of and phosphoinositide hydrolysis in
mediating platelet activation induced by adrenaline, ADP, 
vasopressin and PAF.
(2) The roles of phosphoinositide hydrolysis and
activation of protein kinase C in mediating the potentiation 
of agonist-induced platelet activation by adrenaline.
(3 ) The mechanism of inhibition of platelet responsiveness by 
agents which elevate cyclic AMP content and the relative 
susceptibility of different responses to inhibition by cyclic 
AMP.
(4) The effects of stimulatory agonists and of activation of 
protein kinase C on platelet cyclic AMP metabolism.
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The responses of platelets to combinations of agents 
(both, stimulatory and inhibitory) in the more physiological 
of whole blood were examined by measuring platelet 
aggregation in this medium.
I also attempted to develop a simply assay for cyclic 
AMP—dependent protein kinase activity in crude platelet extracts 
which would allow the effects of platelet stimulatory and 
inhibitory agonists on this enzyme to be determined. The 
rationale behind this study was: (a) to examine the relationship
between activation of cyclic AMP-dependent protein kinase and 
inhibition of the various platelet responses and (b) to 
investigate the controversial proposition that agonist 
(particularly adrenaline)-induced platelet activation could 
result from a decrease in the basal level of cyclic AMP, 
perhaps in a specific subcellular pool, by examining the 
effects of adrenaline and other stimulatory agonists on cyclic 
AMP-dependent protein kinase activity.
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MATERIALS AND METHODS
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I.l. Materials
The drugs and reagents used in the course of this project 
are listed below and the sources indicated. Except where 
stated, reagents were dissolved in glass-distilled water and 
further dilutions were made using 0.9% saline. Adenosine 
3'“diphosphate (ADP); ATP; adenosine 3',3*-cyclic monophosphate 
(cyclic amp); 8 bromo-cyclic AMP ; 8—arginine vasopressin; 
bovine serum albumin; HEPES; apyrase (grade III); creatine 
phosphate; creatine phosphokinase; histone (type IIA); 
3“isobutyl 1-methyl xanthene (iBMX); ethylene glycol bis- 
( 1^ -amino ethyl ether) N,N,N’,N’-tetraacetic acid (EGTA) ; phorbol 
12-myristate 13-acetate (PMA); 4aphorbol 12,13-didecanoate 
(4aPDD); sepharose 2B and dimethylsulphoxide (DMSO) were all 
obtained from Sigma (U.K.). EGTA was dissolved in 0.4N NaOH 
at a concentration of 0.4M (pH < 8). PMA and 4aPDD were 
dissolved in DMSO. Quin2-acetoxymethyl ester (Quin2-AM) was 
obtained from Lancaster Synthesis (Morecambe, England) and was 
dissolved in DMSO. 2-acetyl-l-alkyl-sn-glycero-3-phosphocholine 
(platelet-activating factor, PAF) was from Bachem (Bubbendorf, 
Switzerland) and was dissolved at 1 mg per ml in 0.9% saline 
containing 0.23% BSA, with subsequent dilutions in saline alone. 
Adrenaline-tartrate was purchased from Koch-Light Laboratories 
(U.K.) and ionomycin (dissolved in DMSO) was from Calbiochem. 
Prostaglandin I^ (PGI^), PGE^» 6 keto-PGE^ and PGD^ were gifts 
from Dr J.E. Pike (Upjohn, U.S.A.). PGI2 was dissolved in 
Tris-HCl buffer, pH 9.2. The other prostaglandins were dissolved 
initially in ethanol and diluted with 9 volumes of Na^CO^
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(3 mM) to give 3*3 niM stock solutions. Further dilutions 
were made in saline. The heat—stable inhibitor of cyclic 
AMP—dependent protein kinase was obtained from Sigma and a 
more purified preparation of this was a gift from Dr J.D. Scott, 
Howard Hughes Medical Institute, Research Laboratories, Seattle.
Adenosine 3*>5'“Cyclic phosphoric acid
2'—O-succinyl-3- iodotyrosine methyl ester
( ^ ^^^I jj -cyclic AMP ; 600 Ci per mMole) and adenosine
5'- ^  -^^P j triphosphate, tri ethyl ammonium salt ( j^ ^^ P J -ATP;
20.8 Ci per mMole) were from Amersham International (Amersham,U.K. 
Carrier-free ^^^pj -orthophosphate (P\) was supplied by the 
Regional Isotope Dispensary, Western Infirmary, Glasgow, U.K.
1.2. Buffers
Buffer A (Hepes-buffered Tyrodes solution);-
NaCl 129 mM
trisodium citrate - 10.9 mM
NaHCO^ 8.9 mM
dextrose — 0.56 mM
Hepes - 5 mM
KCl 2.8 mM
KH^PO^ 0.8 mM
MgClg 0.84 mM
CaCl^ 2. 4 mM
bovine serum albumin - 0 .35# (w/v)
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7.4 using NaOH (1N).
- 52 -
Buffer B (calcium—free, phosphate—free buffer);—
NaCl - 150 mM
KCl — 4 mM
MgClg - 1 mM
dextrose - 10 mM
Hepes - 5 mM
bovine seium albumin - 0.35%
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7.4 using HCl (1N).
Buffer C (lOO mM potassium phosphate buffer):- 
K^HPO^ (200 mM) - 66.25 ml
KH^PO^ (200 mM) - 183.75 ml
Glass distilled water - 250 ml
The above were mixed and the pH was adjusted to 6.4 using HCl
(i o n ).
Buffer D
NaCl - 129 mM
NaHCO^ - 8.9 mM
KCl - 2.8 mM
K^HPO^ - 0.81 mM
MgCl - 0.84 mM
dextrose - O.3& mM
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7*^ using NaOH (1N).
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Buffer E (62 niM Potassium phosphate buffer)
K^HPO^ (125 mM) - 122.5 ml
KH^PO^ (125 mM) - 127.5 ml
Glass-distilled water - 25O ml
The above were mixed and the pH was adjusted to 6.8 using 
HCl (i o n ).
II. Preparation of platelets
II.1 Preparation of platelet-rich plasma (PRP)
Blood was obtained by anteciibital venepuncture from healthy 
human volunteers who denied taking drugs known to affect 
platelet function. Blood was collected into 10% (volume/volume, 
v/v) trisodium citrate (0 .I3 molar, M) and centrifuged (lOOOg;
5 minutes ; room temperature) to sediment erythrocytes and other 
blood cells. The supernatant PRP was aspirated (Pollock a^. ,
1984).
II.2. Isolation of platelets
(a) Gel-filtration.
Columns of sepharose 2B (5O—100 ml bed volume) were 
equilibrated with buffer A. PRP was layered onto the column 
and when this had entered the gel, further buffer was added.
The column eluate was collected. The platelets (now suspended 
in buffer A; 2 x 10^ platelets per ml) eluted immediately 
after the dead volume and preceded the plasma proteins and 
other plasma constituents (Pollock et al., 1984).
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(b) PGI^ Centrifugation
PRP was centrifuged (800g; 10 minutes; room temperature) 
in the presence of PGI^ (0.3 V-M) to prevent activation. The 
supernatant plasma was decanted and the platelet pellet re- 
suspended in buffer B (see Section II) to give a final platelet 
count of approximately 3 x 10^ per ml (MacIntyre & Pollock,
1983).
(c) Low [ca^^J /low pH centrifugati on
PRP was treated with EGTA (4 mM) to chelate extracellular 
Ca ^ ions and the pH was adjusted to 6.8 with citric acid 
(10 p,M) to prevent platelet activation during centrifugation 
(800g; 10 min; room temperature). The supernatant plasma was 
decanted and the platelet pellet was resuspended in one tenth 
volume of buffer D to give a platelet count of approximately 
3 X 10^ per ml.
III. Platelet Function Assays
III.l Shape change
Shape change was monitored photometrically using PRP or 
gel-filtered platelets. This involved measuring the decrease 
in light transmission that followed agonist addition to stirred 
(700 rev/min) platelet suspensions {0.6 ml; 37°C) and was 
monitored using a Mallin clinical aggregation recorder. In 
these studies, to reduce extracellular Ca^* and hence prevent 
aggregation, EGTA (4 mM) was added to each platelet sample 
60 seconds before agonist addition (Bom, I962; Michel & Bom,
1971).
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III.2* Secretion
Secretion of platelet dense granule constituents was 
monitored by measuring ATP release using firefly luciferin- 
luciferase luminescence. This was measured simultaneously 
with aggregation in stirred (700 rev/min) platelet samples 
(0.45 ml; 37^0) by using a Chronolog Corporation luminescence 
aggregometer (Feinman ^  al*> 1977).
111.3 .(a) Photometric (turbidometric) measurement of aggregation.
Aggregation was monitored in PRP and in gel-filtered
platelets by measuring increases in light transmission through 
stirred (700 rev/min) platelet suspensions using either a 
Chronolog Corporation luminescence aggregometer (0.45 ml samples] 
or a Mallin clinical aggregation recorder (0.6 ml samples)
(Born, 1962).
111.3.(b) Single platelet counting method for monitoring 
aggregation.
Platelet aggregation was monitored in whole blood by an 
electrical impedence method. By utilising the Clay Adams 
Ultra-Flow 100 whole blood platelet counter, platelet numbers 
before and after addition of an aggregating agent were counted 
electronically without the need to separate platelets from 
other blood cell types (Day et al., I980). Immediately 
following blood collection, an initial platelet count was 
obtained f^om the * stock’ citrated blood. Aliquots of blood 
(0.5 ml) were transferred to polystyrene vials which, where 
stated, contained aspirin to give a final concentration of 
2 mM. The vials were gassed with a mixture of 5% CO^ in air.
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capped and placed into racks in a shaking water bath (Grant 
Model SS3O; 37 C; 90-100 shake s/min ). After 30 min., a 10 p,l 
sample was taken from each aliquot, mixed with a pre-filled 
diluent pot (Clay Adams) and duplicate control counts were 
taken and the mean count recorded. An aggregating agent was 
then added to the blood, the tube was re-gassed, capped and 
returned to the water bath. Further 10 p,l samples were taken 
for counting at standard times (]^  1 min) after agonist addition 
(Lumley & Humphrey, I98I).
III«3»(c) Comparison of photometric and electronic methods for 
monitoring platelet aggregation.
These studies involved removing 10 p,l aliquots of PRP 
from aggregometer cuvettes before and at regular intervals 
(30 sec - 5 min) after agonist addition for the electronic 
measurement of platelet count. Each 10 p,l aliquot was mixed 
with a pre-filled diluent pot (Clay Adams) containing formaldehyde 
(1%) and platelet count was determined later (l-2 hours) using 
the Clay Adams platelet counter. Thus, changes in light 
transmission monitored in the aggregometer could be correlated 
with changes in platelet count.
IV. Platelet Cytosolic Free Calcium Ion Concentration : [ca^‘*~] ^
Platelet |ca^^j ^  was monitored using the fluorescent 
quinoline dye. Quin 2, which displays high affinity for Ca^* 
and undergoes fluorescent changes as a result of Ca^* binding 
(Rink et ^ .  , 1982; Tsien et al., 1982a,b,c). PRP was 
incubated with Quin 2 acetoxymethyl ester (lO )iM; 30 min; 37°C)
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which is membrane permeant and crosses the plasma membrane where
it is rapidly hydrolysed by cytosolic esterases to form the
hydrophilic polycarboxylate anion that is Quin 2. Quin 2 is
thus trapped within the cytosol of intact platelets and can
report the resting | c a ^ ^ a n d  the changes which result from
exposure to agonists. Quin 2-loaded platelets were separated
from plasma containing extraneous dye by gel-filtration (Section
I.2.(a)). The Quin 2 content of the platelets was around
1 mmole/litre of cell water. Gel-filtered platelets were stored
at 37^G in stoppered plastic tubes. Immediately before use,
the external free Ca^^ concentration ^Ca^^ ^  was adjusted either
to 1 mM by the addition of CaCl^ or to 1-10 nM by the addition
of EGTA (4 mM). Platelets (0.3 ml) were placed in 1 cm square
7quartz cuvettes and platelet count was adjusted to 3 x 10 
platelets/ml by the addition of 1.3 ml of buffer A. Fluorescence 
was monitored in a Perkin-Elmer LS3 Fluorescence Spectrometer 
with standard monochromater settings of 339 um - excitation 
and 492 nm - emission (MacIntyre ejb al. , 1983c). j^ Ca^ j^ ^  
calculated from the observed fluorescence according to the 
following equation:-
was
[Ca^^] = Kd X (F - Fmin)/(Fmax "
where Kd is the effective dissociation constant of Quin 2 for 
Ca^* (Kd = 113 nM under these conditions); F is the relative 
fluorescence reading and F and F . are the fluorescences
IXIJL LX
at very high and very low respectively (Tsien ^  ,
(l982a). F was obtained by the addition of 30 y.'M digitonin 
 ^ ■' max
to lyse the platelets and expose all of the Quin 2 to the
2 "f* o I
extracellular Ca and to liberated iutracellular Ca i.e.
Ca > 1 mM, and was obtained by the later addition
of EGTA (4 mM) to chelate all of the Ca^^ (Rink ejt al. , I982).
V . Inositol Phospholipid Studies
Inositol phospholipid studies were performed by Mr A.
McNicol essentially as described by MacIntyre & Pollock (I983). 
Agonist—induced hydrolysis of inositol phospholipids was 
monitored by measuring the formation of |^ ^^ P j -Ptd OH in 
platelets prelabelled with j^ ^^ P j -orthophosphate (-P\). Platelet 
suspensions (prepared by centrifugation; Section II.2.(b)) were 
incubated (37°C; 90 min) with carrier-free ] -P^  ^ (30 p,Ci/ml).
Platelets were then pelleted by centrifugation (800g; 10 min; 
room temperature) in the presence of PGI^ (0.3 jiM) and re­
suspended in 1.5 times the labelling volume of fresh buffer B. 
Radiolabelled platelets (0.4 ml containing 0.5 - 1 mg protein) 
were dispensed into plastic tubes at 37°C. Reactions were 
initiated by the addition of agonist(s) or vehicle and terminated 
by transferring the entire platelet sample into a glass test- 
tube containing 2 ml of chloroform/methanol/lOM-HCl (23:30:4, 
by volume) at room temperature (Lloyd ejfc al^ . , 1972; MacIntyre 
& Pollock, 1983). Platelet lipids were extracted (Lloyd at al.,
1972), dried at 40°C under nitrogen, separated by two-dimensional 
thin layer chromatography (Yavin & Zutra, 1977) and detected 
by exposure to iodine vapour and/or autoradiography on Ilford 
23 EP X-ray film (13-20 hours). The spots corresponding to 
Ptd OH were scraped into vials and counted for radioactivity
by liquid scintillation spectrometry. Under these conditions, 
the platelets were functionally viable (MacIntyre & Pollock, 
1983). Changes in ^^^P J-Ptd OH reflect changes in Ptd OH 
concentration (Holmsen et ^ . , 1984) and the DG precursor of 
Ptd OH is most probably derived via hydrolysis of phospho— 
inositides (MacIntyre & Pollock, I983).
VI. Platelet Cyclic AMP Content
Cyclic AMP was extracted from gel-filtered platelet samples 
(0.4 - 1 ml) by the addition of two volumes of ethanol. The 
samples were vortex-mixed, left at room temperature for 3 miu —
1 hour and then centrifuged (300g; 10 min; room temperature) 
and the supernatant, ethanol-soluble fraction, was decanted 
and evaporated at 60^C. The dried samples were resuspended in 
sodium acetate buffer (30 mM; pH 3 ) to give a cylcic AMP 
concentration in the range of 0.01 - 30 pmoles/lOO p,l. The 
samples were then stored at -20^0 prior to assay for cyclic 
AMP. The cyclic AMP concentration was estimated by radio­
immunoassay essentially as described by Brooker e_t al. (1979)* 
Authentic cyclic AMP standard concentrations (O.OI - 100 pmoles/ 
100 )il; triplicate samples) were prepared in sodium acetate 
buffer. To maximise assay sensitivity, samples (lOO p,l ) were 
acetylated by the addition of 3 }Ll of a freshly made mixture 
of acetic anhydride and triethylamine, 1:2 by volume (Prandsen 
& Krishna, I976) and the samples were rapidly vortex-mixed.
To each tube was added I30 p,l of a l/l0,000 dilution (in 0.1% 
bovine serum albumin) of anti-cyclic AMP antiserum (raised in 
goats against human serum albumin conjugated to succinyl cyclic 
amp) and 23 p-l of a l/l73 dilution of -cyclic AMP
—  6 o  —
(approximately 3000 cpm/sample). Samples were mixed and 
incubated for l6 hours at 4°C« After this incubation period,
0.5 ml of a suspension of washed charcoal (l%, w/v) in Buffer C 
containing 0.23% bovine serum albumin (4°C) was added. The 
samples were mixed and the charcoal sedimented by centrifugation 
(4000g; 4 min; 4°C). Aliquots (0.3 ml) of the supernatant were 
taken to assess antibody—bound [^^^1] —cyclic AMP which was 
counted (3 min) in an EMI gamma counter. Standard calibration 
curves in each experiment were plotted as radioactivity bound 
(cpm) against concentration of cyclic AMP or as B/B^ against 
concentration of cyclic AMP where B and B^ represent the amount 
of [^^^I] -cyclic AMP bound in the presence and absence, 
respectively, of unlabelled cyclic AMP. In the absence of 
unlabelled cyclic AMP, approximately 30% of the total added 
^123jj -cyclic AMP was bound. Amounts of cyclic AMP in unknown 
samples were determined by reference to the calibration curve.
The specificity of the anti-serum was tested by measuring 
the ability of a range of adenine and guanine nucleotides to 
compete with [^^^I ] -cyclic AMP for binding to the anti-serum.
As illustrated in Figure 6, the anti-serum is relatively specific
o
for cyclic AMP with 10 -fold (cyclic GMP), 10 —fold (AMP, ADP, 
ATP) and 10^-fold (adenosine) higher concentrations of the 
other nucleotides required to produce 30% displacement of the 
[^^^l] -cyclic AMP.
1 .0-1
B/B,
0.5 -
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Figure 6. Effects of a range of nucleotides on the binding of j -
cyclic AMP to anti-cyclic AMP antiserum.
The ability of the acetylated forms of cyclic AMP ( # ) ; cyclic GMRL (A); 
ATP (o); ADP (□); AMP (■) and adenosine (A) to compete with p  i]" 
cyclic AMP for binding to the anti-cyclic AMP antiserum was measured 
as described in Methods Section.
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• Preliminary studies of cyclic AMP—dependent protein kinase 
activity in crude platelet extracts
* Preparation of platelet particulate and soluble fractions 
Platelet suspensions were prepared by low /low pH
centrifugation. Aliquots (0.12 ml) were incubated (l—5 min;
37 C ) with saline or modulators of platelet adenylate cyclase 
activity. After this incubation period, 20 )xl samples were 
removed for the estimation of cyclic AMP content and 400 pi 
of ice-cold buffer E containing EGTA (k mM) was added to the 
remaining platelet sample. The samples were then rapidly 
frozen by immersion in a mixture of solid CO^/acetone and then 
thawed in a water bath at 37^0 with shaking. The samples were 
re-frozen and thawed a further three times. All further 
manipulations were carried out at 4°C. Any remaining unlysed 
platelets were pelleted by centrifugation (lOOOg; 5 min; h^C) 
using a *Koolspin' refrigerated centrifuge (Surkard). The 
supernatant was decanted into labelled thick-walled ultra- 
centrifuge tubes (Beckman, U.K.). Soluble and particulate 
fractions were separated by centrifugation (lOO,OOOg; 30 min; 
4°C) using a Beckman ultra-centrifuge. Platelet particulate 
fractions were resuspended in 0.3 ml of a potassium phosphate 
buffer (lOO mM; pH 6.8; 4°C). Platelet soluble and particulate 
fractions were assayed for protein kinase activity within 
30 min of preparation.
VII.2. Protein kinase assay
Cyclic-AMP-dependent protein kinase activity was determined 
by the filter paper assay procedure described by Corbin {1983). 
In principle, the assay is based upon the ability of cyclic
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AMP—dependent protein kinase to catalyse the incorporation of 
^ P from [ y p j  -ATP onto a protein substrate (mixed histone, 
Sigma type IIA):-
Mg^ '^ ’.ATP + HISTONE ---^ Mg^‘*’.ADP + HISTONE-^^P
The phosphorylated histone is then trapped by precipitation 
onto filter paper. Assay mixtures (final volume 0.25 ml) 
contained Mg. acetate (2.4 mM) ; histone (8 mg per ml); [^(-^^p] -AT 
(0.l4 mM, around 10 cpm per pmole) with or without cyclic AMP 
(4 pM). The composition of this assay mixture was varied and 
other reagents were included in these preliminary experiments 
in an attempt to optimise the assay conditions. The reaction 
was initiated by the addition of 0.1 ml of platelet soluble or 
particulate fraction to the mixtures which were incubated for 
up to 10 min at 30°C. At the end of this incubation period, 
an excess of unlabelled ATP (50 p,l of 40 mM) was added to the 
reaction mixtures and the samples were transferred to ice 
to effectively stop the reaction. A sample (o.l ml) of the 
mixture was then spotted onto filter paper disks (Whatman, 3 MM, 
2.4 cm diameter) numbered with pencil lead. The disks were 
left at room temperature for 15—30 min to allow all of the 
histone to be absorbed. They were then dropped into a stainless 
steel basket located in a beaker containing 10^ TCA (around 
5 ml per disk) on ice. The basket was constructed so that 
space was provided for a magnetic stirr bar underneath the 
basket (Corbin & Reimann, 1974). The filters were washed for 
15 min at 4°C with stirring. The TCA was then replaced with 
fresh 109^ TCA at room temperature and this washing procedure 
was repeated a further three times. The filter disks were
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then washed in 939° ethanol and then diethyl-ether for 5 min 
each* The disks (which should now contain only histone-bound 
radioactivity) were dried for around 3 min using a hair-dryer 
and then placed in a vial containing 10 ml scintillant. The 
radioactivity bound to the histone substrate was determined 
by liquid scintillation counting using a Packard Tri-carb 
Liquid Scintillation Spectrometer. To correct for phosphoryl­
ation of endogenous platelet protein substrates, a blank 
containing no histone was included in each assay and this value 
was subtracted from the other samples.
Results are expressed as units of kinase activity or as 
cyclic AMP-dependent protein kinase activity ratio. A unit 
is defined as the amount of enzyme activity catalysing the 
transfer of 1 pmole of phosphate from j -ATP onto a
histone mixture in 1 min at 30°C (Corbin & Reimann, 1974).
The activity ratio is a measure of the fraction of the enzyme 
in the active form:-
R^C^ + 4 cyclic AMP —  > R^* cyclic AMP^ + 2C 
inactive active
ACTIVITY RATIO = C/(C + '^ 2 ^ 2 ^
The activity ratio is obtained by dividing the activity 
detected in the absence of added cyclic AMP (i.e. C) by the 
total activity which is detected in the presence of an excess 
of cyclic AMP, 4 )iM (i.e. 0 + R^Cg* Corbin & Reimann, 1974).
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VIII. Protein determination
The protein content of platelet samples was determined 
by the method of Lowry ^  (1931).
IX. Analysis of results
Experiments were normally performed in triplicate and 
each experiment was performed at least three times. Results 
are expressed as mean values - standard error of the mean 
(SEM). Groups of data were compared statistically using 
Student's t-test and probability (p) values of less than
0.05 were taken to be significant.
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RESULTS
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^ • Platelet responses to addition of single agonists
The effects of adrenaline, ADP, vasopressin and PAF on 
a range of platelet functions and putative transduction 
processes were examined. The responses monitored were:—
1 . aggregation in whole blood,
2. aggregation in PRP,
3» aggregation and ATP secretion in Quin 2-loaded, gel- 
filtered platelets,
4. changes in
5 * inositol phospholipid hydrolysis.
I*1• Agonist-induced platelet aggregation in whole blood
The main agonists utilised in the course of this study 
were adrenaline, ADP, vasopressin and PAF, each of which induced 
concentration-dependent reductions in single platelet count 
(i.e. platelet aggregation) in whole blood. Adrenaline-induced 
aggregation reached a peak approximately 10-13 min after agonist 
addition with a maximum 70^ reduction in platelet count (Fig. 7A). 
In comparison, ADP-, PAF- and vasopressin-induced aggregation 
were more rapid (peak within 1-2 min) and transient and these 
agonists induced up to 80^ reductions in platelet count (Fig.7B-C) 
In some cases (l4/24 individuals) vasopressin induced a maximum 
reduction in platelet count of less than 30% (Fig. 8 ). Platelets 
from these individuals consistently failed to respond to 
vasopressin when tested on different days. Responses to 
adrenaline, ADP, vasopressin and PAF were not significantly 
affected by incubation (30-90 min) with aspirin (2 mM), not 
shown.
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100-,
- 5 — — — 5  30nM 
^  500nM
50-
0-*
B. ADP
300nM
lOpM
C. PAF
•5 100-,
30nM
lOOnM
300nM50-
D. Vasopressin
300nM
Time (min)
Figure 7. Aqonist-inducecj platelet aggregation in whole blood.
Citrated human whole blood samples were prepared and agonist-induced 
reductions in single platelet count were monitored as described in 
Methods Section. Platelet count was measured before and at the indicated 
times after addition of (A) adrenaline: 30 nM (o), 300 nM ( , 1 "P-M (o )
and 3 p.M (• ); (B) ADP: 300 nM (o), 1 pM (&), 3 )iM (n ) and 10 (#);
(C) PAF: 30 nM (o), 100 nM (^ ), 300 nM (a ) and 1 )iM ( • );
(D) vasopressin: 10 nM (□)» 30 nM (^ )> 100 nM (O ) and 300 nM ( •).
Data are means and standard errors from four to six experiments using 
blood from different donors.
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Figure 8. Vasopressin-induced decreases in whole blood platelet count - 
poor responses seen in some individuals.
Changes in whole blood platelet count were monitored in response to addition 
of vasopressin: 10 nM (o), 100 nM (A), 1 p-M (o) and 10 (•). Data
are the means and standard errors from four experiments using blood from 
different donors.
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Agonist-induced platelet aggregation in PRP; a comparison 
of* turbidometric and electronic methods for monitoring 
platelet aggregation
Agonist-induced changes in light transmission and reductions 
in single platelet count were monitored simultaneously in PRP 
as described in Methods (Section 111*3)• The aim of this study 
was to compare the sensitivity of the turbidometric and single 
platelet counting methods for monitoring platelet aggregation. 
Incubation with 10 M adrenaline resulted in a significant 
reduction in platelet count with very little change in the 
light transmission recording (Fig. 9A> B). Increasing 
concentrations of adrenaline (up to 3 x 10 ^M) resulted in 
greater and more rapid reductions in platelet count and 
significant increases in light transmission (Fig. 9)» The 
concentration-response relationships for maximum adrenaline- 
induced reductions in platelet count and increases in light 
transmission are shown in Figure 10. The electronic single 
platelet counting technique provided a more sensitive index 
of aggregation (EC^q> i.e. concentration producing 50^ of 
maximum response, ~ 3 x 10 M) than the light transmission 
measurements (EC^^ ^  2 x 10 ^M). Similarly, ADP- (Figs. 11
& 12), vasopressin - (Figs. 13 & l4) and PAF- (Figs. 13 & l6) 
induced reductions in single platelet count could be detected 
in the absence of significant increases in light transmission. 
Reductions in platelet count of up to 30% occurred without 
significant changes in light transmission. In each case the 
EC^q values for agonist-induced reductions in single platelet 
count were significantly less than the corresponding EC^^ 
values for agonist-induced increases in light transmission
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Figure 9. Platelet-rich plasma: adrenaline-induced reductions in platelet 
count and increases in light transmission.
Platelet-rich plasma was prepared, aggregation was monitored photometrically 
and samples were removed at the times indicated for the determination of 
platelet count as described in Methods Section. Aggregation was induced by 
100 nM (•), 1 "pM (a ) and 3 p.M (o) adrenaline or vehicle (A). Data 
are the means and standard errors from six experiments.
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Figure 10. Platelet-rich plasma; comparison of concentration-effect 
relationships for maximal adrenaline-induced increases in 
light transmission and reductions in platelet count.
The data shows the peak increase in light transmission (#) and reduction
in platelet count (a ) induced by adrenaline at the concentrations
indicated. Data are the means and standard errors from six experiments.
100 -1
oo
(U
OJ-M ^  CD
CL
OJ
O'C
oo
co
co
co
coc
CD
JCen
CD
co
CD
CD
l_
o
50 -
0
100
50 -
0
6
• — Zi
1---- 1—
2 3
Time (min)
Figure 11. Platelet-rich plasma; APP-induced réductions in platelet count 
and increases in light transmission.
Platelet-rich plasma was prepared, aggregation was monitored photometrically 
and samples were removed at the times indicated for the determination of 
platelet count as described in Methods Section. Aggregation was induced 
by 100 nM (•), 300 nM (a ), ll^M (o) and 3 M (■) ADP or vehicle (A).
Data are the means and standard errors from four different experiments.
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Figure 12. Platelet-rich plasma; comparison of concentration-effect 
relationships for maximal ADP-induced increases in light 
transmission and reductions in platelet count.
The data shows the peak increases in light transmission (# ) and reductions
in platelet count (A) induced by ADP at the concentrations indicated. Data
are the means and standard errors from four different experiments.
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Figure 13. Platelet-rich plasma: vasopressin-induced réductions in 
platelet count and increases in light transmission.
Platelet-rich plasma was prepared, aggregation was monitored photometrically 
and samples were removed at the times indicated for the determination of 
platelet count as described in Methods Section. Aggregation was induced 
by 10 nM ( » ), 30 nM (a ), 100 nM (o) and 300 nM ( ■ ) vasopressin or vehicle 
(a ). Data are the means and standard errors from three different experiments.
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Figure 14. Platelet-rich plasma; comparison of the concentration-effect 
relationships for maximal vasopressin-induced increases in 
light transmission and reductions in platelet count.
The data show peak increases in light transmission ( • ) and reductions 
in platelet count (A ) induced by vasopressin at the concentrations 
indicated. Data are the means and standard errors from three different 
experiments.
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Tiqure 15. Platelet-rich plasma: PAF-induced reductions in platelet
count and increases in light transmission.
Platelet-rich plasma was prepared, aggregation was monitored photometrically 
and samples were removed at the times indicated for the determination of 
platelet count as described in Methods Section. Aggregation was induced 
by 10 nM (•), 30 nM (A), 100 nM (o) and 300 nM ( m  ) PAF or vehicle ( ^  ). 
The data are means and standard errors from four different experiments.
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Figure 16. Platelet-rich.plasma; comparison of the concentration-effect 
relationships for maximal PAF-induced increases in light 
transmission and reductions in platelet count.
The data show peak increases in light transmission ( • ) and reductions in
platelet count ( jk ) induced by PAF at the concentrations shown. The data
are means and standard errors from four different experiments.
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^ 0 .05)» Those donors whose platelets responded poorly to 
vasopressin addition in whole blood (Fig. 8) Failed to respond 
to vasopressin in PRP and were excluded From this study.
I*3* Agonist-induced platelet aggregation and ATP secretion in 
gel-Filtered platelets
Adrenaline» ADP> vasopressin and PAF induced concentration- 
dependent aggregation (monitored turbidometrically) and ATP 
secretion From Quin 2—loaded, gel-Filtered platelets. Figures 
17-20 show typical aggregation and secretion traces. Responsiveness 
to ADP diminished rapidly (around 30 min) aFter preparation oF 
gel-Filtered platelets.
Having examined the platelet Functional responses to 
agonists, I next assessed the transduction processes activated 
by these same agonists.
1.4. Agonist-induced changes in |ca^^j^
The resting |ca^^jin Quin 2-loaded platelets suspended 
in buFFer A containing 1 mM Ca^^ was 9 0 - 3  riM (mean - S.E.M., 
n = 42). This was elevated in a concentration-dependent manner 
by ADP (0.3 - 10 iiM), vasopressin (l-lOO hM) and PAF (l - I8O nM) 
but was not aFFected by adrenaline ( ^  10 pM). Figure 21 shows 
typical Quin 2 Fluorescence changes in response to these agonists 
From a single experiment. The concentration-response relation­
ships For agonist-induced elevations in ^ are shown in
Figure 22. The rank order oF eFFectiveness in elevating 
^Ca^*] . was PAF > vasopressin ADP > adrenaline = zero. The 
agonist—induced elevations in jca were reduced by
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Figure 17. Aggregation and ATP secretion of Quin 2-loaded, gel-filtered 
platelets induced by adrenaline.
Plasma-free suspensions of Quin 2-loaded platelets were exposed to adrenaline 
at the concentrations indicated and aggregation and ATP secretion were 
monitored as described in Methods Section. The traces show typical responses 
from a single representative experiment.
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Figure 18. Aggregation and ATP secretion of Quin 2-loaded gel-filtered 
platelets induced by ADP.
Piasma-free suspensions of Quin 2-loaded platelets were exposed to ADP 
at the concentrations indicated and aggregation and ATP secretion were 
monitored as described in Methods Section. The traces show typical 
responses from a single representative experiment.
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Figure 19. Aggregation and ATP secretion of Quin 2-loaded gel-filtered 
platelets induced by vasopressin.
Plasma-free suspensions of Quin 2-loadad platelets were exposed to 
vasopressin at the concentrations indicated and aggregation and ATP 
secretion were monitored as described in Methods Section. The traces 
show typical responses from a single representative experiment.
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Figure 20. Aggregation and ATP secretion of Quin 2-loaded gel-filtered 
platelets induced by PAF.
Plasma-free suspensions of Quin 2-loaded platelets were exposed to PAF at 
the concentrations indicated and aggregation and ATP secretion were 
monitored as described in Methods Section. The traces show typical 
responses from a single representative experiment.
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Figure 21. Effects of agonists on platelet
Quin 2-loaded gel-filtered platelets were prepared and exposed to (A) 
vasopressin, (B) ADP, (C) PAF or (O) adrenaline^gt the concentrations 
indicated. Fluorescence was monitored and Ica 
described in Methods Section. Traces show typic; 
single representative experiments.
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Figure 22. Concentration-response relationships for agonist-induced
elevations in p q r
Agonists, at the concentrations indicated, were added to Quin_2-^abelled 
platelets suspended in a medium Ca = 1  mM. Changes in Ca . were
calculated from the observed changes in dye fluorescence. Results are 
means and standard errors from three to nine experiments using platelets 
from different donors.
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Figure 23. Agonist-induced j-Ptd OH formation in human platelets.
Samples (0.4 ml) of | ^^pl-pre-labelled platelets were incubated L
60s) with agonists at the concentrations indicated and levels of| P 1-Ptd
OH were measured as described in.Meth&^s Section. To compensate_for
variations in the basal level ofl PJ -Ptd OH in different experiments 
(range = 202-608 cpm/mg protein) resuTts are expressed as ’fold stimulation’ 
of the basal value (=l). Data shown are representative of at least three
similar experiments using platelets from different donors.
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approximately 80^ by incubation with EGTA (4 mM) to reduce 
the jca ] Q to around 1 - 10 nM (see MacIntyre et al » » 1984).
This elevation of [ca^”^] ^  in the presence of low [ca^ "^ ] ^  is 
taken to represent mobilisation of Ca^ "*" from intracellular 
storage sites (Hallam et , 1984a,b; MacIntyre ^  ad., 1985c).
AgoniSt-induced hydrolysis of inositol phospholipids 
Using ] -P^-labelled platelets suspended in Buffer B,
vasopressin (lO nM - 1 >iM), and PAP (30nM - 1 jiM) induced 
concentration dependent increases in -Ptd OH formation.
In contrast, adrenaline ( <: 30 |lM) and ADP ( ^ 100 p,M) had 
no effect on [^^p] -Ptd OH levels in platelets (Pig. 23)»
II. Platelet responses to addition of more than one stimulatory 
agonist
Having measured the platelet responses to addition of 
single agonists, I then examined the effects of agonist 
combinations on these responses and the accompanying changes 
in the transduction processes.
II.1. Effects of adrenaline on agonist-induced platelet 
aggregation in whole blood
(a) Effects of varying adrenaline pre-incubation time.
This study examined the effects of adding low concentrations 
of adrenaline simultaneously with or up to five minutes before 
ADP, vasopressin or PAP on the extent of agonist-induced 
platelet aggregation. Addition of sub-maximal concentrations 
of adrenaline (causing 5-13^ loss of single platelets)
- 70 -
simultaneously with or 10, 30> 6o, 120 or 300 seconds before 
©qiii—effective concentrations of ADP, vasopressin or PAF 
resulted in the synergistic stimulation of aggregation with 
rapid reductions in single platelet count of up to 80^^
(Figs* 24-26). The magnitude of the synergistic responses were 
independent of the adrenaline pre-incubation time (i.e. the 
maximum responses were not significantly different as judged 
by Student’s t-test; P > 0.1).
(b) Concentration-response relationships.
In order to quantify the degree of potentiation of 
aggregation by adrenaline, the effects of pre-incubation 
(lO sec; 37°C) with sub— and supra-threshold concentrations of 
adrenaline on the agonist concentration-response relationships 
were determined. Adrenaline produced leftward shifts in the 
ADP, vasopressin and PAF concentration-response curves which 
were dependent upon the concentration of adrenaline used 
(Figs. 27A - 29A). The degree of potentiation of agonist- 
induced platelet aggregation was not significantly affected 
by incubation with aspirin (2 mM) to prevent the biosynthesis 
of prostaglandin endoperoxides and TxA^ (Figs. 27B - 29B).
In those cases where vasopressin failed to elicit more than 
50^ aggregation, adrenaline increased the maximum vasopressin- 
induced reduction in platelet count by 10-30^ (Fig. 30A,B).
These effects of adrenaline on agonist-induced platelet 
aggregation differed markedly from the merely additive responses 
seen when a low concentration of an agonist, e.g. PAF, was 
added 10 seconds before increasing concentrations of the same 
agonist (Fig. 31)•
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Figure 24. Effects of adrenaline on ADP-induced reductions in whole blood 
platelet count - effects of varying adrenaline pre-incubation 
time.
Platelet count was measured before and at one minute intervals after the
addition of submaximal concentrations of adrenaline, 10-300 nM (---) or
ADP The solid lines show the changes in platelet count after
the addition of both adrénaline and ADP to the blood samples where 
adrenaline was added simultaneously with (o), 10 seconds (A), 30 seconds 
(u), 1 minute (m ), 2 minutes (•) or 5 minutes ( A ) before the ADP.
The data are mean values from six different experiments. Error bars 
have been omitted for the sake of clarity. In each case, the peak drop 
in platelet count in response to addition of the combination of adrenaline 
and ADP was significantly greater (P <0.05) than the sum of the individual 
responses to adrenaline and ADP added alone.
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Figure 25. Effects of adrenaline on vasopressin-induced reductions in 
whole blood platelet count - effect of varying adrenaline 
pre-incubation time.
Platelet count was measured before and at one minute intervals after the
addition of sub-maximal concentrations of adrenaline, 30-300 nM (-- ) or
vasopressin, 10 nM - 1 ^M The solid lines show changes in
platelet count after the addition of both adrenaline and vasopressin to 
the blood samples where adrenaline was added simultaneously with (o),
10 seconds (A), 30 seconds (O ), 1 minute (■), 2 minutes ( • ) or 
5 minutes ( À ) before the vasopressin. The data shows mean values from 
six different experiments. Error bars have been omitted for the sake of 
clarity. In each case the peak drop in platelet count in response to 
addition of the combination of adrenaline and vasopressin was significantly 
greater (P < 0.05) than the sum of the individual responses to adrenaline 
and vasopressin added alone.
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Figure 26. Effects of adrenaline on PAF-induced reductions in whole 
blood platelet count - effects of varying adrenaline 
pre-incubation time.
Platelet count was measured before and at one minute intervals after the
addition of adrenaline 10-300 nm (-- ) or PAF, 10-100 nM The
solid lines show changes in platelet count after the addition of both 
adrenaline and PAF to the blood samples where adrenaline was added 
simultaneously with (o), 10 seconds (A), 30 seconds (O), 1 minute (# ) , 
2 minutes ( • ) or 5 minutes (A ) before the PAF. The data shows mean 
values from six different experiments. Error bars have been omitted 
for the sake of clarity. In each case the peak drop in platelet count 
in response to addition of the combination of adrenaline and PAF was 
significantly greater (P < 0.05) than the sum of the individual responses 
to adrenaline or PAF added alone.
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Figure 27. Effects of adrenaline on the concentration-effeet relationships 
for reduction in whole blood platelet count induced by ADP.
The maximum reduction in whole blood platelet count was monitored in 
response to ADP (•); ADP plus a sub-threshold concentration of adrenaline, 
30 nM (a ) or ADP plus a concentration of adrenaline giving 5-10% 
reduction in platelet count when added alone, 100 nM ( Q ) in the absence
(a ) or presence (B) of aspirin (2 mM). Adrenaline, where present, was 
added 10 seconds before the ADP. The data are from a single experiment 
representative of five.
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Figure 28. Effects of adrenaline on the concentration-effeet relationships 
for reduction in whole blood platelet count induced by PAF.
The maximum reduction in whole blood platelet count was monitored in response 
to PAF (•); PAF plus a sub-threshold concentration of adrenaline,
100 nM (A ) or PAF plus a concentration of adrenaline giving 5-10% reduction 
in platelet count when added alone, 300 nM (□) in the absence (A) and 
presence (B) of aspirin (2 mM). Adrenaline, when present, was added 10 
seconds before the PAF. The data are from a single experiment representative 
of five.
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Figure 29. Effects of adrenaline on the concentration-effect relationships
for reduction in whole blood platelet count induced by vasopressin
The maximum reduction in whole blood platelet count was monitored in 
response to vasopressin (•); vasopressin plus a sub-threshold concentration 
of adrenaline, 30 nM (A) or vasopressin plus a concentration of adrenaline 
giving 5-10% reduction in platelet count when added alone, 100 nM (Q) in 
the absence (A) or presence (B) of aspirin (2 mM). The data are from a 
single experiment representative of three.
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Figure 30. Effects of adrenaline on the concentration-effect relationships
for reduction in whole blood platelet count induced by vasopressin: 
poor responses seen in some individuals.
The maximum reduction in whole blood platelet count was monitored in response 
to vasopressin (•); vasopressin plus a sub-threshold concentration of 
adrenaline, 30 nM (A) or vasopressin plus a concentration of adrenaline 
giving 5-10% reduction in platelet count when added alone (a) in the 
absence (A) and presence (B) of aspirin (2 mM). The data are from a 
single experiment representative of four.
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Figure 31» Effects of pre-addition of a sub-maximal concentration of PAF 
of the concentration-effect relationship for reduction in 
whole blood platelet count induced by PAF.
The maximum PAF-induced reduction in whole blood platelet count was 
monitored in control samples (•) and in samples pre-incubated (10 sec) 
with PAF, 10 nM (A ). The data are from a single experiment representative 
of four.
- 71 -
Effects of adrenaline on agonist—induced activation of 
Quin 2-loaded gel-filtered platelets
This study examined the effects of subthreshold concentrations 
of adrenaline on aggregation and ATP secretion induced by ADP, 
vasopressin and PAF in Quin 2-loaded gel-filtered platelets*
In agreement with previous reports using PRP (Ardlie ^  al.,
1966; Grant & Scrutton, 1980a; Vargaftig et al., I982), 
aggregation induced by sub-maximal concentrations of ADP 
(0.3 - 3 pM), vasopressin (3 - 30 nM) and PAF (l - 18 hM) were 
augmented significantly by simultaneous or prior (lO - 60 sec) 
addition of sub-threshold concentrations of adrenaline 
(0.1 - 1 p,M). The degree of potentiation observed was independ­
ent of the adrenaline pre-incubation time (Figs* 32A - 3^)* 
Adrenaline (O* 1 - 1 p,M) also potentiated agonist-induced ATP 
secretion (shown in Figure 32B for vasopressin)*
The mechanisms underlying potentiation of platelet 
activation by adrenaline were assessed by examining the effects 
of (a) adrenaline on agonist-induced elevation of [ca^^j ;
(b) adrenaline on agonist-induced ^ ^ P  ] -Ptd OH formation
and (c) activation of protein kinase C and elevation of C^a^ '*^ j ^
alone and in combination on agonist-induced platelet activation*
II.3 . The roles of [ca^^]^ and inositol phospholipid hydrolysis 
in the potentiation of platelet activation by adrenaline
(a) Effects of adrenaline on agonist-induced elevation of
[ca^ '*']^  was monitored in parallel with the aggregation and 
secretion responses described above (Section II* 2)* Addition of 
adrenaline (0*1 - 1 p.M) simultaneously with or up to 60 sec
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Figure 32(A). Effects of adrenaline on vasopressin-induced aggregation of 
Quin 2-loaded gel-filtered platelets - typical aggregometer 
traces.
Vasopressin, VP (3 nM) was added to stirred samples of Quin 2-loaded 
platelets which had been incubated with saline or adrenaline, ADR (100 nPl) 
for the times indicated and aggregation was monitored photometrically as 
described in Methods Section. Prolonged incubation with adrenaline (100 nM) 
did not result in any increase in light transmission and inclusion of the 
cyclo-oxygenase inhibitor flurbiprofen (10 P M) in the incubation medium 
did not affect the pattern of responsiveness.
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Figure 33. Effects of adrenaline on ADP-induced aqgreqatloim of 
loaded gel-filtered platelets*
ADP (300 nM) was added to stirred samples of Quin 2-loaded platelets 
which had been incubated with adrenaline, Adr (100 mM) for the times 
indicated and aggregation was monitored photometrically as described 
in Methods Section. Traces show typical aggregation responses from a 
single representative experiment.
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Figure 34. Effects of adrenaline on PAF-induced aggregation of Quin 2- 
loaded gel-filtered platelets.
PAF (3 nM) was added to stirred samples of Quin 2-loaded platelets which 
had been incubated with adrenaline, ADR (100 nPl) for the times indicated 
and aggregation was monitored photometrically as described in Methods 
Section. Traces show typical aggregation responses from a single 
representative experiment.
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before sub-maximal concentrations of ADP (l p,M), vasopressin 
(3 — 10 nM) or PAF (l — 18 nM) resulted in enhancement of 
agonist-induced elevations in (Figs. 35A-C). The
degree of potentiation of [oa^^J^ was apparently dependent 
upon the adrenaline pre—incubation time. Potentiation of 
vasopr es sin-induced elevation of ^Ca^^j by adrenaline (lO sec 
incubation) was not significantly affected by incubation 
(30—60 min) with the cyclo-oxygenase inhibitor flurbiprofen,
10 p,M (Fig. 36). Vasopressin (lO nM)-induced mobilisation of 
internal Ca^^ (i.e. the ^Ca^^j rise monitored in the presence 
of EGTA, kr mM) also was potentiated by 60 - 179^  (mean - S.E.M. , 
n = 3 ) following pre-incubation (lO sec) with adrenaline (o.l p,M). 
It should be noted that, in all cases, the magnitude of the 
elevations in |ca^^j were relatively small, even in the presence 
of adrenaline where maximal aggregation and ATP secretion 
occurred. The rises elicited by the various agonists in the 
presence of 1 mM |ca^^j ^  are listed in Table 3*
(b) Effects of adrenaline on vasopressin-induced inositol 
phospholipid hydrolysis.
To investigate the possible involvement of inositol phospho­
lipid hydrolysis and DG formation in the potentiation of platelet 
activation, the effects of adrenaline on vasopressin-induced 
j^ ^^ P J -Ptd OH formation were examined. The stimulation of 
^^^P J-Ptd OH formation by sub-maximal concentrations of 
vasopressin (lO - 100 nM) was augmented by adrenaline; significant 
potentiation was observed when adrenaline was added simultaneously 
with or 10-60 sec before vasopressin (Fig. 37)»
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Saline-PAF 
Adr-0 sec-PAF 
Adr-10 sec-PAF 
Adr-30 sec-PAF 
Adr-60 sec-PAF
Sallne-ADP 
Adr-0 sec-ADP 
Adr-10 sec-ADP 
Adr-30 sec-ADP 
Adr-60 sec-ADP
H *
Figure 35. Effects of adrenaline on agonist-induced elevation of  ^ ^.
Quin 2-loaded gel-filtered platelets, prepared as described in Methods 
Section, were incubated with saline or adrenaline (iP-M) for the times 
indicated prior to the addition of (A) vasopressin (3-10 nM); (B) PAFg^
(1-18 nM) or (C) ADP (0.3 - l^M). Fluorescence was monitored and Ca  ^
was calculated as described in Methods Section. The data are means 
and standard errors from three to seven experiments and are ex^Çessed 
as percentage of the control jCsaline-treated) elevation of [ca 1. above 
the resting leypl,.<Basal ^as 90 - 3 nM and the control “(iOO?S)
elevations in [Ca J. were (A) 8 0 - 8  nM; (B) PAF: 70 - 12 nM and
(C) ADP; 35 - 9 nM. ^Data were compared to saline controls using Student's 
t-test: *P < 0.05.
% of control response
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__L_
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— i ■ 300_I
(a) Control 
Saline + VP
Adr + VP
----- 1
(b) Flurbiprofen;- 
Saline + VP 
Adr + VP
Figure 36. Effects of flurbiprofen on potentiation of vasopressin-induced
elevation of
.ur
a by adrenaline.
Quin 2-loaded gel-filtered platelets prepared as described in Methods Section 
were incubated with saline or adrenaline (100 nM) for 10 seconds prior to 
the addition of vasopressin (10 nM) in the absence (a) or presence (b) of 
flurbiprofen (10 >iM; 30 min incubation). Elevations in [Ca above the
resting level (90 - 3 nM) were monitored as described in Methods Section.
The control rises in |^ Ca . were (a) 4-5 — 15 nM and (b) 30 — 5 nM. Data 
are from a single experiment (representative of three similar) and were 
compared to saline controls using Student's t—test: *P<0.05.
TABLE 3. Effects of adrenaline on agonist—induced elevations in ^Ca^
Agonist Elevation in ^Ca (nM)
Control
Adrenaline preincubation time 
0" 10" 30" 60"
ADP (1 PM) 35 i 5 50 i 4 77 i 11 85 - 14 74 - 20
UP (10 nM) 80 i 8 125 i 30 160 - 25 95 i 15 100 - 10
PAF (1 nM) 75 i 9 105 ± 3 130 - 20 105 i 15 115 - 15
Samples (2 ml) were incubated (37°C) with saline (vehicle) or adrenaline 
(O.l - 1 p-M) for the times indicated prior to the addition of ADP (ipM), 
vasopressin (10 nM) or PAF (1 nM) and increases in | Ca were monitored 
as described in Methods Section. The data are means and standard errors 
from three to seven experiments using blood from different donors.
% of control response
Additions
r
100 
I__
200
_J
Saline-VP 
ADR-Osec-VP 
ADR-1Osec-VP 
ADR-30sec-VP
ADR-60sec-VP
A
H
A
Figure 37. Effects of adrenaline on vasopressin-induced ]-Ptd OH
formation.
Plasma-free suspensions of [^^Pj-P. labelled platelets, prepared as described 
in Methods Section, were incubated^with saline or adrenaline, ADR (100 nM) 
for the times indicated prior to the addition of vasopressin, VP (30 nM) for 
a further 30 seconds. [ P |-Ptd OH formation was monitored as described in 
Methods Section. Incubations were carried out in the presence of flurbiprofen 
(10 pM). Results are expressed as percentage of the saline control which 
represents a 2-3 fold stimulation of ^^P -Ptd OH formation. Data are means 
and standard errors from a single experiment which was typical of three 
similar experiments. Data were compared to saline control using Student's 
t-test; *P<0.05; **P< 0.005.
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(c) Effects of ionomycln on ^ and vasopressin—induced
platelet activation.
To clarify the role of elevation of in potentiati
of platelet activation, the effects of the Ca^*—ionophore, 
ionomycin on |ca^^j and on aggregation and ATP secretion 
induced by sub—maximal concentrations of vasopressin were 
examined. In these studies, due to the strong affinity of 
ionomycin for albumin, bovine serum albumin was omitted from 
the buffer (Buffer A). Under these conditions, approximately 
ten-fold lower concentrations of vasopressin were required to 
induce platelet activation. Ionomycin (lO - 100 nM) evoked 
elevations in which were approximately additive with
vasopressin (l nM)-induced rises in when the ionomycin
was added 10 sec before vasopressin (Table 4). Ionomycin at 
concentrations which produced small elevations in jca^ '*’j ^
(Table 4) and which did not induce platelet aggregation (as 
monitored turbidometrically) or ATP secretion, slightly enhanced 
the rate and extent of vasopressin-induced platelet aggregation 
(Fig. 38). However, at these concentrations, ionomycin failed 
to convert the vasopressin-induced reversible response ('primary* 
aggregation) to an irreversible ('secondary') aggregation 
associated with secretion (Fig. 38A, B). In contrast, under 
the same conditions, sub-threshold adrenaline markedly 
potentiated the vasopressin responses resulting in 'secondary* 
aggregation and ATP secretion (Fig. 38A). Note that under 
these experimental conditions, the elevations in |ca J 
induced by ionomycin in combination with vasopressin were 
greater than or equivalent to those produced by vasopressin
TABLE 4. Effects of ionomycin and vasopressin on platelet
Ionomycin
(nM)
Increase in [Ca"^]. (nM)
Without VP With VP
0 - 70 - 15
10 15 i 3 80 - 15
50 50 - 10 180 i 45
100 210 i 45 300 - 60
Samples (2 ml) were incubated with vasograssin (l nM) and/or ionomycin
at the concentrations indicated and 
in Methods Section. DMSO (0.5^), th 
on vasopressin-induced elevation of
standard errors from three experiments using blood from different donors
Ca“' I. was monitored as described 
ignomycin vehicle, had no effect 
Ca L. The data are means and
50 n
£1en
0-1
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PMA I VP 
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Figure 38(A). Effects of ionomycin and PMA on vasopressin-induced
aggregation of Quin 2-loaded gel-filtered platelets - 
typical aggregometer traces.
Vasopressin, VP (1 nM) was added to stirred samples of Quin 2-loaded 
platelets which had been incubated with ionomycin (100 nM) and/or PMA 
(10 nM) for the times indicated and aggregation was monitored photo­
metrically as described in Methods Section. DMSO (0.5^), the vehicle 
for ionomycin and PMA had no significant effect on vasopressin-induced 
platelet aggregation. The effect of adrenaline pre-incubation is shown 
for comparison.
n.
Additions
X of control response 
100 200
DMSO-VP 
iONO (lOnM)-VP 
lONO (SOnM)-VP 
IONO (lOOnM)-VP
PMA (2nM)-VP 
PMA (lOnM)-VP
PMA(1OnM)-IONO(1OOnM)-VP
300 600
-\V-^
650
Figure 38(B). Effects of ionomycin and PMA on vasopressin-induced 
aggregation and ATP secretion of Quin 2-loaded gel- 
filtered platelets - bar graphs.
Vasopressin was added to stirred samples of Quin 2-loaded gel-filtered 
platelets which had been incubated with DMSO (0.5%), ionomycin (100 nM) 
and/or PMA (10 nM) and the initial rate of aggregation (open bars) and the 
degree of ATP secretion (solid bars) were determined as described in 
Methods Section. The data are means and standard errors from five 
different experiments. Data were compared to DMSO controls using Student's 
t-test: *P <0.05; **P <0.005.
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in combination with adrenaline (Tables 3 and 4).
(d) Effects of PMA and ionomycin on vasopressin-induced platelet 
activation.
To clarify the role of enhanced inositol phospholipid 
hydrolysis and DG formation in the potentiation of platelet 
activation by adrenaline, the effects of PMA (effectively a 
mimic of endogenous DG) on aggregation and ATP secretion induced 
by a sub-maximal concentration of vasopressin were examined.
Pre—incubation of platelets with sub-threshold concentrations 
of PMA ( ^  10 nM; 30 sec) resulted in a small but significant 
potentiation of vasopressin-induced primary aggregation with 
no enhancement of ATP secretion (Fig. 38A, B). Higher 
concentrations of PMA resulted in full aggregation and ATP 
secretion, when added alone (not shown). Incubation of platelets 
with PMA (10 nM) and ionomycin (lOO nM) had little direct effect 
on platelet aggregàtion (as monitored turbidometrically) or 
ATP secretion (Fig. 38A). However, the subsequent addition 
of vasopressin resulted in rapid, irreversible aggregation 
accompanied by secretion of ATP, and the extent of the response 
was comparable to that elicited by adrenaline and vasopressin 
in combination (Fig. 3^A, B).
III. Effects of adenylate cyclase stimulants (PGI_ and PGD_)
on platelet responses
In this study I examined the effects of elevation of cyclic 
AMP levels on different platelet responses and the underlying 
transduction processes. The aims of this study were (a) to 
examine the relative susceptibility of whole blood aggregation
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induced by different agonists (which utilise different 
transduction processes) to inhibition by adenylate cyclase 
stimulants and (b) to examine the mechanism of inhibition of 
platelet responsiveness by cyclic AMP and the relative 
susceptibility of different responses and transduction processes 
to inhibition by cyclic AMP.
lll-l* Effects of PGI_ and PGD^ on aggregation in whole blood
(a) Effects of varying prostaglandin pre—incubation time.
Incubation (37^C) of blood samples for 90 sec, 3 or 3 min 
with PGDg (lO ^M) or PGI^ (3 x 10 ^M) resulted in inhibition 
of ADP-induced platelet aggregation in whole blood. The 
degree of inhibition was independent of the PGD^ or PGI^ 
pre-incubation time and largely could be overcome by increasing 
concentrations of ADP (Figs. 39 and 4o).
(b) Differential effects of PGI^ and PGD^ on agonist 
concentration-response relationships.
This study examined the effects of single concentrations 
of the adenylate cyclase stimulants PGD^ (lOO nM) and PGI^
(3 nM) on whole blood platelet aggregation induced by adrenaline, 
ADP (both adenylate cyclase inhibitors) and vasopressin and PAF 
(which do not affect adenylate cyclase activity in intact 
platelets). Pre-incubation (90 sec; 37^0) with PGD^ (lO ^M) 
had no significant effect on adrenaline-induced aggregation of 
platelets in whole blood (Fig. 41A). This concentration of 
PGD^ produced an approximate 10-fold shift to the right of the 
ADP concentration-response curve (Fig. 41B) and, apparently, 
irreversibly inhibited aggregation induced by PAF and vasopressin
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Figure 39. Effects of incubation for 90 seconds, 3 and 5 minutes with PGI. 
on ADP-induced aggregation in whole blood.
ADP-induced platelet aggregation in whole blood was monitored as described 
in Methods Section in control samples ( • ) and in samples pre-incubated 
for 90 seconds (&), 3 minutes (Q) or 5 minutes (o) with PGIg (3 nM).
Data are from a single experiment representative of five.
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Figure 40. Effects of incubation for 90 seconds, 3 and 5 minutes with 
PGDL on ADP-induced aggregation in whole blood.
ADP-induced platelet aggregation in whole blood was monitored as described 
in Methods Section in control samples ( • ) and in samples incubated for 
90 seconds (A), 3 minutes (D) or 5 minutes (o) with PGDg (100 nM). Data 
are from a single experiment representative of five.
100-,
(a) a d r e naline (b) ADP
(c) PAF2  100 vasopressin
/
/
(Agonist] (moles/lItre)
Figure 41. Effects of PGOL on agonist-induced platelet aggregation in 
whole blood.
Aggregation was monitored in response to (a) adrenaline, (b) ADP, (c) PAF 
and (d) vasopressin in control (•) and PGD - (100 nM; 90 second pre-incubation) 
“treated (A ) whole blood samples as described in Methods Section. The data 
are from single experiments representative of at least three others.
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Figure 42. Effects of PGI_ on agonist-induced platelet aggregation 
in whole blood.
Aggregation was monitored in response to (a) adrenaline, (b) ADP,
(c) PAF and (d) vasopressin in control (•) and PGIg-flOO nM; 90 second 
pre-incubation)-treated (A) whole blood samples as described in Methods 
Section. The data are from single experiments representative of at least 
three others.
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(Fig* 4lC and D) • Similarly, the inhibitory effects of PGI^
(3 X 10 ^M) on platelet aggregation in whole blood could be 
overcome by increasing concentrations of adrenaline (Fig* 42a) 
and ADP (Fig* 42b) but not PAF (Fig* 42c) or vasopressin 
(Fig* 42d) * Higher concentrations of PGl^ PGD^ did inhibit
adrenaline-induced aggregation in whole blood (not shown)*
111*2* Effects of elevation of platelet cyclic AMP content on 
agonist-induced platelet responses in Quin 2-loaded, 
gel-filtered platelets
In order to determine the relationship between elevation of 
cyclic AMP content and the degree of inhibition of distinct 
platelet functional responses and transduction processes, the 
effects of PGD^ on cylcic AMP content and PAF-induced shape 
change, aggregation, ATP secretion, stimulation of [^^pj-Ptd OH 
formation and elevation of |ca^^j ^  were examined* Incubation 
with 18 nM PAF resulted in sub-maximal aggregation, ATP secretion, 
shape change, ] -Ptd OH formation and elevations in
(as described in Sections 1*3 — 1*3)* PGD^ ( l  — 300 nM) caused 
concentration-dependent inhibition of PAF (l8 nM)-induced 
aggregation, ATP-secretion, shape change, p^p]-Ptd OH formation 
and elevation of ^ monitored both in the presence and in
the absence of EGTA (Fig* 43)* PGD^ was more potent as an 
inhibitor of PAF-induced ATP secretion (l^^, i*e* the 
concentration causing O^io inhibition, 2 nM) and aggregation 
(l^Q 3 nM) than of [^^p] -Ptd OH formation (l^^ 10 nM),
shape change (l^^ ^  30 nM) and elevation of (^50 ?iM)*
Mobilisation of internal Ca^* (i*e* monitored in the presence
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of EGTA, h ihM) and the elevation of [oa^^J ^  that results from 
both influx and mobilisation (i.e. monitored in the presence 
of j^ Ca "*’Jq = 1 mM) were equally susceptible to inhibition by 
PGD^ (Eig. 43e and f). During these experiments, sub-samples 
(0.5 ml) of platelets were removed from the aggregometer or 
fluorimeter cuvettes prior to the addition of PAF, for the 
estimation of cyclic AMP content. In the phospholipid studies, 
cyclic AMP content was monitored in parallel samples which had 
not been treated with ^^^P j -P^. The effects of PGD^ on cyclic 
AMP content under these conditions are shown in Figure 44.
The degree of inhibition of the various platelet responses 
could be correlated with the rise in cyclic AMP content elicited 
by PGD^ in the same (or parallel samples for [^^p] -Ptd OH 
formation) platelet samples (Fig. 43)* PAF-induced ATP secretion 
and aggregation were very susceptible to small increments in 
the cyclic AMP content, both being abolished by a doubling 
in the cyclic AMP content. However, [^^p] -Ptd OH formation, 
shape change and elevation of ^ were less susceptible;
maximal inhibition of these responses did not occur until 
the cyclic AMP content had been elevated by greater than ten­
fold (Fig. 45)*
To test whether this apparent increased sensitivity of 
aggregation over shape change to inhibition by PGD^ also 
occurred with other stimulants of platelet adenylate cyclase, 
gel-filtered platelets were incubated (90 sec; 37°C) with PGIg 
(0.1 - 3 nM) which also resulted in concentration-dependent 
elevation of platelet cyclic AMP content (Fig. 46). PAF- 
induced platelet responses were also differentially inhibited 
by PGI^: PAF (I.8 nM)-induced shape change was less susceptible 
to inhibition by PGI^ than was aggregation induced by 18 nM
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Figure 43. Effects of PGDn on PAF-induced platelet responses
Plasma-free platelet suspensions, prepared as described in Methods Section, 
were incubated with PGD„ (90 sec; 37 C) at the concentrations indicated 
before the addition of PAF (18-180 nM). Inhibition of PAF-induced (a)
aggregation, (b) ATP^^ecretion, (c) shape change, (d)_ I^ P^j -Ptd OH formation 
(e) elevation of [Ca J . in the presence of 1 mM- [Ca J and (f) Ca 
mobilization in the presence of EGJA (4 mM) were monitored as described 
in Methods Section. Note t^at [Ca changes in part (e) result from 
mobilisation of internal Ca stores and influx of external Ca ^ whilst 
those in part (f) result from mobilisation of internal Ca ^ stores alone.
The data are mean values and standard errors from between two and seven 
different experiments each performed in triplicate. The date were compared 
to control values using Student's t-test: *P<0.05; **P <0.005.
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Figure 44. Effects of PGD^ on platelet cyclic AMP content.
Plasma-free platelet samples (0.2 - 0.4 ml) were incubated(90 seconds; 
37°C) with PGD„ at the concentrations indicated and cyclic AMP content 
was measured as described in Methods Section. The data are mean values 
and standard errors from sixteen different experiments each performed 
in triplicate and results were compared to control values using Student's 
t-test: *P<0.05; **P <0.005.
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Figure 45. Relationship between platelet cyclic AMP content and inhibition 
of PAF-induced platelet responses»
Plasma-free platelet suspensions were incubated with PGD_ (1-300 nM;
90 seconds; 37°C) before the addition of PAF (18 - 180 nM) and/or removal 
of a sample for estimation of cyclic AMP content^ Inhibition of PAF- 
induced ATP-secretion (M), aggregaiiog i □  ), I pj -PtdOH formation (A)» 
shape change (•) and elevation of Ca . (o) are^shown as a function of 
the fold-rise in cyclic AMP content of eichugjatelet sample (or parallel 
samples for the phospholipid studies where I P|—P^ wgs omitted). The 
basal cyclic AMP content was 6.9 — 0.4 pmoles per 10 platelets. The 
data are mean values from 2—7 experiments and error bars were omitted 
for the sake of clarity.
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Figure 46. Effects of PGI_ on platelet cyclic AMP content.
Gel-filtered platelets (0.4 ml) were incubated with PGIg (90 seconds; 
37 C) at the concentrations indicated and cyclic AMP content was 
determined as described in Methods Section. The data are mean values 
and standard errors from three different experiments and results were 
compared to control values using Student's t-test; *P < 0.005.
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Figure 47. Effects of PGI_ on PAF-induced platelet aggregation and shaom 
change.
Gel-filtered platelets were incubated with PGIg (90 sec; 37°C) at the 
concentrations indicated and PAF (18 nM)-induced aggregation (A) and 
shape change (•) were monitored as described in Methods Section. The 
data are from a single experiment representative of three and show 
inhibition of the extent of PAF (18 nM)-induced aggregation and ATP 
secretion.
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PAF in parallel samples (Fig. 47).
• Reversal of* prostagiandin—induced elevations in cyclic AMP 
content and inhibition of platelet function by stimulatory 
agonists
The effects of combinations of platelet stimulatory and 
inliibitory agonist on cyclic AMP levels and various platelet 
responses were investigated. The aim of this study was to 
examine the regulation of platelet responsiveness and transduction 
processes by cyclic AMP in the presence of multiple agonists.
IV.1. Effects of adrenaline and vasopressin on inhibition of 
PAF-induced platelet aggregation in whole blood by PGT^ 
and PGD_
Inhibition by PGD^ of PAF-induced platelet aggregation in
—7
whole blood was reversed by adrenaline (lO M) added 30 sec 
after the PGD^ (Fig. 48). This concentration of adrenaline 
produced 5 - 3^ aggregation when added, alone, to blood samples.
In contrast, the inhibition of PAF-induced aggregation by PGD^ 
was not reversed by vasopressin (3 x 10 M) (Fig. 48). This 
concentration of vasopressin, when added alone, produced 
6o i 3^ aggregation. Similarly, inhibition of PAF-induced 
aggregation by PGI^ (3 x 10~^M) could be reversed by adrenaline 
(lO"^M) but not by vasopressin (lO ^M) (Fig. 49)•
IV.2. Effects of agonists on PGI^-induced inhibition of platelet 
function and elevations in cvclic AMP content in Quin 2- 
loaded, gel-filtered -platelets 
Aggregation, ATP secretion and elevation of in
response to PAF (l8 nM) were significantly inhibited in platelets
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Figure 48. Effects of vasopressin and adrenaline on the inhibition of 
PAF-induced aggregation in whole blood by PGD_.
PAF-induced whole blood platelet aggregation was monitored as described 
in Methods Section in control samples (#); samples incubated with PGD^:
100 nM, 90 seconds (A); PGD.: 100 nM, 90 seconds plus vasopressin:
300 nM, 60 seconds (o) or PGD^: 100 nM, 90 seconds plus adrenaline:
100 nM, 60 seconds (□)•’ The data are from a single experiment representative
of four.
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Figure 49. Effects of vasopressin and adrenaline on the inhibition of 
PAF-induced aggregation in whole blood by PGI..
PAF-induced whole blood platelet aggregation was monitored as described 
in Methods Section in control samples (#); samples incubated with PGIg 
3 nM, 90 seconds (A); PGI„: 3 nM, 90 seconds plus vasopressin:
1 p-M, 60 seconds (o) or PGI^: 3 nM, 90 seconds plus adrenaline: 100 nM, 
60 seconds (O ). The data are from a single experiment representative 
of four.
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pre-incubated (90 sec; 37^C) with (5 nM) (Fig. 50).
The inhibitory effects of PGI^ on these responses were reversed 
by adrenaline ( and ADP (3 pM) but not by vasopressin
(2 pM) (Fig. 30)* Vasopressin (30 nM)—induced aggregation, 
ATP-secretion, elevation of [ca^‘‘] ^  and p ^ P  ] -PtdOH formation 
were also inhibited in platelets treated (90 sec; 37°C) with 
PGI^ (3 nM) (Fig. 31)* Inhibition of vasopressin-induced 
platelet responses was also prevented by adrenaline (3 pM)
(Fig. 31)» Under these conditions, inhibition of platelet 
function by PGI^ was associated with elevation of the platelet
cyclic AMP content from the basal value of around 3 pmoles
8 8 per 10 platelets to 3O-6O pmoles per 10 platelets (Fig. 32).
This PGI^-induced elevation in cyclic AMP content was prevented
by adrenaline (3 pM) and ADP (3 pM) but was unaffected by
vasopressin ( 2 pM) or PAF (9OO nM) (Fig. 32).
IV.3 . Effects of adrenaline on inhibition of platelet function 
by IBMX and 8 bromo-cyclic AMP 
Incubation of gel-filtered platelets (30 min; 37°C) with 
the cyclic AMP phosphodiesterase inhibitor IBMX (l mM) resulted 
in an approximate doubling of the platelet cyclic AMP content.
The IBMX-induced rise in cyclic AMP content was not significantly 
altered by further incubation (90 sec; 37°C) of platelets with 
adrenaline (3 pM) (Table 3). Under these conditions, IBMX 
inhibited aggregation and ATP secretion induced by PAF (I8 nM) 
and these effects were not attenuated by adrenaline (3 pM)
(Fig. 33). Similar findings were obtained using 8 bromo-cyclic 
AMP (data not shown). In addition, PAF (l8 nM)-induced 
elevation of was suppressed by pre-incubation (30 min;
Additions % of control response
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1
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Elevation of CCa^ '^ lj
Figure 50. Effects of adrenaline, ADP and vasopressin on the inhibitipp of 
PAF-induced aggregation, ATP secretion and elevation of fca 17 
by PGÏ_. [
PAF (18 nM)-induced gggregation (cpen bars), ATP secreticn (hatched bars) 
and elevation of Ca |. (solid bars) were monitored in parallel in Quin 2- 
loaded gel-filtered platelets as described in Methods Section. Where 
indicated, platelets were pre-treated with PGI_ (3 nM) or vehicle (Tris pH 9) 
for 90 seconds and saline, adrenaline (5 M), ADP (5>iM) or vasopressin (2p-M) 
for 60 seconds. The data are means and standard errors from a single 
experiment (representative of three) performed in triplicate.
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Figure 51. Effects of adrenaline on the inhibition of V/asopressin-induced 
aggregation, ATP secretion, elevation of |Ca^+l\ and 1-Ptd 
OH formation.  ^  ^ ^
Vasopressin (30 nM)-inducad aggregation (open_barsl, ATP-secretion (hatched 
bars), elevation of jCa (solid bars) and I P -Ptd OH formation (dotted 
bars) were monitored^in pÆsma-free platelet suspensions as described in 
Methods Section. Where indicated, platelets were pre-treated with PGI^
(5 nM) or vehicle (Tris pH 9) for 90 seconds and saline or adrenaline 
(5 yM) for 60 seconds. The data are means and standard errors from single 
experiments (representative of at least two similar experiments) performed 
in triplicate.
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Figure 52. Effects of agonists on PGI^-induced elevation of platelet 
cyclic AMP content.
Gel-filtered platelets (0.4 ml) were incubated (37°C) with PLI^ (5 nM) 
or vehicle (Tris pH 9) for 90 seconds and with saline, adrenaline (B^lM), 
ADP (5pM), vasopressin (2 p,M) or PAF (900 nM) for 50 seconds. Cyclic 
AMP content was monitored as described in Methods Section. The data are 
means and standard errors from a single experiment (representative of 
three) performed in triplicate. Agonist-treated samples were compared to 
the PGIn-saline control using Student's t-test: **P < 0.005. Adrenaline,
ADP, vasopressin or PAF had no significant effect on the basal cyclic AMP 
content when added alone (not shown).
TABLE 5. Effects of adrenaline and IBMX on platelet cyclic AMP content,
Treatment Cyclic AMP content 
(pmol/lO^ platelets)
Control 8.6 i 0.4
IBMX (1 mM) 19.8 i 3.2
IBMX + Adrenaline
(imM) (5 vlM) 17.8 - 3.7
Adrenaline (5 p-M) 8.4 i 0.3
Control or IBMX (1 mM; 10-30 min; 37°C)-treated gel-filtered platelet 
samples (0.4 ml) were incubated (30 sec; 37°C) with saline or 
adrenaline (5p.M) and cyclic AMP content was measured as described in 
Methods Section. The data are means and standard errors from a single 
experiment representative of three similar.
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Figure 53. Effects of adrenaline on the inhibition of PAF-induced 
aggregation and ATP secretion by IBMX.
PAF (18 nM)-induced.aggregation (open bars) and ATP secretion (hatched bars) 
were monitored in gel-filtered platelets as described in Methods Section. 
Where indicated, platelets were pre-incubatod with IBMX (1 mM; 10-30 min; 
37°C) and saline or adrenaline (5p.M; 30 sec; 37 C). The data are means 
and standard errors from a single experiment (representative of three) 
performed in triplicate. Results were compared to the PAF control using 
Student's t-test: **P <0.005.
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Figure 54. Effects of adrenaline on the inhibition of PAF-induced elevation 
of ^Ca^+j  ^by 8 bromo-cvclic AMP.
PAF (18 nM)-induced elevation of Fca^^J. was monitored in Quin 2-loaded 
gel-filtered platelets as described in Aethods Section. Where indicated, 
the platelets were pre-incubated (37°C) with 8-bromo-cyclic AMP (l mM;
30 min) and saline or adrenaline (5 p,M; 30 sec). The data are means and 
standard errors from a single experiment (representative of three) 
performed in triplicate. Results were compared to PAF control using 
Student's t-test: *P < 0.05.
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37 C) with 8 bromo-cyclic AMP (l mM) and this inhibitory effect 
was not modified by adrenaline (5 ]iM) (Fig. 5k),
V . Effects of activation of protein kinase C by PMA on platelet 
cyclic AMP metabolism
This study examined the possible regulation of platelet 
cyclic AMP metabolism by activation of protein kinase C.
V.1. Effects of phorbol esters on basal, IBMX- and PGD^-elevated 
platelet cyclic AMP content
Incubation (4 min; 37°C) of gel-filtered platelets with 
PMA (3 - 300 nM) had no significant effect on the cyclic AMP 
content of control (untreated) or IBMX (imM)-treated platelets 
(Fig. 5 5 )• However, elevation of platelet cyclic AMP content 
induced by PGD^ (3OO nM; 2 min) was inhibited, in a concentration- 
dependent manner, by pre-incubation (2 min; 37°C) with PMA 
(3 _ 300 nM). The 1^^ for this effect was around 7» 3 tlM* This 
effect of PMA was not shared by the inactive, non-tumour- 
promoting, phorbol ester 4aPDD (Fig. 3^).
As PMA is known to induce platelet activation, degranulation 
and eicosanoid biosynthesis, it was possible that the effects 
of the tumour-promoting phorbol ester on agonist-induced cyclic 
AMP formation were mediated by agents (e.g. ADP, TxA^) released 
by platelets and which are claimed to inhibit adenylate cyclase.
To investigate the role of PMA-induced TxA^ formation in this 
effect, platelets were incubated (13 - 60 min; 37°C) with the 
cyclo-oxygenase inhibitor flurbiprofen (lO )iM) to prevent the 
biosynthesis of prostanoids. Flurbiprofen had no significant 
effect on the inhibition of the PGD^-induced rise in cyclic AMP
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Figure 55. Effects of PMA on basai and IBMX-elevated cyclic AMP content,
Control (•) and IBMX (1 mM; 30-60 minj-treated gel-filtered platelet 
samples (A) were incubated (4 min; 37 C) with PMA at the concentrations 
indicated and cyclic AMP content was monitored as described in Methods 
Section. The data are means and standard errors from three different 
experiments.
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Figure 56. Effects of PMA and 4 aPDD on PGD^-induced elevation of platelet 
cyclic AMP content.
Gel-filtered platelet samples (0.4 ml) were incubated (37°C) with PMA (•) 
or 4&PDD ( A ) at the concentrations indicated for 2 minutes before the 
addition of PGDL (300 nM) for a further 2 minutes. Cyclic AMP content 
was monitored as described in Methods Section. For the sake of comparison 
between different experiments, results are expressed as percentage of the 
control rise in cyclic AMP content induced by PGD^ (300 nM) in the presence 
of the PMA vehicle, DMSO (0.25%). The basal cyclic AMP content was 8.3 - 
0.4 nM and this was raised to 124 - 10 nM in the presence of PGD^ (300 nM). 
The data are means and standard errors from three different experiments.
- 81 -
although there was a slight increase in the I^q to around 
10 nM (Fig. 57).
The role of PMA-induced ADP release in blocking PGD^— 
induced cyclic AMP formation were investigated by treating 
platelets (lO - 50 min; 37^0) with the ADP scavengers; apyrase 
(10 units of ADPase activity per ml of gel-filtered platelets) 
or creatine phosphate (2 mM) plus creatine phosphokinase (50 units 
per ml). Apyrase (lO units per ml) prevented the inhibition 
of PGD^-induced elevation of cyclic AMP by exogenously added 
ADP (1 - 10 p,M) but had no significant effect on the inhibition 
by PMA (3 - 300 nM). The 1^^ for inhibition by PMA in the 
presence of apyrase was around 11 nM (Fig. 58). In the presence 
of creatine phosphate/creatine phosphokinase, PMA inhibited the 
rise in cyclic AMP content with an 1^^ of around 2.6 nM (Fig. 59)»
Thus, PMA-induced inhibition of the rise in platelet 
cyclic AMP content cannot be attributed to formation or release 
of endogenous inhibitors of adenylate cyclase. Activation of 
phosphodiesterase by protein kinase C could contribute, at 
least in part, to the actions of PMA. Accordingly, the effects 
of PMA on PGD^-induced cyclic AMP formation were examined in 
the presence of IBMX. PGD^-induced elevation of cyclic AMP 
content was doubled in platelets incubated (15 - 60 min; 37°C) 
with IBMX, 1 mM (Table 6). Under these conditions, IBMX only 
partially inhibited the abrogation of PGD^-induced elevation 
of cyclic AMP content by PMA. In the presence of IBMX (l mM),
PMA inhibited PGD^-induced cyclic AMP formation with an 1^^ 
of around 30 "uM (Fig. 60).
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Figure 57» Effects of flurbiprofen on the inhibition of PGD^-induced 
elevation of cyclic AMP content by PMA.
Control (•) and flurbiprofen (10 p, n)-treated ( ^  ) gel-filtered platelet 
samples (0.4 ml) were incubated (37°C) for 2 minutes with PMA at the
concentrations indicated before the addition of PGDg (300 nM) for a
further 2 minutes and cyclic AMP content was monitored as described in
Methods Section. For the sake of comparison between different experiments,
results are expressed as percentage of the control rise in cyclic AMP 
content induced by POOL in the presence of the PMA vehicle, DMSO (0.25^). 
The data are means and standard errors from three different experiments.
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Figure 58. Effects of apyrase on the inhibition of PGP -induced elevation 
of cyclic AMP content by (A) PMA and (s) ADP.
Control (• ) and apyrase (10 units of ADPase activity per ml; 10 min)- 
treated (a ) gel-filtered platelet samples (0.4 ml) were incubated (37°C) 
for 2 minutes with (A) PMA or (B) ADP at the concentrations indicated 
before the addition of PGDg (300 nM) for a further 2 minutes. Cyclic 
AMP content was monitored as described in Methods Section. For the sake 
of comparison between different experiments, results are expressed as 
percentage of the control rise in cyclic AMP content induced by PGD^
(300 nM) in the presence of the PMA vehicle, DMSO (0.25%). The data are 
means and standard errors from three different experiments.
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Figure 59. Effects of creatine phosphate/creatine phosphokinase on the
inhibition of PGDU-induced elevation of cyclic AMP content bv PMA
Control (•) and creatine phosphate (2 mM)/creatine phosphokinase (50 units 
of activity per ml; 10-40 min incubation)-treated gel-filtered platelet 
samples (A ) were incubated (37°C) for 2 minutes with PMA at the 
concentrations indicated before the addition of PGDg (300 nM) for a further 
2 minutes. Cyclic AMP content was monitored as described in Methods Section. 
For the sake of comparison between different experiments, results are 
expressed as percentage of the control rise in cyclic AMP content induced 
by PGD_ in the presence of the PMA vehicle, DMSO (0.25%). The data are 
means and standard errors from three different experiments.
TABLE 6. Effect of IBMX on PGDg-induced elevation of platelet cyclic AMP
content.
Treatment Cyclic AMP content 
(pmol/10® platelets)
Control 9 - 0.6
PGDg (300 nM) 124 i 10
PGD + IBMX 
(300nM) (ImM)
231 :ii
Control or IBMX (1 mM; 10-30 min; 37 C)-treated gel-filtered platelet 
samples (0.4 ml) were incubated (90 sec; 37°C) with saline or PGDg 
(300 nM) and cyclic AMP content was measured as described in Methods 
Section. Data are means and standard errors from three experiments 
using blood from different donors.
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Figure 60. Effects of IBMX on the inhibition of PGDu-induced elevation 
of cyclic AMP content by PMA.
Control (•) and IBMX (l mM; 20-50 min)-treated gel-filtered platelet 
samples (A ) were incubated (37°C) with PMA for 2 minutes at the 
concentrations indicated before the addition of PGOg (300 nM) for a 
further 2 minutes. Cyclic AMP content was monitored as described in 
Methods Section. For the sake of comparison between different experiments, 
results are expressed as percentage of the control rise in cyclic AMP 
content induced by PGDg in the presence of the PMA vehicle, DMSO (0.25%). 
The control rise in cyclic AMP was approximately doubled in the presence 
of IBMX (see Table 4). The data are means and standard errors from three 
different experiments.
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V.2. Effects of PMA on elevation of cyclic AMP content 
induced by PGI^> PGE^ , 6-keto-PGE^, adenosine and 
reduction in cyclic AMP content induced by adrenaline
To investigate the specificity of this action, I next 
examined the effects of PMA on some other adenylate cyclase 
stimulants. Elevations in platelet cyclic AMP content induced 
by PGI^ (lOO nM), PGE^ (l p,M) 6—keto—PGE^, (l jiM) and adenosine, 
unlike PGD^, were not significantly affected by pre-incubation 
(2 min: 37°C) with PMA, 300 nM (Figs. 6I-63).
Possible effects of PMA on the ability of agonists (e.g. 
adrenaline) to inhibit adenylate cyclase were also assessed. 
Inhibition of PGI^ (lOO nM)-, PGD^ (l %M)- and PGE^ (l p,M)- 
induced elevation in cyclic AMP content by adrenaline (5 P-M;
30 sec pre-incubation) was unaffected by addition of PMA 
(300 nM) 90 sec before the adrenaline (Figs. 6l and 62).
VI. Protein kinase activity in crude platelet extracts
The aim of this study was to develop a simple assay for 
cyclic AMP-dependent protein kinase activity in crude platelet 
extracts which would allow the effects of platelet agonists 
and inhibitors on this enzyme to be determined.
VI.1. Effects of varying incubation time, platelet protein 
concentration and cyclic AMP concentration on kinase 
activity
Platelet protein kinase activity was stimulated by cyclic 
AMP (4 pM) and was linearly related to the incubation time at
Effects of PMA on stimulation and inhibition of platelet cAMP formation,
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Figure 61. Effects of PMA on the modulation of platelet cyclic AMP 
levels bv PGI^ and adrenaline.
Where indicated, gel-filtered platelet samples (0.4 ml) were incubated 
(37°C) with DMSO (0,15%; 4 min) or PMA (300 nM; 4 min) and/or adrenaline
Platelet cyclic AMP content 
The data are means and 
standard errors from a single experiment representative of three.
(5 pM; 2 min) and/or PGIg (100 nM; 1 min). 
was monitored as described in Methods Section.
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Figure 62. Effects of PMA on the modulation of platelet cyclic AMP levels 
bv PGE^, 6-keto-PGE^ and adrenaline.
Where indicated, gel-filtered platelet samples (0.4 ml) were incubated 
(37°C) with DMSO (0.15%; 4 min) or PMA (300 nM; 4 min) and/or adrenaline 
(5>iM; 2 min) and/or PGE^ (l p.M; 1 min) or 6-keto-PGE^ (iV-M; 1 min).
Platelet cyclic AMP content was monitored as described in Methods Section.
The data are means and standard errors from a single experiment representative 
of three.
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Figure 63. Effects of PMA (300 nM) on adenosine-induced elevation of 
platelet cyclic AMP content.
Control (a ) and creatine phosphate (2 mf*l)/creatine phosphokinase (50 units 
per ml; 10 min incubation)-treated (B) gel-filtered platelet samples (0.4 ml) 
were incubated (2 min; 37°C) with PMA (300 nM) (#) or the vehicle (DMSO,
0.25%) (o) before addition of adenosine at the concentrations indicated for 
a further two minutes. Cyclic AMP content was measured as described in 
Methods Section. The data are means and standard errors from a single 
experiment representative of three similar.
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30°C as shown in Figure 64. Platelet protein kinase activity 
also was linearly related to the concentration of platelet 
protein present in the assay mixture (Fig. 65)* The protein 
concentrations normally used were 70-90 )ig per assay of soluble 
protein and 20-30 ng per assay of particulate protein.
Inclusion of increasing concentrations of cyclic AMP in the 
assay mixture resulted in concentration-dependent stimulation 
of kinase activity with an of around O.36 p-M cyclic AMP
as shown in Figure 66 for soluble protein kinase activity.
VI.2. Effects of kinase and phosphatase inhibitors on platelet 
kinase activity 
Inclusion of 25 units of the heat-stable inhibitor protein 
of cyclic AMP-dependent protein kinase (Ashby & Walsh, 1972) 
in the kinase assay mixture prevented stimulation of platelet 
protein kinase activity by cyclic AMP (4 pM) but had no 
significant effect on the basal enzyme activity (Fig. 67). 
Stimulation of soluble enzyme activity by cyclic AMP was also 
inhibited by the crude preparation of this inhibitor (25 units 
per assay) which was purchased from Sigma (Fig. 68). In 
contrast, inclusion of the calmodulin antagonist chlorprothixene 
(100 pM) and/or the combined calmodulin and protein kinase C 
antagonist trifluperazine (20 pM) (Sanchez e_t ad., I983) had 
no significant effect on soluble platelet protein kinase 
activity in the presence or absence of cyclic AMP, 5 pM 
(Fig. 68). Inclusion of NaF (40 mM) in the platelet lysis 
buffer (Buffer E) to inhibit phosphatase and ATP-ase activity
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(Corbin ad., 1973) had no significant effect on basal or 
cyclic AMP (4 pM)-stimulated protein kinase activity (Table 7)«
VI.3• Effects of stimulators of adenylate cyclase on platelet 
protein kinase activity 
Incubation (2 min; 37°C) of platelet suspensions with PGI^ 
(O.l - 3 tiM) or PGD^ (3 - 300 nM) resulted in elevation of 
platelet cyclic AMP content but had no significant effect on 
platelet cyclic AMP-dependent protein kinase activity ratio 
(Table 8).
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Figure 64. Effects of increasing incubation time on platelet protein 
kinase activity.
Platelet soluble (A) and particulate (B) fractions were incubated (30°C) 
for the times indicated in the presence (&) and absence ( • ) of cyclic 
AMP (4 p M) and protein kinase activity was monitored as described in 
Methods Section. The deta are means and standard errors from a single 
experiment representative of three.
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Figure 65. Effects of platelet protein concentration on kinase activity.
Platelet soluble (A) and particulate (B) protein fractions were incubated 
(10 min; 30 C) at the concentrations shown in the presence (A ) or absence 
( • ) of cyclic AMP (4^M) for the measurement of protein kinase activity 
as described in Methods Section. The data are means and standard errors 
from a single experiment representative of two.
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Figure 66. Effects of cyclic AMP on platelet soluble protein kinase activity.
Platelet soluble fractions were prepared and assayed for protein kinase 
activity in the presence of cyclic AMP at the concentrations indicated as 
described in Methods Section. The data are means and standard errors from 
a single experiment representative of two.
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Figure 67. Effects of the inhibitor of cyclic AMP-dependent protein kinase 
on platelet protein kinase activity.
Platelet soluble (A) and particulate (B) fractions were prepared and assayed 
for protein kinase activity, as described in Methods Section, in the presence 
(where indicated) of cyclic AMP (4^M) and/or the inhibitor of cyclic AMP- 
dependent protein kinase (25 inhibitory units per assay). The data are means 
and standard errors from a single experiment representative of three similar 
experiments. The data (presence versus absence of inhibitor) were compared 
using Student's t-test; *P< 0.05, **P < 0.005.
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Figure 68. Effects of protein kinase inhibitors on platelet soluble 
protein kinase activity.
Platelet soluble fractions were prepared and assayed for protein kinase 
activity in the absence (open bars) or presence (hatched bars) of cyclic 
AMP (4pM) and cyclic AMP-dependent protein kinase activity was monitored 
as described in Methods Section. Where indicated, the Sigma inhibitor of 
cyclic AMP-dependent protein kinase (20 inhibitory units per assay) and/or 
trlfiuperazine (2Gp,M) and/or chlorprothixene (100p,M) were included in the 
assay mixture. The data are means and standard errors from a single 
experiment representative of two and were compared to controls (no inhibitors 
present) using Student's t-test; *P <0.05.
TABLE 7. Effects of sodium fluoride on platelet soluble protein kinase 
activity.
Protein kinase activity (units)
-cAMP +CAMP
Activity
Ratio
-NaF 13.8 - 0.4 27 i 0.7 0.51
+NaF 15.1 - 1.3 27.3 i 0.3 0.55
Platelet soluble fractions were prepared and assayed for protein kinase 
activity as described in Methods Section. The assay was performed in 
the absence and presence of cyclic AMP (4p<M) and NaF (40 mM). The data 
are means and standard errors from a single experiment representative of 
two.
TABLE 8. Effects of PGI and PGD_ on platelet protein kinase activity ratio.
Soluble kinase (n) Particulate kinase (n)
Control 0.50 - 0.05 (18) 0.48 i 0.07 (12)
0.1 nM 
PGIg 0.3 nM 
3 nM
0.32 i 0.05 (6) 
0.51 - 0.08 (6) 
0.53 - 0.09 (5)
0.35 i 0.05 (3) 
0.34 - 0.17 (3) 
0.40 i 0.17 (3)
3 nM
PGDg 30 nM 
300 nM
0.52 - 0.07 (7) 
0.57 - 0.05 (7) 
0.66 - 0.08 (7)
0.61 - 0.11 (5) 
0.72 i 0.19 (5) 
0.72 - 0.08 (5)
Washed platelet suspensions (O.l ml) were incubated (2 min; 37 C) with 
vehicle, PGI^ or PGOL at the concentrations indicated, the reaction was 
terminated by freezing in solid CO^/acetone and protein kinase activity 
ratio was determined as described in Methods Section. Data are means 
and standard errors from three experiments using blood from different 
donors.
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DISCUSSION
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The objective of this study was to examine the molecular 
mechanisms by which exogenous agents, and in particular 
combinations of agents, regulate platelet reactivity. To this 
end, the effects of agonists and agonist combinations on 
platelet functional responses and transduction processes were 
examined. This approach also allowed the interactions of the 
different second messenger systems in platelets to be examined. 
The possible functional relevance of the responses monitored 
using isolated platelets were assessed throughout this study 
by examining the responses of platelets in the more physiological­
ly relevant milieu of whole blood. Due to the importance of 
platelets in haemostasis and thrombosis and the ease of 
preparation of an allegedly homogeneous population of platelets 
suspended in a buffer of defined composition, the study of 
platelet transduction processes is an extremely fast-moving 
research area. Hence, in the following discussion I shall 
attempt to place my results in perspective with respect to 
our current understanding of the molecular mechanisms of 
platelet activation and inhibition.
I. Measurement of platelet aggregation
In this study, aggregation was monitored in response to 
addition of adrenaline, ADP, vasopressin and PAT to whole blood, 
platelet-rich plasma or gel-filtered platelet suspensions. 
Photometric detection of aggregation in platelet-rich plasma 
or washed platelet suspensions, initially described by Born 
(1962), is the most commonly used technique for monitoring 
this response. A light beam is shone through a stirred platelet
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sample (perpendicular to the axis of stirring) and transmitted 
light is detected by a photometer. An increase in light 
transmission is taken to reflect platelet aggregation. This 
technique, although immensely useful in the study of platelet 
physiology and pharmacology, has a number of inherent drawbacks, 
some of which were recognised as early as 1967* It is only 
semi-quantitative. Examination of ADP-induced aggregation 
directly, by light microscopic methods or electronic particle 
size analysis, indicates that extensive aggregation can occur 
in the absence of light transmission changes (Born & Hume, I967; 
Nichols & Bosmann, 1979)* Born & Hume (1967) reported 879^  
loss of single platelets with only 79° change in light trans­
mission. A recent report has indicated that platelet aggregation 
can produce either decreases or increases in light transmission 
depending on the size and shape of the aggregate particles 
formed (Malinski & Nelsestuen, I986). An additional complication 
in the analysis of light transmission data is the decrease in 
light transmission associated with shape change and increased 
platelet density (Michal & Bom, 1971)* Hence, quantitative 
analysis of aggregation traces, with respect to the absolute 
degree of aggregation present, is difficult.
In agreement with these findings. Figures 9-16 of this 
study show that adrenaline-, ADP-, vasopressin- and PAF-induced 
reductions in single platelet count occurred in response to 
lower agonist concentrations than were required for the 
induction of changes in light transmission in platelet-rich 
plasma. Changes in light transmission in response to higher 
agonist concentrations were preceded by reductions in platelet 
count (Figs. 9> II» 13 8.nd 13)*
—  o o  —
Photometric measurement of aggregation requires separation 
of platelets from other blood cells. Hence, aggregation in 
whole blood, a situation which more closely approximates the 
physiological milieu, cannot be examined photometrically.
Since platelet reactivity may be modulated by agents released 
by other blood cell types, it would be advantageous to be able 
to correlate effects seen in platelet-rich plasma or washed 
platelets to responses in whole blood. Cardinal & Flower (1980) 
described an indirect method of monitoring platelet aggregation 
in whole blood which involved measuring the changes in electrical 
conductance through a blood sample which result from aggregate 
formation. In the present study, aggregation in whole blood 
was measured directly using the whole blood single platelet 
counting method of Lumley & Humphrey (198I). Using this method, 
adrenaline, ADP, vasopressin and PAF induced concentration- 
dependent aggregation in whole blood (Figs. 7> 8), indicating 
that these agonists could stimulate platelet activation i^ vivo. 
However, the concentrations of these agonists required to induce 
platelet aggregation in whole blood are at least an order of 
magnitude higher than those concentrations present in the 
circulation under physiological or pathological conditions 
(Grant & Scrutton, 1980a). Throughout this study, the 
physiological significance of responses (to agonists or agonist 
combinations) observed in platelet-rich plasma or isolated 
platelets was investigated by monitoring the responses in 
whole blood.
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II• Calcium and inositol phospholipid hydrolysis in stimulus— 
response coupling
(a) PAF and vasopressin.
PAF and vasopressin induced [^^p] -Ptd OH formation and 
elevation of ^Ca^^j^ over similar concentration ranges which 
induced platelet activation (Figs. 19-23). These findings are 
in agreement with other reports (MacIntyre & Pollock, I983; 
Hallam et al., 1984a,b; Pollock & MacIntyre, I986) and indicate 
that platelet receptors for PAF (paf^) and vasopressin (V^) 
are coupled to elevation of ^Ca^^j and phosphoinositide 
hydrolysis. Kinetic analysis of agonist-induced elevations 
in ^Ca^^j and phosphoinositide hydrolysis indicates that they 
precede the platelet responses and, hence, could act as 
transduction processes linking receptor occupancy to platelet 
activation (Fig. 21; MacIntyre ejfc al., 1985c; Pollock & 
MacIntyre, I986). The concentration-response relationships 
for PAF- and vasopressin-induced ^^^P j -Ptd OH formation and 
elevation of |ca^^j are superimposable (MacIntyre ejb al. , 
1985c; Pollock & MacIntyre, I986); this is compatible with 
the theory that elevations in ^Ca^^ ^ are mediated by products 
of phosphoinositide hydrolysis (Berridge, 1985)*
(b) ADP.
ADP induced aggregation and ATP secretion in washed 
platelet suspensions (Fig. 18) and this was associated with 
elevation of |ca^^j ^  (Figs. 21, 22) but not [^^pj —Ptd OH 
formation (Fig. 23). This lack of effect of ADP on phospho­
inositide hydrolysis contrasts with studies using rat or
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rabbit platelets (Vickers et , 1982; MacIntyre & MacMillan, 
1985) but is in agreement with another recent report using 
human platelets (Fisher ^  , I985). There are at least
two possible explanations for these results. It is possible 
that ADP is a very weak activator of phosphoinositide hydrolysis 
in human platelets and that the technique used is not sensitive 
enough to detect small changes in Ptd OH formation. Alternatively, 
species variations may exist such that calcium fluxes can occur 
in human platelets in the absence of phosphoinositide hydrolysis. 
Indeed, Sage & Rink (1986) have recently reported that there 
are kinetic differences between the calcium fluxes induced by 
thrombin (a potent activator of phosphoinositide hydrolysis) 
and ADP. These authors suggested that thrombin- and ADP-induced 
calcium fluxes are mediated via distinct mechanisms. It is 
possible that human platelet ADP receptors could be directly 
coupled to opening of ROC (see introduction Section V). Receptor 
occupancy would then result in rapid influx of Ca^* from the 
extracellular space in the absence of phosphoinositide hydrolysis 
or Ins(l,^)P^ formation. The slower thrombin-induced elevation 
of |ca^^j detected by Sage & Rink could be mediated by products 
of phosphoinositide hydrolysis.
(c) Adrenaline.
Adrenaline-induced ATP secretion and aggregation in washed 
platelet suspensions (Fig. 17) was apparently not associated 
with elevation of ^Ca^^j (Figs. 21, 22) or phosphoinositide 
hydrolysis (Fig. 23). The lack of effect of adrenaline on 
platelet jca^^j monitored using Quin 2, contrasts with the 
reported adrenaline-induced changes in chlortetracycline
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fluorescence (Le Breton et , 1976), uptake (Owen
Gt al., 1980) and luminescence of platelets loaded with the 
calcium-sensitive photoprotein aequorin (Ware et al., I986). 
These findings may indicate that adrenaline induces increases 
in |ca which are sufficiently small and/or sufficiently
localised that it does not disturb the spatial average ^a^^j . 
which is reported by Quin 2 (Blinks et , I982; Johnston 
et al., 1985)* The mechanism by which adrenaline might 
produce such a change in |ca^^j is obscure since it is not 
accompanied by phosphoinositide hydrolysis, at least as 
monitored by measurement of j -Ptd OH formation (Fig. 23;
MacIntyre et al., 1983c). Whether adrenaline-induced platelet 
activation could result from a decrease in the basal level 
of cyclic AMP, perhaps in some specific pool, is controversial 
and remains to be resolved (Salzman, 1972; Haslam ejb al. ,
1978; see below; Section VII).
III. Synergistic activation of platelets
III.l Potentiation of platelet activation by adrenaline
Addition of low concentrations of adrenaline simultaneously 
with or up to 5 minutes before addition of ADP, vasopressin 
or PAF resulted in potentiation of aggregation monitored 
either in whole blood or gel-filtered platelets, and also 
potentiation of ATP secretion (Figs. 24-34). Potentiation 
occurred in the presence of the cyclooxygenase inhibitors 
aspirin (in whole blood) and flurbiprofen (in gel-filtered 
platelets) and therefore is not mediated via prostaglandin 
endoperoxide or TxA- formation (Figs. 24-34). These results
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are in agreement with reports in platelet-rich plasma and 
washed platelets (Ardlie ^  , I966; Rao ^  , I98O;
Grant & Scrutton, 1980a; Vargaftig e_t al. , I982). It has 
recently been suggested that synergistic activation of platelets 
is not evident when aggregation is monitored by a single platelet 
counting method (Kerry & Scrutton, 1985)» The results of this 
study (Figs. 24-31) indicate that this suggestion does not hold 
true, at least in whole blood. The finding of synergism in 
whole blood further supports the hypothesis that synergistic 
stimulation of platelet aggregation may also occur in vivo 
and may be of importance in haemostasis and in the pathogenesis 
of occlusive vascular disease.
III.2. Possible mechanisms of the potentiation of platelet 
activation by adrenaline 
Since adrenaline and vasopressin utilise distinct trans­
duction processes to evoke platelet activation, this combination 
was the major one, but not the only one chosen to examine 
synergism and to investigate the roles, if any, of phospho­
inositide hydrolysis and elevation of |ca^^j^ in potentiation 
of platelet activation by adrenaline. The results of this 
study demonstrate that the synergistic effects of adrenaline 
in combination with vasopressin, ADP or PAF are accompanied 
by enhancement of agonist—induced elevations in |^ Ca j ^
(Fig. 33A-C) that derives partly from increased Ca^* influx 
and partly from mobilisation of intracellular Ca^ '*’. This 
enhancement was unaffected by incubation with flurbiprofen 
and, therefore, is not mediated via prostanoid formation (Fig. 
36). Adrenaline also potentiated vasopressin-induced phospho-
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inositide hydrolysis (monitored as ] -Ptd OH formation)
(Fig. 37)• The apparent dissociation between the temporal 
effects of adrenaline on vasopressin-induced phosphoinositide 
hydrolysis (Fig. 37) and elevation of |ca^^j (Fig. 33A) may 
merely reflect the greater resolution of the assay of ^^P -Ptd 
OH, especially as the trend in Ca^* ^ was always in the 
direction of an increase.
Even in the presence of adrenaline, agonist—induced 
elevations in ^a^^j only attain levels of around I3O-3OO nM 
(i.e. some 30-200 nM above basal). At those concentrations 
|ca^’^j^, per se, is insufficient to account for the near-maximal 
stimulation of aggregation and ATP secretion observed under 
these circumstances (Rink e_t e^. , I982). This is confirmed by 
the observation that co-addition of vasopressin and ionomycin, 
at concentrations which elevated |ca^^j^ to an extent comparable 
to or greater than that evoked by vasopressin and adrenaline 
in combination (Table 4), resulted in only slight enhancement 
of aggregation with no increment in ATP secretion (Fig. 38). 
Thus, potentiation of vasopressin-induced platelet activation 
by adrenaline cannot be attributed to enhanced elevation of 
j^ Ca^ '*"j ^  alone.
PMA mimics the effects of endogenous DG in activating 
protein kinase C and modulating platelet reactivity (Nishizuka, 
1984). Incubation with PMA at subthreshold concentrations (at 
least for aggregation as measured photometrically) resulted 
only in marginal enhancement of vasopressin-induced platelet 
aggregation with no augmentation of ATP secretion (Fig. 38).
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Thus, potentiation of vasopressin-induced platelet activation 
by adrenaline cannot be mimicked by an exogenous activator 
of protein kinase C and therefore, may not be attributable to 
enhanced DG formation alone.
In contrast, the effects of adrenaline on vasopressin- 
induced platelet aggregation and ATP secretion could be 
reproduced by subthreshold concentrations of PMA and ionomycin 
in combination (Fig. 38). Consequently, the mechanisms 
underlying potentiation of platelet activation by adrenaline 
may involve enhanced inositol phospholipid hydrolysis (ergo 
DG formation) and elevation of |ca^^j ^ , perhaps consequent 
upon Ins(l,4,5)P^ formation (Berridge, 1983)»
These effects may be explained were adrenaline, either as 
a direct consequence of a^-adrenoceptor occupancy or as a 
consequence of reduction in cyclic AMP concentration in a 
specific intracellular compartment, to induce a change in 
membrane lipid architecture (Irvine, 1982) or in a guanine 
nucleotide binding regulatory protein (Haslam & Davidson,
1984) and thus promote coupling of receptors to hydrolysis 
of PIP^ via phospholipase C. Clearly, clarification of the 
roles of products of inositol phospholipid metabolism in the 
potentiation of platelet activation by adrenaline would 
require further investigation.
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IV• Inhibition of platelet activation by cyclic AMP
IV•1 Inhibition of platelets in whole blood
Agonist-induced aggregation in whole blood was inhibited 
by the adenylate cyclase stimulants PGD^ and PGI^ (Figs.
39-42). This is in agreement with other studies using 
platelet-rich plasma and washed platelet suspensions (Di 
Minno et al., 1979? Feinstein et al.> I98I). The degree of 
inhibition of ADP-induced aggregation was independent of the 
prostaglandin pre-incubation time (90 sec - 3 min) (Figs. 39; 
4o). Incubation (90 sec; 37°C) with PGD^ (lOO nM) or PGI^
(3 nM) had little or no effect on adrenaline-induced aggregation 
but inhibited aggregation induced by ADP, vasopressin and 
PAF (Figs. 4l, 42). Inhibition of the response to ADP, but 
not PAF or vasopressin, could be overcome by increasing the 
agonist concentration. This differential susceptibility to 
inhibition by prostaglandins is in agreement with a study in 
platelet-rich plasma (Di Minno e_t aT. , 1979) which demonstrated 
that higher concentrations of PGD^j PGE^ and PGI^ were required 
to inhibit adrenaline compared to ADP or collagen.
It is widely accepted that these inhibitory prostaglandins 
act by raising the platelet intracellular cyclic AMP 
concentration (Feinstein ejb al. , I98I). The receptors for 
adrenaline and ADP but not vasopressin or PAF can be coupled 
to inhibition of adenylate cyclase in intact platelets (Haslam 
& Rosson, 1973; Haslam & Vanderwel, 1982; Vanderwel ejb al. ,
1983; Aktories & Jakobs, 1983)# Hence, adrenaline and ADP but 
not vasopressin or PAF can reverse prostaglandin-induced
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elevations in platelet cyclic AMP content (Fig. 52). It 
seems likely that the inhibitory effects of adrenaline and 
ADP on platelet adenylate cyclase activity are responsible 
for the relative insensitivity of these agonists (compared to 
vasopressin and PAF) to inhibition by adenylate cyclase 
stimulants.
IV.2. Inhibition of different platelet functional responses 
and transduction processes by cyclic AMP 
It has been proposed that elevated cyclic AMP concentrations 
inhibit platelet function by suppressing the production of the 
stimulatory second messenger molecules Ca^^ (Feinstein ejfc al., 
1983) and DG (Lapetina, 1984). This effect could be mediated 
by inhibition of phospholipase C and prevention of receptor- 
stimulated PTP^ hydrolysis. A recent study by Halenda ejfc al. 
(1986) demonstrated that elevation of cyclic AMP content by 
PGD^ can interfere with the coupling of thrombin receptors 
to a GTP-binding protein in the platelet plasma membrane.
This could be a general mechanism by which cyclic AMP inhibits 
agonist-induced phosphoinositide hydrolysis and elevation of 
. Adenylate cyclase stimulants cause a decrease in 
the elevated |ca^^j ^  when added after stimulatory agonists 
(Feinstein ejt , 1983)* This effect might be mediated by 
increased Ca^* sequestration or extrusion (Feinstein aT. ,
1983; Kaser-Glanzmann ^ *  > 1977); however, this seems 
incompatible with the reported lack of effect of cyclic AMP 
on ionophore-induced elevations in |ca^^j ^  (Pannochia &
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Hardisty, 1985). In addition, cyclic AMP-dependent protein 
kinase has been shown to inhibit platelet myosin light chain 
kinase activity, a Ca^^-activated enzyme (Hathaway et al.,
1981). Hence, cyclic AMP can modify the rate of production 
and (possibly) inactivation of the stimulatory second messengers 
and can antagonise their effects to prevent or reverse agonist- 
induced platelet activation.
The results of this study show that PGD^ was more potent 
as an inhibitor of PAF-induced ATP secretion (I^q around 2 nM) 
and aggregation (I^q around 3 nM) than of [^^P ] -Ptd OH formation 
(l^Q around 10 nM), shape change (I^q around 30 nM) and elevation 
of |ca^^] (l^Q around 30 nM) (Fig. 43). The degree of inhibitio 
of the various platelet responses could be correlated with 
the rise in cyclic AMP induced by PGD^ iu the same platelet 
samples (Figs. 44, 45)* Small rises in cyclic AMP content (up 
to a 1009  ^increase) induced by PGD^ greatly inhibited PAF- 
induced aggregation and ATP secretion, with lesser inhibition 
of [^^P ] -Ptd OH formation and only marginal inhibitions of 
shape change or elevation of |ca^^j ^ . These results indicate 
that small rises in cyclic AMP content result in inhibition of 
some platelet functional responses (aggregation and secretion) 
but have relatively little effect on the putative underlying 
transduction processes: phosphoinositide hydrolysis and
elevation of [ca^^]^. These findings are consistent with 
cyclic AMP not only acting to prevent the formation or increase 
the inactivation of Ca^^ and DG but also acting at a later 
stage in the activation process to oppose the intracellular 
actions of Ca^* and DG. These latter effects could be mediated
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by inhibition of Ca^^- or DG-dependent phosphorylation reactions 
or by inhibitory phosphorylation of the same target proteins 
that are acted upon by the 'stimulatory' kinases. There is 
some evidence that different protein kinases (Ca^*-, DG- and 
cyclic AMP-dependent) share many phosphate acceptor proteins 
in vitro (Nishizuka, 1984). The observations reported here 
are in accord with a report by Pannochia & Hardisty (1985) 
in which PGT^ and dibutyryl cyclic AMP were shown to inhibit 
platelet functions with little or no inhibition of the 
elevation of . It is concluded from this study that
a major component of inhibition of PAF-induced platelet activatio 
by cyclic AMP is mediated by suppression of certain aspects 
of the activation process that occur distal to the formation 
or elevation of the stimulatory second messengers, Ca^^ and DG.
Clearly, PAF-induced shape change was much less susceptible 
to small rises in cyclic AMP content than were aggregation 
and ATP secretion (Figs. 43» 45)* Similar results were found 
when PGI^ was used as the inhibitory platelet agonist (Fig. 47)* 
The reasons for this discrepancy are unknown, but it might 
suggest that the mechanisms underlying PAF-induced aggregation 
and secretion differ from those that govern shape change.
It is possible that shape change is more dependent upon the 
absolute levels of the stimulatory second messengers, since 
inhibition of shape change parallelled inhibition of elevation 
of [^^P ] -Ptd OH formation and |ca^^] ^ . These findings are 
in disagreement with a report by Steen & Holmsen (1984) 
which demonstrated identical 1^^ values for cyclic AMP-dependent
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inhibition of ADP-induced shape change, aggregation and ATP 
secretion. However, these studies may not be directly 
comparable, since both the stimulatory (ADP) and inhibitory 
(PGE^ and adenosine) agonists used differed from those employed 
in the present study. Indeed, there is evidence that different 
agonists show differential sensitivity to inhibition by 
cyclic AMP (Krishnamurthi ejt al. , 1984; Rink & Sanchez, 1984).
IV.3* Interactions between stimulators and inhibitors of 
adenylate cyclase 
Platelets may be exposed, in vivo, to a combination of 
stimulants (e.g. PGI^» PGD^» adenosine) and inhibitors (e.g. 
circulating adrenaline or released ADP) of adenylate cyclase. 
Hence, in this study I examined the effects of combinations 
of stimulators and inhibitors of adenylate cyclase on agonist- 
induced platelet activation and the underlying transduction 
processes. The inhibition of PAF-induced aggregation in whole 
blood by PGD^ or PGI^ could be reversed by adrenaline (added 
after the PG) but not by vasopressin (Figs. 48, 49)* Using 
washed platelet suspensions, adrenaline and ADP but not 
vasopressin reversed the inhibition of PAF-induced aggregation, 
ATP secretion and elevation of |ca^^j which resulted from 
preincubation with PGI^ (Fig. 50)* Similarly, reversal of 
PGI^-mediated inhibition of vasopressin-induced aggregation,
ATP secretion, elevation of j c a^^jand ^ ^ P  j -Ptd OH formation 
by adrenaline could also be demonstrated (Fig. 5l)* Under 
these conditions, PGI^-knduced elevations in platelet cyclic 
AMP content were prevented/reversed by adrenaline and ADP but
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not vasopressin or PAF (Fig. 52). In contrast to this, 
elevations in platelet cyclic AMP content induced by the 
phosphodiesterase inhibitor IBMX (Table 5) and the inhibition 
of PAF-induced platelet responses by IBMX or 8 bromocyclic AMP 
were not significantly affected by adrenaline (Figs. 53» 54). 
Hence, elevation of cyclic AMP levels and inhibition of platelet 
responsiveness by adenylate cyclase stimulants, but not by 
other mechanisms, can be prevented or reversed by inhibitors of 
adenylate cyclase (adrenaline and ADP) but not by other platelet 
agonists (vasopressin and PAF). These results are in agreement 
with those of Zavoico & Feinstein (1984) who showed that 
inhibition of thrombin-induced elevation of |ca^^j and 
secretion by pre-incubation with adenylate cyclase stimulants 
could be prevented by adrenaline or ADP. This effect was 
evident irrespective of whether adrenaline was added before or 
after the adenylate cyclase stimulant (PGI^» PGD^ or forskolin) 
or after the thrombin (Zavoico & Feinstein, 19&3).
These findings confirm the previous reports that cyclic AMP 
regulates the stimulatory transduction processes of elevation 
of |ca^^jand phosphoinositide hydrolysis (Feinstein al., 
1983; Lapetina, 1984). In the presence of multiple platelet 
agonists, the net effects of the various receptors on the 
guanine nucleotide-binding regulatory proteins and will 
control the rate of cyclic AMP formation. Hence, iji vivo, 
the dynamic balance between stimulation and inhibition of 
adenylate cyclase will control the platelet response i.e. 
inhibition or stimulation. This could be an important- regulatory 
mechanism in the control of haemostasis.
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V . Effects of protein kinase C activation on platelet cyclic
AMP metabolism
A number of recent studies have demonstrated that protein 
kinase C, besides mediating platelet activation, can also 
modulate receptor-controlled transduction processes. Protein 
kinase C can stimulate receptor phosphorylation in a number of 
different cell types (Sibley ejt al. , 1984). In addition, 
activated protein kinase C can inhibit agonist-induced phospho­
inositide hydrolysis and elevation of ^ in platelets
(MacIntyre e_fc ad., 1983d) and other cells (Drummond & MacIntyre 
1983)* This effect may be explained by the finding that, in 
platelets, protein kinase C activation interferes with the 
interaction of stimulatory receptors (e.g. thrombin) with a 
GTP-binding protein (Halenda ejfc al. , I986). It has also been 
suggested that one of the '40K' proteins phosphorylated by 
protein kinase C is an Ins(l,4,3)P^ phosphatase (Connolly &
Majerus, I986). This could also contribute to the inhibition
2+of Ca mobilisation by activators of protein kinase C 
(MacIntyre ejt al. , 1983c, d).
Studies using tumour-promoting phorbol esters such as PMA 
have demonstrated that activated protein kinase 0 can modulate 
cyclic AMP metabolism in a number of different cell types.
Basal cyclic AMP levels may be increased (Grotendorst & 
Schimmel, I98O; Brostrom al. , I983; Cronin and Canonico, 
1983; Quilliam ^  al., I983), decreased (Brostrom ^  al.,
1982) or unaffected (Pick ^  al., 1977; Belman & Garte, I98O) 
after treatment with phorbol esters. Similarly, differential
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effects of phorbol esters on elevated cyclic AMP levels have 
been reported (see references above). In this study, I 
examined the effects of phorbol esters on platelet cyclic 
AMP metabolism. PMA, at concentrations and incubation times 
known to activate protein kinase C (Castagna ^t al., I982), 
had no effect on control or IBMX—elevated platelet cyclic 
AMP content (Fig. 53)•
Inhibition of PGD^-induced elevation of platelet cyclic 
AMP content by PMA was not mimicked by the non-tumour-promoting 
phorbol ester 4a-PDD (Fig. 36) suggesting that this effect 
of PMA is due to activation of protein kinase C rather than 
any non-specific membrane perturbation caused by the detergent­
like nature of the phorbol esters (Castagna ejb al. , I982).
The effect of PMA was not mediated by the liberation of endo­
genous ADP from the dense granules; inhibition of the PGD^- 
induced elevation in cyclic AMP occurred in the presence of 
ADP—removal systems (apyrase and CP/CPK) (Figs. 38, 39)* This 
effect of PMA also occurred in the presence of an inhibitor of 
cyclooxygenase (flurbiprofen) and, therefore, is not mediated 
via prostanoid biosynthesis (Fig. 37)* Incubation with IBMX 
resulted in only marginal inhibition of the effect of PMA 
suggesting that it is not mediated by increased phospho­
diesterase activity (Fig. 60). Taken together, these results 
indicate that activation of protein kinase C by PMA directly 
interferes with PGD^-induced cyclic AMP formation. Possible 
mechanisms of this action include (l) inactivation of the DP 
receptor for PGD^; (2) inactivation of the stimulatory G- 
protein N ; (3 ) activation of the inhibitory G-protein
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or (4) inactivation of the adenylate cyclase catalytic 
subunit (Fig. 2).
Elevations in cyclic AMP content induced by adenylate 
cyclase stimulants which act via IP receptors (PGI^» PGE^^, 
6-keto-PGEj^ ) and A^-purinoreceptors (adenosine) were unaffected 
by PMA (Figs. 61-63)» The specificity of this effect of PMA 
suggests that it is mediated via an action at the DP receptor 
rather than the G—proteins or the adenylate cyclase catalytic 
subunit which are presumably common to different agonists 
(Fig. 69). In this context, it would be of interest to examine 
in more detail the nature of the inhibition of PGD^ by PMA 
and the effects of PMA on the numbers and affinity of platelet 
DP, IP and A^ receptors. Ashby e_fc al. (1983) reported that 
PMA or the synthetic DG analogue, l-oleoyl-2-acetyl glycerol 
(OAG), had no effect on PGI^- or forskolin-induced cyclic AMP 
formation in platelets. This confirms the lack of any direct 
effect of protein kinase C on the catalytic subunit of adenylate 
cyclase. Jakobs ejb aT. (1983) reported that forskolin- and 
PGIg-induced stimulation of adenylate cyclase activity in 
platelet membrane preparations was slightly enhanced by pre­
treatment of the platelets with PMA.
It is perhaps worthy of note here that PGD^> unlike the 
other inhibitory agonists studied, can be produced by stimulated 
platelets (Hamberg & Fredholm, 1976). The specificity of this 
effect of PMA may suggest that activation of protein kinase C 
in platelets could provide a regulatory mechanism to abrogate 
the effects of the endogenous adenylate cyclase stimulant
PGI
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Figure 69. Scheme depicting the effects of PMA on receptor-controlled 
cyclic AMP metabolism in platelets.
Activation of protein kinase C by PMA inhibits DP- but not IP- or Ag- 
receptor-mediated cyclic AMP formation. See text for details.
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(PGD^) without compromising the actions of exogenous stimulants 
of adenylate cyclase such as endothelium-derived PGI^* However, 
the possible physiological or pathological importance of this 
phenomenon in the regulation of platelet reactivity remains 
to be ascertained.
In intact platelets, PMA had no effect on the inhibition 
of PGD^-, PGI^-, PGE^- or 6-keto-PGE^-induced elevation of 
cyclic AMP content by adrenaline (Figs. 6l, 62). However, 
Jakobs et al. (1983) reported that PMA pretreatment abolished 
N^-mediated inhibition of adenylate cyclase by adrenaline in 
platelet membranes. It was proposed that this effect of PMA 
was mediated by protein kinase C-catalysed phosphorylation of 
(Watanabe ejfc al. , I985; Katada al. , 1985)» The reasons 
for this discrepancy are unknown, however, it does suggest 
that studies using platelet lysates do not always reflect 
the situation in intact cells where there may be complex 
interactions between the different second messenger systems. 
This is confirmed by a report by Murayami & Ui (I985) who 
found that the coupling of thrombin receptors on mouse 3T3 
fibroblasts to and inhibition of adenylate cyclase was 
attenuated by cell disruption and preparation of membrane 
fractions.
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VI• Platelet cyclic AMP-dependent protein kinase activity
The object of this study was to develop a simple, 
reproducible assay for cyclic AMP—dependent protein kinase 
activity in crude platelet extracts and to examine the effects 
of platelet agonists on this enzyme. Since kinase activity 
is coupled very closely to changes in cyclic AMP concentration 
in a range of cell and tissue types, measurement of the activity 
of this enzyme provides a very sensitive index of small changes 
in intracellular cyclic AMP concentration (Corbin, 1983)» It 
was hoped that development of such an assay in platelets might 
help resolve the contentious issue of the possible involvement 
of reductions in the basal level of cyclic AMP, perhaps in 
some specific intracellular pool, in the activation of platelets 
by stimulatory agonists, particularly adrenaline (Salzman,
1972; Haslam ^t al. , 1978; Jakobs ejfc al. , I986). Although 
stimulatory agonists do not have any effect on the basal 
platelet cyclic AMP content (Haslam et al., 1978), there is 
some evidence that agonists can alter specific pools of cyclic 
AMP in rabbit platelets (Hashimoto, 1983)» There is also 
evidence of compartmentalisation of cyclic AMP binding proteins 
in platelets (Lyons, I98O) and other cells (Buxton & Brunton,
1983)»
In agreement with previous reports (Salama & Haslam,
1981; 1984) kinase activity was present in both soluble and 
particulate platelet fractions. The degree of kinase activity 
detected varied linearly with incubation time (Fig. 64) and 
platelet protein concentration (Fig. 63) and was stimulated
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in a concentration-dependent manner by cyclic AMP (Fig. 66). 
Activity in the presence, but not the absence, of added 
cyclic AMP was inhibited by the specific heat-stable inhibitor 
of cyclic AMP-dependent protein kinase (Ashby & Walsh, 1972) 
but not by inhibitors of calmodulin (chlorprothixene and 
trifluperazine) and protein kinase C (trifluperazine) (Fig.
67, 68). These results indicate that I was able to detect 
the activity of a functional cyclic AMP-dependent protein 
kinase enzyme extracted from platelets and that this resembled 
(functionally) the cyclic AMP-dependent protein kinase of 
other tissues (Corbin, I983).
However, I was unable to detect any reproducible stimulation 
of this enzyme in platelets treated with the adenylate cyclase 
stimulants PGT^ and PGD^ (Table 8). There are a number of 
possible explanations for this discrepancy including (l) 
artificial dissociation of the regulatory, R, and catalytic, C, 
subunits of the enzyme during platelet lysis; (2) artificial 
reassociation of R and C; (3 ) binding of C to particles other 
than R; (4) inhibition of kinase by salts present in the 
assay mixture; (5 ) presence of proteases and (6) release of 
sequestered cyclic AMP during platelet lysis (reviewed by 
Corbin, 1983)* These problems would have to be resolved before 
the possible effects of stimulatory agonists, such as adrenaline, 
could be assessed. I believe that given enough time, these 
possible pitfalls could be systematically evaluated and the 
technical difficulties of this assay could be overcome. This 
might yield important new insights into the mechanisms by 
which agonists, particularly adrenaline, control platelet 
function.
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Another possible approach to the problem of detecting veiy 
small changes in cyclic AMP levels is to measure the functional 
pool of cyclic AMP which is bound to the R subunit of cyclic 
AMP-dependent protein kinase. This approach has been used 
successfully in adrenocortical cells (Podesta e_t aT. , 1979) 
in order to demonstrate the role of small changes in cyclic AMP 
concentration in the stimulation of corticosterone production 
by low concentrations of corticotropin. This assay technique 
might profitably be applied to platelets.
In conclusion, this study has addressed several questions 
in relation to the mechanisms by which agonists and agonist 
combinations control platelet reactivity. Some of these 
questions have been answered whilst several others have been 
generated. Many aspects of the study are incomplete and might 
fruitfully be pursued further. In particular, further 
investigation would be required to elucidate fully the mechanisms 
underlying potentiation and synergistic stimulation of platelet 
reactivity. Platelets could be exposed simultaneously or 
sequentially to several different agonists dji vivo. Therefore, 
it would be of interest to examine the effects of co-addition 
of multiple stimulatory agonists (as opposed to agonist pairs) 
on platelet reactivity and the mechanisms which mediate these 
effects. Detailed understanding of the mechanisms underlying 
synergism might facilitate the rational development and selection 
of agents which impinge upon the processes involved in 
potentiation. Such agents may more effectively inhibit 
platelet reactivity in whole blood vivo, and could be of
benefit in the prevention and treatment of occlusive vascular 
disease.
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